Indacaterolacetat / Glycopyrroniumbromid / Mometasonfuroat (Enerzair® Breezhaler®)

Novartis Pharma GmbH

Modul 4 A, Anhang 4-H-3

ARGON-Teilpopulation, die mit einer mitteldosierten ICS/LABA-Therapie nicht ausreichend kontrolliert ist

CQVM149B2306 (ARGON)
AMNOG Analysis

Table of Contents

Tables 12
1. Patient Disposition and Baseline Characteristics 12
Table 1.1 Patient Disposition and Compliance (RAN, FAS) 12
Table 1.2 Demographic Patient Characteristics (FAS) 13
Table 1.3 Asthma Related Patient Characteristics (FAS) 15
Table 1.4 Duration of Study Participation (FAS) 19
Table 1.5 Overview Subgroups (FAS) 20
Table 1.6 OCS Use (FAS) 21
2. All-cause Mortality - Binary Analysis 24
Table 2.1 All-cause Mortality - Binary Analysis (FAS) 24
3. ACQ-5 - Return Rate / Change from Baseline 25
Table 3.1 ACQ-5 - Return Rate (FAS) 25
Table 3.2 ACQ-5 - Change from Baseline (FAS) 26
Table 3.3 ACQ-5 - Change from Baseline by Age (FAS) 27
Table 3.4 ACQ-5 - Change from Baseline by Gender (FAS) 29
Table 3.5 ACQ-5 - Change from Baseline by Region (FAS) 30
Table 3.6 ACQ-5 - Change from Baseline by History of Asthma Exacerbation (FAS) 32
4. ACQ-5 - Responder Analysis 33
Table 4.1a ACQ-5 - Responder Analysis (as observed) (FAS) 33
Table 4.1b ACQ-5 - Responder Analysis (LOCF) (FAS) 34
Table 4.2a ACQ-5 - Responder Analysis by Age (as observed) (FAS) 35
Table 4.2b ACQ-5 - Responder Analysis by Age (LOCF) (FAS) 36
Table 4.3a ACQ-5 - Responder Analysis by Gender (as observed) (FAS) 37
Table 4.3b ACQ-5 - Responder Analysis by Gender (LOCF) (FAS) 38
Table 4.4a ACQ-5 - Responder Analysis by Region (as observed) (FAS) 39
Table 4.4b ACQ-5 - Responder Analysis by Region (LOCF) (FAS) 40
Table 4.5a ACQ-5 - Responder Analysis by History of Asthma Exacerbation (as observed) (FAS) 41
Table 4.5b ACQ-5 - Responder Analysis by History of Asthma Exacerbation (LOCF) (FAS) 42
5. AQLQ-S - Return Rate / Change from Baseline 43
Table 5.1 AQLQ-S - Return Rate (FAS) 43
Table 5.2 AQLQ-S - Change from Baseline (FAS) 44
Table 5.3 AQLQ-S - Change from Baseline by Age (FAS) 46
Table 5.4 AQLQ-S - Change from Baseline by Gender (FAS) 52
Table 5.5 AQLQ-S - Change from Baseline by Region (FAS) 56
Table 5.6 AQLQ-S - Change from Baseline by History of Asthma Exacerbation (FAS) 63
6. AQLQ-S - Responder Analysis 67
Table 6.1a AQLQ-S - Responder Analysis (as observed) (FAS) 67
Table 6.1b AQLQ-S - Responder Analysis (LOCF) (FAS) 68
Table 6.2a AQLQ-S - Responder Analysis by Age (as observed) (FAS) 69

Table 6.2b AQLQ-S - Responder Analysis by Age (LOCF) (FAS) ... 70
Table 6.3a AQLQ-S - Responder Analysis by Gender (as observed) (FAS) ... 71
Table 6.3b AQLQ-S - Responder Analysis by Gender (LOCF) (FAS) ... 72
Table 6.4a AQLQ-S - Responder Analysis by Region (as observed) (FAS) ... 73
Table 6.4b AQLQ-S - Responder Analysis by Region (LOCF) (FAS) ... 74
Table 6.5a AQLQ-S - Responder Analysis by History of Asthma Exacerbation (as observed) (FAS) 75
Table 6.5b AQLQ-S - Responder Analysis by History of Asthma Exacerbation (LOCF) (FAS) ... 76
7. SGRQ - Return Rate / Change from Baseline ... 77
Table 7.1 SGRQ - Return Rate (FAS) ... 77
Table 7.2a SGRQ - Change from Baseline (as observed) (FAS) ... 78
Table 7.2b SGRQ - Change from Baseline (LOCF) (FAS) ... 79
Table 7.3a SGRQ - Change from Baseline by Age (as observed) (FAS) ... 81
Table 7.3b SGRQ - Change from Baseline by Age (LOCF) (FAS) ... 84
Table 7.4a SGRQ - Change from Baseline by Gender (as observed) (FAS) ... 87
Table 7.4b SGRQ - Change from Baseline by Gender (LOCF) (FAS) ... 90
Table 7.5a SGRQ - Change from Baseline by Region (as observed) (FAS) ... 93
Table 7.5b SGRQ - Change from Baseline by Region (LOCF) (FAS) ... 97
Table 7.6a SGRQ - Change from Baseline by History of Asthma Exacerbation (as observed) (FAS) ... 101
Table 7.6b SGRQ - Change from Baseline by History of Asthma Exacerbation (LOCF) (FAS) ... 104
8. SGRQ - Responder Analysis ... 107
Table 8.1 SGRQ - Responder Analysis (LOCF) (FAS) ... 107
Table 8.2 SGRQ - Responder Analysis by Age (LOCF) (FAS) ... 108
Table 8.3 SGRQ - Responder Analysis by Gender (LOCF) (FAS) ... 109
Table 8.4 SGRQ - Responder Analysis by Region (LOCF) (FAS) ... 110
Table 8.5 SGRQ - Responder Analysis by History of Asthma Exacerbation (LOCF) (FAS) ... 111
9. E-Diary - Symptoms ... 112
Table 9.1 Symptoms - Documentation Rate (FAS) ... 112
Table 9.2 Symptoms - Change from Baseline (FAS) ... 120
Table 9.3 Symptoms - Change from Baseline by Age (FAS) ... 126
Table 9.4 Symptoms - Change from Baseline by Gender (FAS) ... 144
Table 9.5 Symptoms - Change from Baseline by Region (FAS) ... 157
Table 9.6 Symptoms - Change from Baseline by History of Asthma Exacerbation (FAS) ... 180
10. E-Diary - Rescue Medication ... 193
Table 10.1 Rescue Medication - Documentation Rate (FAS) ... 193
Table 10.2 Rescue Medication - Change from Baseline (FAS) ... 195
Table 10.3 Rescue Medication - Change from Baseline by Age (FAS) ... 197
Table 10.4 Rescue Medication - Change from Baseline by Gender (FAS) ... 201
Table 10.5 Rescue Medication - Change from Baseline by Region (FAS) ... 204
Table 10.6 Rescue Medication - Change from Baseline by History of Asthma Exacerbation (FAS) ... 210
11. Exacerbations - Time-to-event Analysis ... 213

Table 11.1 Exacerbations - Time-to-event Analysis (FAS) ... 213
Table 11.2 Exacerbations - Time-to-event Analysis by Age (FAS) ... 215
Table 11.3 Exacerbations - Time-to-event Analysis by Gender (FAS) ... 220
Table 11.4 Exacerbations - Time-to-event Analysis by Region (FAS) ... 224
Table 11.5 Exacerbations - Time-to-event Analysis by History of Asthma Exacerbation (FAS) ... 231
12. Exacerbations - Annualized Exacerbation Rate ... 235
Table 12.1 Exacerbations - Annualized Exacerbation Rate (FAS) ... 235
Table 12.2 Exacerbations - Annualized Exacerbation Rate by Age (FAS) ... 237
Table 12.3 Exacerbations - Annualized Exacerbation Rate by Gender (FAS) ... 241
Table 12.4 Exacerbations - Annualized Exacerbation Rate by Region (FAS) ... 245
Table 12.5 Exacerbations - Annualized Exacerbation Rate by History of Asthma Exacerbation (FAS) ... 251
13. Adverse Events - Binary Analysis (SAF) ... 254
Table 13.1 Adverse Events - Binary Analysis (SAF) ... 254
Table 13.2 Adverse Events - Binary Analysis by Age (SAF) ... 255
Table 13.3 Adverse Events - Binary Analysis by Gender (SAF) ... 257
Table 13.4 Adverse Events - Binary Analysis by Region (SAF) ... 259
Table 13.5 Adverse Events - Binary Analysis by History of Asthma Exacerbation (SAF) ... 261
14. Any AE by SOC and PT - Binary Analysis (SAF) ... 263
Table 14.1 Any AE by SOC, PT and Severity - Binary Analysis (SAF) ... 263
Table 14.2 Any AE by SOC and PT - Binary Analysis by Age (SAF) ... 266
Table 14.3 Any AE by SOC and PT - Binary Analysis by Gender (SAF) ... 268
Table 14.4 Any AE by SOC and PT - Binary Analysis by Region (SAF) ... 269
Table 14.5 Any AE by SOC and PT - Binary Analysis by History of Asthma Exacerbation (SAF) ... 271
Table 14.7 Any severe AE by SOC and PT - Binary Analysis by Age (SAF) ... 272
Table 14.8 Any severe AE by SOC and PT - Binary Analysis by Gender (SAF) ... 273
Table 14.9 Any severe AE by SOC and PT - Binary Analysis by Region (SAF) ... 274
Table 14.10 Any severe AE by SOC and PT - Binary Analysis by History of Asthma Exacerbation (SAF) ... 275
15. Any SAE by SOC and PT - Binary Analysis (SAF) ... 276
Table 15.1 Any SAE by SOC and PT - Binary Analysis (SAF) ... 276
Table 15.2 Any SAE by SOC and PT - Binary Analysis by Age (SAF) ... 277
Table 15.3 Any SAE by SOC and PT - Binary Analysis by Gender (SAF) ... 278
Table 15.4 Any SAE by SOC and PT - Binary Analysis by Region (SAF) ... 279
Table 15.5 Any SAE by SOC and PT - Binary Analysis by History of Asthma Exacerbation (SAF) 280
16. Any AE leading to Study Discontinuation by SOC and PT - Binary Analysis ... 281
Table 16.1 Any AE leading to Study Discontinuation by SOC and PT - Binary Analysis (SAF) ... 281
17. Any AE leading to Study Drug Discontinuation by SOC and PT - Binary Analysis ... 282
Table 17.1 Any AE leading to Study Drug Discontinuation by SOC and PT - Binary Analysis (SAF) ... 282
18. AESI - Binary Analysis (SAF) ... 283

Table 18.1 AESI by Severity - Binary Analysis (SAF) ... 283
Table 18.2 AESI - Binary Analysis by Age (SAF) ... 290
Table 18.3 AESI - Binary Analysis by Gender (SAF) ... 291
Table 18.4 AESI - Binary Analysis by Region (SAF) ... 292
Table 18.5 AESI - Binary Analysis by History of Asthma Exacerbation (SAF) ... 294
19. Trough FEV1 - Change from Baseline ... 295
Table 19.1 Trough FEV1 - Change from Baseline (FAS) ... 295
Table 19.2 Trough FEV1 - Change from Baseline by Age (FAS) ... 296
Table 19.3 Trough FEV1 - Change from Baseline by Gender (FAS) ... 298
Table 19.4 Trough FEV1 - Change from Baseline by Region (FAS) ... 300
Table 19.5 Trough FEV1 - Change from Baseline by History of Asthma Exacerbation (FAS) ... 302
Figures ... 304
3. Boxplot: ACQ-5 - Change from Baseline (FAS) ... 304
3.1 Boxplot: ACQ-5 - Change from Baseline (FAS) ... 304
3.2 Boxplot: ACQ-5 - Change from Baseline by Age (FAS) ... 305
3.3 Boxplot: ACQ-5 - Change from Baseline by Gender (FAS) ... 308
3.4 Boxplot: ACQ-5 - Change from Baseline by Region (FAS) ... 310
3.5 Boxplot: ACQ-5 - Change from Baseline by History of Asthma Exacerbation (FAS) ... 314
5. Boxplot: AQLQ-S - Change from Baseline (FAS) ... 316
5.1 Boxplot: AQLQ-S (Total Score) - Change from Baseline (FAS) ... 316
5.2 Boxplot: AQLQ-S (Total Score) - Change from Baseline by Age (FAS) ... 317
5.3 Boxplot: AQLQ-S (Total Score) - Change from Baseline by Gender (FAS) ... 320
5.4 Boxplot: AQLQ-S (Total Score) - Change from Baseline by Region (FAS) ... 322
5.5 Boxplot: AQLQ-S (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 326
5.7 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline (FAS) ... 328
5.8 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by Age (FAS) ... 329
5.9 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by Gender (FAS) ... 332
5.10 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by Region (FAS) ... 334
5.11 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 338
5.13 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline (FAS) ... 340
5.14 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by Age (FAS) ... 341
5.15 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by Gender (FAS) ... 344
5.16 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by Region (FAS) ... 346
5.17 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 350
5.19 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline (FAS) ... 352
5.20 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by Age (FAS) ... 353
5.21 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by Gender (FAS) ... 356
5.22 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by Region (FAS) ... 358

5.23 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 362
5.25 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline (FAS) ... 364
5.26 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Age (FAS) ... 365
5.27 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Gender (FAS) ... 368
5.28 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Region (FAS) ... 370
5.29 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 374
7. Boxplot: SGRQ - Change from Baseline (FAS) ... 376
7.1 Boxplot: SGRQ (Total Score) - Change from Baseline (FAS) ... 376
7.2 Boxplot: SGRQ (Total Score) - Change from Baseline by Age (FAS) ... 377
7.3 Boxplot: SGRQ (Total Score) - Change from Baseline by Gender (FAS) ... 380
7.4 Boxplot: SGRQ (Total Score) - Change from Baseline by Region (FAS) ... 382
7.5 Boxplot: SGRQ (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 386
7.7 Boxplot: SGRQ (Symptoms Score) - Change from Baseline (FAS) ... 388
7.8 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by Age (FAS) ... 389
7.9 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by Gender (FAS) ... 392
7.10 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by Region (FAS) ... 394
7.11 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 398
7.13 Boxplot: SGRQ (Activity Score) - Change from Baseline (FAS) ... 400
7.14 Boxplot: SGRQ (Activity Score) - Change from Baseline by Age (FAS) ... 401
7.15 Boxplot: SGRQ (Activity Score) - Change from Baseline by Gender (FAS) ... 404
7.16 Boxplot: SGRQ (Activity Score) - Change from Baseline by Region (FAS) ... 406
7.17 Boxplot: SGRQ (Activity Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 410
7.19 Boxplot: SGRQ (Impacts Score) - Change from Baseline (FAS) ... 412
7.20 Boxplot: SGRQ (Impacts Score) - Change from Baseline by Age (FAS) ... 413
7.21 Boxplot: SGRQ (Impacts Score) - Change from Baseline by Gender (FAS) ... 416
7.22 Boxplot: SGRQ (Impacts Score) - Change from Baseline by Region (FAS) ... 418
7.23 Boxplot: SGRQ (Impacts Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 422
9. Boxplot: Symptoms - Change from Baseline (FAS) ... 424
9.1 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline (FAS) ... 424
9.2 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Age (FAS) ... 425
9.3 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Gender (FAS) ... 428
9.4 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Region (FAS) ... 430
9.5 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 434

9.7 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline (FAS) ... 436

9.8 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Age (FAS) ... 437

9.9 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Gender (FAS) ... 440

9.10 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Region (FAS) ... 442

9.11 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 446

9.13 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline (FAS) ... 448

9.14 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Age (FAS) ... 449

9.15 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Gender (FAS) ... 452

9.16 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Region (FAS) ... 454

9.17 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 458

9.19 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline (FAS) ... 460

9.20 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Age (FAS) ... 461

9.21 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Gender (FAS) ... 464

9.22 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Region (FAS) ... 466

9.23 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 470

9.25 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline (FAS) ... 472

9.26 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Age (FAS) ... 473

9.27 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Gender (FAS) ... 476

9.28 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Region (FAS) ... 478

9.29 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 482

9.31 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline (FAS) ... 484

9.32 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Age (FAS) 485

9.33 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Gender (FAS) ... 488

9.34 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Region (FAS) ... 490

9.35 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 494

9.37 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline (FAS) 496

9.38 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Age (FAS) 497

9.39 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Gender (FAS) 500

9.40 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Region (FAS) 502

9.41 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS) 506

9.43 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline (FAS) 508

9.44 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Age (FAS) 509

9.45 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Gender (FAS) 512

9.46 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Region (FAS) 514

9.47 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by History of Asthma Exacerbation (FAS) 518

9.49 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline (FAS) 520

9.50 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Age (FAS) 521

9.51 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Gender (FAS) 524

9.52 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Region (FAS) 526

9.53 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by History of Asthma Exacerbation (FAS) 530

9.55 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline (FAS) 532

9.56 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Age (FAS) 533

9.57 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Gender (FAS) 536

9.58 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Region (FAS) 538

9.59 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by History of Asthma Exacerbation (FAS) .. 542

9.61 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline (FAS) 544

9.62 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Age (FAS) 545

9.63 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Gender (FAS) 548

9.64 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Region (FAS) 550

9.65 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 554

9.67 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline (FAS) ... 556

9.68 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Age (FAS) ... 557

9.69 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Gender (FAS) ... 560

9.70 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Region (FAS) ... 562

9.71 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 566

9.73 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline (FAS) ... 568

9.74 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Age (FAS) ... 569

9.75 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Gender (FAS) ... 572

9.76 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Region (FAS) ... 574

9.77 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 578

9.79 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline (FAS) ... 580

9.80 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Age (FAS) ... 581

9.81 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Gender (FAS) ... 584

9.82 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Region (FAS) ... 586

9.83 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 590

10. Boxplot: Rescue Medication Change from Baseline (FAS) ... 592

10.1 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline (FAS) ... 592

10.2 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by Age (FAS) ... 593

10.3 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by Gender (FAS) ... 596

10.4 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by Region (FAS) ... 598

10.5 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 602

10.7 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline (FAS) ... 604

10.8 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by Age (FAS) ... 605

10.9 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by Gender (FAS) ... 608

10.10 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by Region (FAS) ... 610

10.11 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 614

10.13 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline (FAS) ... 616

10.14 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by Age (FAS) ... 617

10.15 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by Gender (FAS) ... 620

10.16 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by Region (FAS) ... 622

10.17 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by History of Asthma Exacerbation (FAS) ... 626

11. Kaplan-Meier-Plot: Asthma exacerbations (FAS) ... 628

11.1 Kaplan-Meier-Plot: Asthma Exacerbation (All) (FAS) ... 628

11.2 Kaplan-Meier-Plot: Asthma Exacerbation (All) by Age (FAS) ... 629

11.3 Kaplan-Meier-Plot: Asthma Exacerbation (All) by Gender (FAS) ... 632

11.4 Kaplan-Meier-Plot: Asthma Exacerbation (All) by Region (FAS) ... 634

11.5 Kaplan-Meier-Plot: Asthma Exacerbation (All) by History of Asthma Exacerbation (FAS) ... 638

11.7 Kaplan-Meier-Plot: Severe Asthma Exacerbation (FAS) ... 640

11.8 Kaplan-Meier-Plot: Severe Asthma Exacerbation by Age (FAS) ... 641

11.9 Kaplan-Meier-Plot: Severe Asthma Exacerbation by Gender (FAS) ... 644

11.10 Kaplan-Meier-Plot: Severe Asthma Exacerbation by Region (FAS) ... 646

11.11 Kaplan-Meier-Plot: Severe Asthma Exacerbation by History of Asthma Exacerbation (FAS) 650

11.13 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS) ... 652

11.14 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by Age (FAS) ... 653

11.15 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by Gender (FAS) ... 656

11.16 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by Region (FAS) ... 658

11.17 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by History of Asthma Exacerbation (FAS) ... 662

11.19 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS) ... 664

11.20 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by Age (FAS) ... 665

11.21 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by Gender (FAS) ... 668

11.22 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by Region (FAS) ... 670

11.23 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by History of Asthma Exacerbation (FAS) ... 674

11.25 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation (FAS) 676
11.26 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by Age (FAS) 677
11.27 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by Gender (FAS) 680
11.28 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by Region (FAS) 682
11.29 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by History of Asthma Exacerbation (FAS) 686
11.31 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation (FAS) 688
11.32 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by Age (FAS) 689
11.33 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by Gender (FAS) 692
11.34 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by Region (FAS) 694
11.35 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by History of Asthma Exacerbation (FAS) 698

Tables

1. Patient Disposition and Baseline Characteristics

Table 1.1 Patient Disposition and Compliance (RAN, FAS)

	Treatment groups		
Disposition/Reason (RAN/SAF)	**IND/GLY/ MF 160 n (%)**	**SAL/FLU + TIO n (%)**	**Total n (%)**
Randomized (RAN)	**230 (100,0)**	**241 (100,0)**	**471 (100,0)**
Full Analysis Set (FAS)	**230 (100,0)**	**240 (99,6)**	**470 (99,8)**
Reasons for exclusion			
Subject was randomized but did not receive any study drug	0 (0,0)	1 (0,4)	1 (0,2)
Study Discontinuation (FAS)	**4 (1,7)**	**7 (2,9)**	**11 (2,3)**
Reasons for study discontinuation			
Subject/guardian decision	**2 (0,9)**	**5 (2,1)**	**7 (1,5)**
Adverse event	**1 (0,4)**	**0 (0,0)**	**1 (0,2)**
Dysphonia	1 (0,4)	0 (0,0)	1 (0,2)
Physician decision	**0 (0,0)**	**1 (0,4)**	**1 (0,2)**
Pregnancy	**1 (0,4)**	**0 (0,0)**	**1 (0,2)**
Protocol deviation	**0 (0,0)**	**1 (0,4)**	**1 (0,2)**
Selection criteria not met	0 (0,0)	1 (0,4)	1 (0,2)
Treatment Discontinuation (FAS)	**5 (2,2)**	**13 (5,4)**	**18 (3,8)**
Discontinued study directly afterwards	0 (0,0)	4 (1,7)	4 (0,8)
Continued in study for a while	4 (1,7)	3 (1,2)	7 (1,5)
Completed study	1 (0,4)	6 (2,5)	7 (1,5)
Primary reason for discontinuation from study treatment			
Subject/guardian decision	1 (0,4)	6 (2,5)	7 (1,5)
Technical problems	0 (0,0)	5 (2,1)	5 (1,1)
Adverse event	2 (0,9)	0 (0,0)	2 (0,4)
Physician decision	0 (0,0)	2 (0,8)	2 (0,4)
Pregnancy	2 (0,9)	0 (0,0)	2 (0,4)

Percentages refer to the number of randomized patients.

Analysis population: B2306 RAN subpopulation "mid-dose ICS/LABA"

Table 1.2 Demographic Patient Characteristics (FAS)

	Treatment Groups		
Demographic Patient Characteristics (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
Age (years)			
Mean ± SD	51,9 ± 13,60	52,4 ± 13,57	52,1 ± 13,58
Median	53,0	54,0	53,5
Range	21 to 81	18 to 81	18 to 81
Age group (years), n (%)			
18-39 years	44 (19,1)	40 (16,7)	84 (17,9)
40-64 years	144 (62,6)	155 (64,6)	299 (63,6)
>64 years	42 (18,3)	45 (18,8)	87 (18,5)
Sex, n (%)			
Male	97 (42,2)	88 (36,7)	185 (39,4)
Female	133 (57,8)	152 (63,3)	285 (60,6)
Ethnicity, n (%)			
Hispanic or Latino	58 (25,2)	74 (30,8)	132 (28,1)
East Asian	1 (0,4)	1 (0,4)	2 (0,4)
Southeast Asian	21 (9,1)	21 (8,8)	42 (8,9)
South Asian	2 (0,9)	0 (0,0)	2 (0,4)
West Asian	3 (1,3)	6 (2,5)	9 (1,9)
Russian	53 (23,0)	54 (22,5)	107 (22,8)
Mixed Ethnicity	5 (2,2)	2 (0,8)	7 (1,5)
Not Reported	6 (2,6)	3 (1,3)	9 (1,9)
Unknown	6 (2,6)	1 (0,4)	7 (1,5)
Other	75 (32,6)	78 (32,5)	153 (32,6)
Weight (kg)			
Mean ± SD	78,7 ± 17,50	78,0 ± 16,42	78,4 ± 16,94
Median	77,2	78,0	77,6
Range	42,2 to 144,0	36,1 to 143,0	36,1 to 144,0
BMI (kg/m^2)			
Mean ± SD	28,6 ± 5,57	28,5 ± 5,53	28,5 ± 5,55
Median	28,5	27,8	28,3
Range	16,5 to 49,3	15,2 to 51,9	15,2 to 51,9
Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"			

Table 1.3 Asthma Related Patient Characteristics (FAS)

	Treatment Groups		
Asthma Patient Characteristics (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
Duration of asthma (years)			
Mean ± SD	19,8 ± 15,27	19,3 ± 13,81	19,5 ± 14,53
Median	17,2	16,5	16,8
Range	0,7 to 68,9	0,7 to 70,8	0,7 to 70,8
Duration of asthma (years), n (%)			
< 1 year	5 (2,2)	5 (2,1)	10 (2,1)
1 - 5 years	38 (16,5)	26 (10,8)	64 (13,6)
>5 - 10 years	39 (17,0)	44 (18,3)	83 (17,7)
>10 - 15 years	20 (8,7)	37 (15,4)	57 (12,1)
>15 - 20 years	22 (9,6)	29 (12,1)	51 (10,9)
>20 years	106 (46,1)	99 (41,3)	205 (43,6)
Number of asthma exacerbations in the 12 months prior to study start that required treatment, n (%)			
1	196 (85,2)	198 (82,5)	394 (83,8)
2	24 (10,4)	33 (13,8)	57 (12,1)
3	5 (2,2)	8 (3,3)	13 (2,8)
≥ 4	5 (2,2)	1 (0,4)	6 (1,3)
Smoking history, n (%)			
Never smoked	172 (74,8)	186 (77,5)	358 (76,2)
Ex-smoker	50 (21,7)	48 (20,0)	98 (20,9)
Current smoker	8 (3,5)	6 (2,5)	14 (3,0)
Amount of tobacco consumed on average (in pack years)			
Mean ± SD	6,7 ± 4,35	6,3 ± 4,67	6,5 ± 4,49
Median	6,4	5,3	6,0
Range	0,3 to 16,0	0,3 to 19,0	0,3 to 19,0
Time since smoking stopped (years)			
Mean ± SD	15,8 ± 14,36	15,2 ± 11,77	15,5 ± 13,09
Median	11,8	13,0	12,9
Range	0,3 to 58,7	0,6 to 48,2	0,3 to 58,7

	Treatment Groups		
Asthma Patient Characteristics (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
Systolic blood pressure (mmHg)			
Mean ± SD	125,3 ± 13,26	125,4 ± 13,06	125,4 ± 13,15
Median	125,5	125,0	125,0
Range	80 to 197	94 to 169	80 to 197
Diastolic blood pressure (mmHg)			
Mean ± SD	77,1 ± 8,84	77,3 ± 8,29	77,2 ± 8,55
Median	78,0	78,0	78,0
Range	50 to 106	52 to 99	50 to 106
Pulse rate (beats per minute)			
Mean ± SD	71,7 ± 9,15	73,5 ± 8,93	72,6 ± 9,07
Median	72,0	73,0	72,0
Range	47 to 93	50 to 98	47 to 98
QTcF (ms)			
Mean ± SD	405,6 ± 19,13	403,1 ± 20,15	404,3 ± 19,68
Median	406,0	404,0	405,0
Range	355 to 454	348 to 450	348 to 454
AQLQ-S total score			
Mean ± SD	4,7 ± 0,86	4,7 ± 0,91	4,7 ± 0,88
Median	4,7	4,6	4,7
Range	2,2 to 6,9	1,6 to 6,8	1,6 to 6,9
Baseline AQLQ-S score, n (%)			
<0.5	0 (0,0)	0 (0,0)	0 (0,0)
0.5 - <1	0 (0,0)	0 (0,0)	0 (0,0)
1 - <1.5	0 (0,0)	0 (0,0)	0 (0,0)
1.5 - <2	0 (0,0)	1 (0,4)	1 (0,2)
≥ 2	230 (100,0)	239 (99,6)	469 (99,8)
ACQ-5 total score			
Mean ± SD	2,5 ± 0,62	2,6 ± 0,64	2,5 ± 0,63
Median	2,4	2,4	2,4
Range	1,0 to 4,2	1,2 to 4,8	1,0 to 4,8
Baseline ACQ-5 score, n (%)			
<1.5	10 (4,3)	1 (0,4)	11 (2,3)
1.5 - <2	27 (11,7)	30 (12,5)	57 (12,1)
2 - <2.5	92 (40,0)	100 (41,7)	192 (40,9)

	Treatment Groups		
Asthma Patient Characteristics (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
≥ 2.5	101 (43,9)	109 (45,4)	210 (44,7)
ACQ-7 total score			
Mean ± SD	2,5 ± 0,51	2,6 ± 0,55	2,6 ± 0,53
Median	2,6	2,6	2,6
Range	1,3 to 4,0	1,6 to 4,6	1,3 to 4,6
Baseline ACQ-7 score, n (%)			
<1.5	1 (0,4)	0 (0,0)	1 (0,2)
1.5 - <2	28 (12,2)	19 (7,9)	47 (10,0)
2 - <2.5	82 (35,7)	94 (39,2)	176 (37,4)
≥ 2.5	119 (51,7)	127 (52,9)	246 (52,3)
SGRQ total score			
Mean ± SD	39,1 ± 17,54	40,0 ± 18,86	39,6 ± 18,21
Median	37,4	39,2	39,0
Range	0,8 to 89,4	0,0 to 96,1	0,0 to 96,1
Baseline eosinophils count (cells/µL)			
Mean ± SD	358,8 ± 335,82	357,1 ± 309,14	357,9 ± 322,12
Median	265,0	260,0	260,0
Range	20 to 2970	0 to 1670	0 to 2970
Baseline eosinophils count (cells/µL), n (%)			
<300	126 (54,8)	137 (57,1)	263 (56,0)
≥ 300	102 (44,3)	101 (42,1)	203 (43,2)
missing	2 (0,9)	2 (0,8)	4 (0,9)
ICS component background theapy, n (%)			
Low-dose ICS/LABA	0 (0,0)	0 (0,0)	0 (0,0)
Mid-dose ICS/LABA	230 (100,0)	240 (100,0)	470 (100,0)
High-dose ICS/LABA	0 (0,0)	0 (0,0)	0 (0,0)
FEV1 reversibility (%)			
Mean ± SD	27,8 ± 17,99	29,0 ± 19,62	28,4 ± 18,84
Median	22,0	22,0	22,0
Range	0 to 138	12 to 164	0 to 164
FEV1 reversibility (%), n (%)			
<40%	174 (75,7)	187 (77,9)	361 (76,8)
40% - <50%	21 (9,1)	13 (5,4)	34 (7,2)
50% - <60%	9 (3,9)	13 (5,4)	22 (4,7)

	Treatment Groups		
Asthma Patient Characteristics (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
60% - <70%	4 (1,7)	8 (3,3)	12 (2,6)
70% - <80%	3 (1,3)	6 (2,5)	9 (1,9)
≥ 80%	5 (2,2)	5 (2,1)	10 (2,1)
missing	14 (6,1)	8 (3,3)	22 (4,7)
FEV1 predicted			
Mean ± SD	64,0 ± 12,83	63,4 ± 14,32	63,7 ± 13,60
Median	66,3	66,0	66,0
Range	26 to 86	23 to 85	23 to 86
FEV1 predicted (%), n (%)			
≤ 60%	82 (35,7)	85 (35,4)	167 (35,5)
>60%	148 (64,3)	154 (64,2)	302 (64,3)
missing	0 (0,0)	1 (0,4)	1 (0,2)
IgE level (IU/ml), n (%)			
≤ 75	82 (35,7)	73 (30,4)	155 (33,0)
>75 - ≤1500	124 (53,9)	146 (60,8)	270 (57,4)
>1500	18 (7,8)	13 (5,4)	31 (6,6)
missing	6 (2,6)	8 (3,3)	14 (3,0)
Concomitant asthma medication at baseline, n (%)			
ICS/LABA Fixcombination	0 (0,0)	0 (0,0)	0 (0,0)
LABA	0 (0,0)	0 (0,0)	0 (0,0)
LABA/LAMA	0 (0,0)	0 (0,0)	0 (0,0)
LAMA	0 (0,0)	0 (0,0)	0 (0,0)
LTRA	21 (9,1)	25 (10,4)	46 (9,8)
Mepolizumab	1 (0,4)	1 (0,4)	2 (0,4)
OCS	0 (0,0)	1 (0,4)	1 (0,2)
Omalizumab	1 (0,4)	2 (0,8)	3 (0,6)
Reslizumab	0 (0,0)	1 (0,4)	1 (0,2)
SABA	0 (0,0)	1 (0,4)	1 (0,2)
SAMA	0 (0,0)	0 (0,0)	0 (0,0)
Other	11 (4,8)	9 (3,8)	20 (4,3)

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 1.4 Duration of Study Participation (FAS)

	Treatment Groups		
Duration of Study Participation (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
Study participation			
Mean ± SD (in days)	195,7 ± 12,78	196,1 ± 16,20	195,9 ± 14,61
Median (in days)	196,0	197,0	196,5
Minimum, Maximum (in days)	85 to 225	79 to 238	79 to 238
Study participation on treatment			
Mean ± SD (in days)	167,8 ± 18,67	166,9 ± 19,98	167,3 ± 19,33
Median (in days)	169,0	169,0	169,0
Minimum, Maximum (in days)	1 to 190	46 to 203	1 to 203

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"
Study participation was defined as the time from date of informed consent up to the end of follow-up epoch resp. treatment epoch

Table 1.5 Overview Subgroups (FAS)

	Treatment Groups		
Overview Subgroups (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
Age			
18-39	44	40	84
40-64	144	155	299
>64	42	45	87
Gender			
male	97	88	185
female	133	152	285
Region			
Asia	70	72	142
Europe	83	85	168
Latin America	61	75	136
Others	16	8	24
History of asthma exacerbation in the 12 months prior to screening			
1	196	198	394
≥ 2	34	42	76
Patients' prior therapies for at least 1 month prior to visit 1			
mid dose ICS/LABA	230	240	470
Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"			

Table 1.6 OCS Use (FAS)

	Treatment Groups		
OCS Use (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
OCS use at baseline			
At least one OCS			
n (%)	0 (0,0)	1 (0,4)	1 (0,2)
PREDNISONE			
n (%)	0 (0,0)	1 (0,4)	1 (0,2)
OCS dosage (mg/day)			
Mean ± SD		10,0 ± N.E.	10,0 ± N.E.
Median		10,0	10,0
Escalation of OCS during study			
At least one OCS			
n (%)	0 (0,0)	0 (0,0)	0 (0,0)
New onset of OCS during study			
At least one OCS			
n (%)	24 (10,4)	32 (13,3)	56 (11,9)
BETAMETHASONE			
n (%)	0 (0,0)	1 (0,4)	1 (0,2)
OCS dosage (mg/day)			
Mean ± SD		3,6 ± N.E.	3,6 ± N.E.
Median		3,6	3,6
Duration of use (days)			
Mean ± SD		11,0 ± N.E.	11,0 ± N.E.
Median		11,0	11,0
DEFLAZACORT			
n (%)	1 (0,4)	0 (0,0)	1 (0,2)
OCS dosage (mg/day)			
Mean ± SD	30,0 ± N.E.		30,0 ± N.E.
Median	30,0		30,0
Duration of use (days)			
Mean ± SD	9,0 ± N.E.		9,0 ± N.E.
Median	9,0		9,0
MEPREDNISONE			
n (%)	3 (1,3)	2 (0,8)	5 (1,1)

	Treatment Groups		
OCS Use (FAS)	**IND/GLY/ MF 160 (N=230)**	**SAL/FLU + TIO (N=240)**	**Total (N=470)**
OCS dosage (mg/day)			
Mean ± SD	27,8 ± 10,72	38,0 ± 2,83	31,9 ± 9,53
Median	23,3	38,0	36,0
Duration of use (days)			
Mean ± SD	5,3 ± 0,58	14,0 ± 8,49	8,8 ± 6,38
Median	5,0	14,0	6,0
METHYLPREDNISOLONE			
n (%)	6 (2,6)	11 (4,6)	17 (3,6)
OCS dosage (mg/day)			
Mean ± SD	25,6 ± 11,20	19,7 ± 8,62	21,8 ± 9,70
Median	28,0	16,0	20,0
Duration of use (days)			
Mean ± SD	8,2 ± 5,04	7,7 ± 3,00	7,9 ± 3,69
Median	6,0	8,0	6,0
PREDNISOLONE			
n (%)	9 (3,9)	8 (3,3)	17 (3,6)
OCS dosage (mg/day)			
Mean ± SD	30,9 ± 8,82	29,7 ± 17,03	30,3 ± 12,89
Median	31,1	20,0	30,0
Duration of use (days)			
Mean ± SD	5,8 ± 2,17	7,3 ± 5,65	6,5 ± 4,11
Median	5,0	6,0	5,0
PREDNISONE			
n (%)	6 (2,6)	10 (4,2)	16 (3,4)
OCS dosage (mg/day)			
Mean ± SD	35,6 ± 4,98	40,0 ± 10,54	38,4 ± 8,93
Median	36,9	40,0	40,0
Duration of use (days)			
Mean ± SD	4,7 ± 2,34	5,5 ± 2,27	5,2 ± 2,26
Median	4,5	5,0	5,0

An escalation is any daily dose higher than the baseline dose. For the duration of escalation all days with a so defined dose have been summed up, no matter if these days were consecutive or not.
A new onset of OCS is any post-baseline onset of OCS in patients who have no OCS use at baseline. For the duration of use all days of post-baseline OCS use have been summed up, no matter if these days were consecutive or not.
Medication data up to end of treatment phase have been included.
N.E.: not estimable
Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

2. All-cause Mortality - Binary Analysis

Table 2.1 All-cause Mortality - Binary Analysis (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
Death, n (%)	0 (0,0)	0 (0,0)	-	-	-

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

3. ACQ-5 - Return Rate / Change from Baseline

Table 3.1 ACQ-5 - Return Rate (FAS)

	Treatment groups		
Patient Reported Outcome - Return Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Return Rate*, n (%)			
Baseline Returns	230 (100,0)	240 (100,0)	470 (100,0)
Week 16 Returns	221 (96,1)	227 (94,6)	448 (95,3)
Week 24 Returns	224 (97,4)	228 (95,0)	452 (96,2)

* The return rate is the proportion of patients with non-missing data for the total score at given visit on the whole study population.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 3.2 ACQ-5 - Change from Baseline (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
ACQ-5 score			
N'	224	231	
Baseline Mean (SD)	2,47 (0,625)	2,56 (0,642)	
Week 16:			
Adjusted Mean Change (SE)	-1,17 (0,090)	-1,16 (0,089)	-0,02 [-0,175; 0,138] 0,820
Week 24:			
Adjusted Mean Change (SE)	-1,32 (0,091)	-1,12 (0,091)	-0,20 [-0,362; -0,034] 0,018 *

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 3.3 ACQ-5 - Change from Baseline by Age (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
ACQ-5 score			
Interaction Test	0,685		
Age = 18-39 years			
N'	42	39	
Baseline Mean (SD)	2,38 (0,455)	2,65 (0,656)	
Week 16:			
Adjusted Mean Change (SE)	-1,37 (0,151)	-1,30 (0,156)	-0,07 [-0,439; 0,308] 0,729
Week 24:			
Adjusted Mean Change (SE)	-1,48 (0,157)	-1,11 (0,165)	-0,37 [-0,763; 0,027] 0,068
Age = 40-64 years			
N'	140	150	
Baseline Mean (SD)	2,52 (0,655)	2,55 (0,642)	
Week 16:			
Adjusted Mean Change (SE)	-1,15 (0,098)	-1,12 (0,097)	-0,03 [-0,222; 0,170] 0,797
Week 24:			
Adjusted Mean Change (SE)	-1,30 (0,101)	-1,11 (0,100)	-0,19 [-0,391; 0,021] 0,078
Age = ≥65 years			
N'	42	42	
Baseline Mean (SD)	2,40 (0,666)	2,50 (0,633)	
Week 16:			
Adjusted Mean Change (SE)	-1,09 (0,151)	-1,16 (0,150)	0,08 [-0,289; 0,439] 0,685

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	-1,24 (0,157)	-1,16 (0,156)	-0,08 [-0,460; 0,303] 0,687

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + age + age * treatment + age * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 3.4 ACQ-5 - Change from Baseline by Gender (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
ACQ-5 score			
Interaction Test	0,245		
Gender = Male			
N'	96	85	
Baseline Mean (SD)	2,40 (0,651)	2,51 (0,604)	
Week 16:			
Adjusted Mean Change (SE)	-1,24 (0,109)	-1,12 (0,117)	-0,12 [-0,373; 0,125] 0,329
Week 24:			
Adjusted Mean Change (SE)	-1,38 (0,112)	-1,08 (0,121)	-0,30 [-0,562; -0,041] 0,023 *
Gender = Female			
N'	128	146	
Baseline Mean (SD)	2,52 (0,602)	2,59 (0,662)	
Week 16:			
Adjusted Mean Change (SE)	-1,10 (0,105)	-1,16 (0,098)	0,06 [-0,146; 0,258] 0,588
Week 24:			
Adjusted Mean Change (SE)	-1,25 (0,107)	-1,12 (0,101)	-0,13 [-0,339; 0,085] 0,241

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + gender + gender * treatment + gender * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 3.5 ACQ-5 - Change from Baseline by Region (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
ACQ-5 score			
Interaction Test	0,440		
Region = Asia			
N'	68	71	
Baseline Mean (SD)	2,47 (0,645)	2,57 (0,663)	
Week 16:			
Adjusted Mean Change (SE)	-1,10 (0,103)	-1,08 (0,101)	-0,03 [-0,312; 0,255] 0,843
Week 24:			
Adjusted Mean Change (SE)	-1,22 (0,107)	-0,98 (0,106)	-0,24 [-0,538; 0,054] 0,109
Region = Europe			
N'	79	80	
Baseline Mean (SD)	2,36 (0,571)	2,48 (0,608)	
Week 16:			
Adjusted Mean Change (SE)	-1,24 (0,096)	-1,16 (0,095)	-0,09 [-0,351; 0,180] 0,527
Week 24:			
Adjusted Mean Change (SE)	-1,32 (0,100)	-1,16 (0,099)	-0,16 [-0,435; 0,117] 0,258
Region = Latin America			
N'	61	72	
Baseline Mean (SD)	2,59 (0,635)	2,58 (0,624)	
Week 16:			
Adjusted Mean Change (SE)	-1,30 (0,109)	-1,34 (0,100)	0,04 [-0,253; 0,327] 0,803
Week 24:			
Adjusted Mean Change (SE)	-1,61 (0,113)	-1,31 (0,105)	-0,30 [-0,605; 0,001] 0,051

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Region = Others			
N'	16	8	
Baseline Mean (SD)	2,54 (0,718)	3,05 (0,798)	
Week 16:			
Adjusted Mean Change (SE)	-1,48 (0,212)	-1,90 (0,300)	0,42 [-0,302; 1,140] 0,255
Week 24:			
Adjusted Mean Change (SE)	-1,42 (0,221)	-1,89 (0,314)	0,47 [-0,282; 1,226] 0,219

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 3.6 ACQ-5 - Change from Baseline by History of Asthma Exacerbation (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
ACQ-5 score			
Interaction Test	0,953		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	191	190	
Baseline Mean (SD)	2,47 (0,593)	2,54 (0,620)	
Week 16:			
Adjusted Mean Change (SE)	-1,18 (0,092)	-1,18 (0,093)	-0,00 [-0,175; 0,165] 0,955
Week 24:			
Adjusted Mean Change (SE)	-1,34 (0,094)	-1,13 (0,095)	-0,21 [-0,390; -0,033] 0,020 *
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	2,48 (0,800)	2,64 (0,735)	
Week 16:			
Adjusted Mean Change (SE)	-1,10 (0,165)	-1,03 (0,151)	-0,08 [-0,472; 0,316] 0,697
Week 24:			
Adjusted Mean Change (SE)	-1,18 (0,172)	-1,07 (0,153)	-0,11 [-0,522; 0,293] 0,582

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

4. ACQ-5 - Responder Analysis

Table 4.1a ACQ-5 - Responder Analysis (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	224	231			
ACQ-5 response (decrease of at least 0.5 points), n (%)	196 (87,5)	193 (83,5)	1,42 [0,95; 2,11] 0,085	1,07 [0,99; 1,17] 0,100	0,04 [-0,03; 0,10] 0,230

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.1b ACQ-5 - Responder Analysis (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
ACQ-5 response (decrease of at least 0.5 points), n (%)	199 (86,5)	200 (83,3)	1,32 [0,90; 1,94] 0,149	1,06 [0,98; 1,16] 0,158	0,03 [-0,03; 0,10] 0,333

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.2a ACQ-5 - Responder Analysis by Age (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	p=0,656				
Age = 18-39 years					
N'	42	39			
ACQ-5 response (decrease of at least 0.5 points), n (%)	39 (92,9)	34 (87,2)	1,87 [0,70; 5,00] 0,212	1,14 [0,97; 1,35] 0,101	0,06 [-0,07; 0,19] 0,394
Age = 40-64 years					
N'	140	150			
ACQ-5 response (decrease of at least 0.5 points), n (%)	119 (85,0)	125 (83,3)	1,22 [0,74; 2,00] 0,427	1,04 [0,93; 1,16] 0,480	0,02 [-0,07; 0,10] 0,697
Age = ≥65 years					
N'	42	42			
ACQ-5 response (decrease of at least 0.5 points), n (%)	38 (90,5)	34 (81,0)	1,74 [0,71; 4,28] 0,229	1,12 [0,92; 1,37] 0,249	0,10 [-0,05; 0,24] 0,208

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.2b ACQ-5 - Responder Analysis by Age (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	p=0,467				
Age = 18-39 years					
N'	44	40			
ACQ-5 response (decrease of at least 0.5 points), n (%)	41 (93,2)	35 (87,5)	1,77 [0,68; 4,59] 0,242	1,13 [0,96; 1,32] 0,141	0,06 [-0,07; 0,18] 0,379
Age = 40-64 years					
N'	144	155			
ACQ-5 response (decrease of at least 0.5 points), n (%)	120 (83,3)	129 (83,2)	1,10 [0,68; 1,77] 0,693	1,02 [0,91; 1,14] 0,721	0,00 [-0,08; 0,09] 0,980
Age = ≥65 years					
N'	42	45			
ACQ-5 response (decrease of at least 0.5 points), n (%)	38 (90,5)	36 (80,0)	1,88 [0,78; 4,54] 0,162	1,15 [0,94; 1,41] 0,177	0,10 [-0,04; 0,25] 0,162

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.3a ACQ-5 - Responder Analysis by Gender (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	p=0,530				
Gender = Male					
N'	96	85			
ACQ-5 response (decrease of at least 0.5 points), n (%)	86 (89,6)	71 (83,5)	1,64 [0,89; 3,00] 0,111	1,10 [0,97; 1,25] 0,130	0,06 [-0,04; 0,16] 0,234
Gender = Female					
N'	128	146			
ACQ-5 response (decrease of at least 0.5 points), n (%)	110 (85,9)	122 (83,6)	1,27 [0,76; 2,13] 0,363	1,05 [0,94; 1,18] 0,385	0,02 [-0,06; 0,11] 0,584

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.3b ACQ-5 - Responder Analysis by Gender (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	p=0,860				
Gender = Male					
N'	97	88			
ACQ-5 response (decrease of at least 0.5 points), n (%)	86 (88,7)	74 (84,1)	1,37 [0,76; 2,46] 0,299	1,07 [0,94; 1,21] 0,323	0,05 [-0,05; 0,14] 0,366
Gender = Female					
N'	133	152			
ACQ-5 response (decrease of at least 0.5 points), n (%)	113 (85,0)	126 (82,9)	1,28 [0,78; 2,10] 0,338	1,06 [0,94; 1,19] 0,337	0,02 [-0,06; 0,11] 0,635

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.4a ACQ-5 - Responder Analysis by Region (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	N.E.				
Region = Asia					
N'	68	71			
ACQ-5 response (decrease of at least 0.5 points), n (%)	53 (77,9)	54 (76,1)	1,61 [0,82; 3,15] 0,167	1,14 [0,94; 1,38] 0,199	0,02 [-0,12; 0,16] 0,792
Region = Europe					
N'	79	80			
ACQ-5 response (decrease of at least 0.5 points), n (%)	71 (89,9)	64 (80,0)	1,68 [0,86; 3,27] 0,126	1,13 [0,97; 1,31] 0,118	0,10 [-0,01; 0,21] 0,079
Region = Latin America					
N'	61	72			
ACQ-5 response (decrease of at least 0.5 points), n (%)	58 (95,1)	67 (93,1)	1,11 [0,49; 2,55] 0,798	1,01 [0,91; 1,13] 0,816	0,02 [-0,06; 0,10] 0,619
Region = Others					
N'	16	8			
ACQ-5 response (decrease of at least 0.5 points), n (%)	14 (87,5)	8 (100,0)	0,18 [0,01; 2,65] 0,212	0,91 [0,68; 1,22] 0,527	-0,13 [-0,29; 0,04] 0,131

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
N.E.: not estimable
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit
Exceptional model(s) for OR: ACQ-5 response (decrease of at least 0.5 points): logit(proportion) = treatment + baseline + visit [by region]

Applied model for RR: log(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.4b ACQ-5 - Responder Analysis by Region (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	N.E.				
Region = Asia					
N'	70	72			
ACQ-5 response (decrease of at least 0.5 points), n (%)	54 (77,1)	55 (76,4)	1,55 [0,82; 2,97] 0,181	1,13 [0,93; 1,37] 0,220	0,01 [-0,13; 0,15] 0,915
Region = Europe					
N'	83	85			
ACQ-5 response (decrease of at least 0.5 points), n (%)	73 (88,0)	69 (81,2)	1,38 [0,73; 2,60] 0,324	1,08 [0,93; 1,26] 0,290	0,07 [-0,04; 0,18] 0,222
Region = Latin America					
N'	61	75			
ACQ-5 response (decrease of at least 0.5 points), n (%)	58 (95,1)	68 (90,7)	1,21 [0,55; 2,69] 0,634	1,03 [0,91; 1,16] 0,638	0,04 [-0,04; 0,13] 0,310
Region = Others					
N'	16	8			
ACQ-5 response (decrease of at least 0.5 points), n (%)	14 (87,5)	8 (100,0)	0,18 [0,01; 2,65] 0,212	0,91 [0,68; 1,21] 0,510	-0,13 [-0,29; 0,04] 0,131

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
N.E.: not estimable
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit
Exceptional model(s) for OR: ACQ-5 response (decrease of at least 0.5 points): logit(proportion) = treatment + baseline + visit [by region]

Applied model for RR: log(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.5a ACQ-5 - Responder Analysis by History of Asthma Exacerbation (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	p=0,864				
Asthma exacerbations in the 12 months prior to screening = 1					
N'	191	190			
ACQ-5 response (decrease of at least 0.5 points), n (%)	167 (87,4)	157 (82,6)	1,44 [0,94; 2,22] 0,097	1,08 [0,98; 1,19] 0,104	0,05 [-0,02; 0,12] 0,188
Asthma exacerbations in the 12 months prior to screening = ≥2					
N'	33	41			
ACQ-5 response (decrease of at least 0.5 points), n (%)	29 (87,9)	36 (87,8)	1,32 [0,50; 3,44] 0,575	1,04 [0,85; 1,27] 0,700	0,00 [-0,15; 0,15] 0,992

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 4.5b ACQ-5 - Responder Analysis by History of Asthma Exacerbation (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
ACQ-5 response (decrease of at least 0.5 points)					
Interaction Test:	p=0,880				
Asthma exacerbations in the 12 months prior to screening = 1					
N'	196	198			
ACQ-5 response (decrease of at least 0.5 points), n (%)	170 (86,7)	163 (82,3)	1,34 [0,88; 2,03] 0,171	1,07 [0,97; 1,17] 0,178	0,04 [-0,03; 0,12] 0,225
Asthma exacerbations in the 12 months prior to screening = ≥2					
N'	34	42			
ACQ-5 response (decrease of at least 0.5 points), n (%)	29 (85,3)	37 (88,1)	1,24 [0,49; 3,14] 0,651	1,04 [0,84; 1,29] 0,696	-0,03 [-0,18; 0,13] 0,722

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

5. AQLQ-S - Return Rate / Change from Baseline

Table 5.1 AQLQ-S - Return Rate (FAS)

	Treatment groups		
Patient Reported Outcome - Return Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Return Rate*, n (%)			
Baseline Returns	230 (100,0)	240 (100,0)	470 (100,0)
Week 16 Returns	223 (97,0)	230 (95,8)	453 (96,4)
Week 24 Returns	225 (97,8)	232 (96,7)	457 (97,2)

* The return rate is the proportion of patients with non-missing data for the total score at given visit on the whole study population.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 5.2 AQLQ-S - Change from Baseline (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
N'	226	235	
Baseline Mean (SD)	4,68 (0,862)	4,66 (0,902)	
Week 16:			
Adjusted Mean Change (SE)	0,77 (0,093)	0,74 (0,092)	0,03 [-0,121; 0,179] 0,702
Week 24:			
Adjusted Mean Change (SE)	0,88 (0,094)	0,78 (0,093)	0,10 [-0,055; 0,254] 0,207
Symptoms score			
N'	226	235	
Baseline Mean (SD)	4,71 (0,887)	4,73 (0,879)	
Week 16:			
Adjusted Mean Change (SE)	0,90 (0,097)	0,82 (0,096)	0,09 [-0,070; 0,243] 0,276
Week 24:			
Adjusted Mean Change (SE)	1,01 (0,097)	0,89 (0,097)	0,12 [-0,037; 0,283] 0,133
Activity limitation score			
N'	226	235	
Baseline Mean (SD)	4,65 (0,899)	4,61 (0,910)	
Week 16:			
Adjusted Mean Change (SE)	0,70 (0,097)	0,71 (0,097)	-0,01 [-0,170; 0,152] 0,910
Week 24:			
Adjusted Mean Change (SE)	0,84 (0,097)	0,74 (0,097)	0,09 [-0,068; 0,254] 0,256
Emotional function score			
N'	226	235	
Baseline Mean (SD)	4,93 (1,286)	4,82 (1,343)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 16:			
Adjusted Mean Change (SE)	0,64 (0,112)	0,64 (0,112)	-0,00 [-0,182; 0,179] 0,986
Week 24:			
Adjusted Mean Change (SE)	0,71 (0,116)	0,62 (0,116)	0,09 [-0,109; 0,288] 0,377
Environmental stimuli score			
N'	226	235	
Baseline Mean (SD)	4,33 (1,355)	4,36 (1,419)	
Week 16:			
Adjusted Mean Change (SE)	0,67 (0,128)	0,67 (0,127)	-0,00 [-0,212; 0,211] 0,999
Week 24:			
Adjusted Mean Change (SE)	0,78 (0,129)	0,71 (0,128)	0,07 [-0,150; 0,283] 0,546

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 5.3 AQLQ-S - Change from Baseline by Age (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,974		
Age = 18-39 years			
N'	43	40	
Baseline Mean (SD)	4,97 (0,955)	4,53 (0,751)	
Week 16:			
Adjusted Mean Change (SE)	0,95 (0,147)	0,99 (0,152)	-0,04 [-0,389; 0,317] 0,841
Week 24:			
Adjusted Mean Change (SE)	1,05 (0,151)	0,96 (0,158)	0,09 [-0,280; 0,458] 0,635
Age = 40-64 years			
N'	141	152	
Baseline Mean (SD)	4,60 (0,859)	4,68 (0,956)	
Week 16:			
Adjusted Mean Change (SE)	0,74 (0,100)	0,71 (0,099)	0,04 [-0,149; 0,225] 0,693
Week 24:			
Adjusted Mean Change (SE)	0,84 (0,101)	0,75 (0,100)	0,09 [-0,100; 0,288] 0,342
Age = ≥65 years			
N'	42	43	
Baseline Mean (SD)	4,63 (0,719)	4,70 (0,838)	
Week 16:			
Adjusted Mean Change (SE)	0,72 (0,149)	0,68 (0,148)	0,04 [-0,306; 0,389] 0,815
Week 24:			
Adjusted Mean Change (SE)	0,88 (0,153)	0,77 (0,151)	0,11 [-0,250; 0,469] 0,550

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Symptoms score			
Interaction Test	0,763		
Age = 18-39 years			
N'	43	40	
Baseline Mean (SD)	4,96 (0,923)	4,65 (0,825)	
Week 16:			
Adjusted Mean Change (SE)	1,09 (0,154)	1,09 (0,159)	0,00 [-0,367; 0,370] 0,994
Week 24:			
Adjusted Mean Change (SE)	1,19 (0,156)	1,03 (0,164)	0,16 [-0,223; 0,539] 0,416
Age = 40-64 years			
N'	141	152	
Baseline Mean (SD)	4,66 (0,849)	4,77 (0,907)	
Week 16:			
Adjusted Mean Change (SE)	0,88 (0,104)	0,76 (0,103)	0,12 [-0,071; 0,320] 0,213
Week 24:			
Adjusted Mean Change (SE)	0,99 (0,105)	0,84 (0,104)	0,15 [-0,050; 0,351] 0,142
Age = ≥65 years			
N'	42	43	
Baseline Mean (SD)	4,61 (0,949)	4,66 (0,833)	
Week 16:			
Adjusted Mean Change (SE)	0,82 (0,156)	0,80 (0,155)	0,01 [-0,349; 0,378] 0,938
Week 24:			
Adjusted Mean Change (SE)	0,91 (0,159)	0,93 (0,156)	-0,02 [-0,394; 0,348] 0,904

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Activity limitation score			
Interaction Test	0,765		
Age = 18-39 years			
N'	43	40	
Baseline Mean (SD)	4,97 (1,005)	4,56 (0,764)	
Week 16:			
Adjusted Mean Change (SE)	0,89 (0,157)	0,95 (0,162)	-0,06 [-0,445; 0,315] 0,737
Week 24:			
Adjusted Mean Change (SE)	1,04 (0,157)	1,01 (0,165)	0,03 [-0,351; 0,415] 0,870
Age = 40-64 years			
N'	141	152	
Baseline Mean (SD)	4,58 (0,909)	4,61 (0,971)	
Week 16:			
Adjusted Mean Change (SE)	0,67 (0,105)	0,69 (0,104)	-0,02 [-0,221; 0,181] 0,843
Week 24:			
Adjusted Mean Change (SE)	0,77 (0,105)	0,71 (0,104)	0,06 [-0,141; 0,262] 0,557
Age = ≥65 years			
N'	42	43	
Baseline Mean (SD)	4,58 (0,675)	4,64 (0,826)	
Week 16:			
Adjusted Mean Change (SE)	0,67 (0,159)	0,61 (0,158)	0,06 [-0,311; 0,437] 0,739
Week 24:			
Adjusted Mean Change (SE)	0,90 (0,159)	0,67 (0,157)	0,23 [-0,142; 0,604] 0,224

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Emotional function score			
Interaction Test	0,656		
Age = 18-39 years			
N'	43	40	
Baseline Mean (SD)	5,31 (1,216)	4,51 (1,099)	
Week 16:			
Adjusted Mean Change (SE)	0,84 (0,178)	0,77 (0,184)	0,07 [-0,352; 0,502] 0,731
Week 24:			
Adjusted Mean Change (SE)	0,87 (0,190)	0,62 (0,201)	0,25 [-0,225; 0,722] 0,303
Age = 40-64 years			
N'	141	152	
Baseline Mean (SD)	4,86 (1,271)	4,86 (1,415)	
Week 16:			
Adjusted Mean Change (SE)	0,59 (0,121)	0,66 (0,120)	-0,07 [-0,291; 0,160] 0,568
Week 24:			
Adjusted Mean Change (SE)	0,67 (0,127)	0,64 (0,125)	0,03 [-0,218; 0,278] 0,815
Age = ≥65 years			
N'	42	43	
Baseline Mean (SD)	4,78 (1,361)	4,93 (1,270)	
Week 16:			
Adjusted Mean Change (SE)	0,60 (0,181)	0,47 (0,179)	0,13 [-0,289; 0,550] 0,542
Week 24:			
Adjusted Mean Change (SE)	0,74 (0,194)	0,60 (0,191)	0,14 [-0,323; 0,596] 0,559

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Environmental stimuli score			
Interaction Test	0,859		
Age = 18-39 years			
N'	43	40	
Baseline Mean (SD)	4,55 (1,428)	4,12 (1,301)	
Week 16:			
Adjusted Mean Change (SE)	0,85 (0,208)	0,96 (0,215)	-0,11 [-0,615; 0,388] 0,657
Week 24:			
Adjusted Mean Change (SE)	0,88 (0,211)	0,92 (0,222)	-0,04 [-0,557; 0,479] 0,881
Age = 40-64 years			
N'	141	152	
Baseline Mean (SD)	4,18 (1,322)	4,33 (1,448)	
Week 16:			
Adjusted Mean Change (SE)	0,66 (0,139)	0,61 (0,138)	0,05 [-0,217; 0,315] 0,720
Week 24:			
Adjusted Mean Change (SE)	0,77 (0,141)	0,68 (0,139)	0,08 [-0,190; 0,355] 0,552
Age = ≥65 years			
N'	42	43	
Baseline Mean (SD)	4,61 (1,348)	4,68 (1,392)	
Week 16:			
Adjusted Mean Change (SE)	0,58 (0,209)	0,67 (0,209)	-0,09 [-0,580; 0,409] 0,735

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	0,75 (0,214)	0,65 (0,211)	0,10 [-0,407; 0,601] 0,705

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + age + age * treatment + age * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 5.4 AQLQ-S - Change from Baseline by Gender (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,595		
Gender = Male			
N'	96	87	
Baseline Mean (SD)	4,84 (0,849)	4,73 (0,867)	
Week 16:			
Adjusted Mean Change (SE)	0,83 (0,109)	0,76 (0,118)	0,06 [-0,174; 0,304] 0,593
Week 24:			
Adjusted Mean Change (SE)	0,95 (0,111)	0,80 (0,120)	0,15 [-0,097; 0,396] 0,234
Gender = Female			
N'	130	148	
Baseline Mean (SD)	4,56 (0,855)	4,61 (0,922)	
Week 16:			
Adjusted Mean Change (SE)	0,72 (0,107)	0,72 (0,100)	-0,00 [-0,195; 0,193] 0,992
Week 24:			
Adjusted Mean Change (SE)	0,82 (0,109)	0,76 (0,102)	0,06 [-0,141; 0,259] 0,562
Symptoms score			
Interaction Test	0,566		
Gender = Male			
N'	96	87	
Baseline Mean (SD)	4,82 (0,885)	4,77 (0,845)	
Week 16:			
Adjusted Mean Change (SE)	0,99 (0,114)	0,83 (0,123)	0,16 [-0,088; 0,411] 0,204

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	1,08 (0,115)	0,94 (0,124)	0,14 [-0,112; 0,396] 0,274
Gender = Female			
N'	130	148	
Baseline Mean (SD)	4,62 (0,882)	4,71 (0,900)	
Week 16:			
Adjusted Mean Change (SE)	0,83 (0,111)	0,80 (0,104)	0,03 [-0,173; 0,231] 0,779
Week 24:			
Adjusted Mean Change (SE)	0,94 (0,113)	0,84 (0,105)	0,10 [-0,108; 0,307] 0,346
Activity limitation score			
Interaction Test	0,244		
Gender = Male			
N'	96	87	
Baseline Mean (SD)	4,80 (0,901)	4,68 (0,877)	
Week 16:			
Adjusted Mean Change (SE)	0,78 (0,116)	0,72 (0,124)	0,05 [-0,202; 0,310] 0,679
Week 24:			
Adjusted Mean Change (SE)	0,96 (0,116)	0,72 (0,124)	0,23 [-0,021; 0,490] 0,072
Gender = Female			
N'	130	148	
Baseline Mean (SD)	4,55 (0,886)	4,57 (0,930)	
Week 16:			
Adjusted Mean Change (SE)	0,62 (0,113)	0,68 (0,105)	-0,06 [-0,266; 0,149] 0,580
Week 24:			
Adjusted Mean Change (SE)	0,73 (0,113)	0,74 (0,106)	-0,01 [-0,217; 0,199] 0,930

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Emotional function score			
Interaction Test	0,948		
Gender = Male			
N'	96	87	
Baseline Mean (SD)	5,15 (1,247)	5,00 (1,290)	
Week 16:			
Adjusted Mean Change (SE)	0,67 (0,132)	0,67 (0,143)	0,00 [-0,285; 0,291] 0,985
Week 24:			
Adjusted Mean Change (SE)	0,73 (0,140)	0,64 (0,150)	0,10 [-0,220; 0,411] 0,554
Gender = Female			
N'	130	148	
Baseline Mean (SD)	4,76 (1,294)	4,71 (1,366)	
Week 16:			
Adjusted Mean Change (SE)	0,60 (0,130)	0,61 (0,122)	-0,01 [-0,242; 0,225] 0,943
Week 24:			
Adjusted Mean Change (SE)	0,69 (0,136)	0,61 (0,128)	0,08 [-0,174; 0,340] 0,526
Environmental stimuli score			
Interaction Test	0,664		
Gender = Male			
N'	96	87	
Baseline Mean (SD)	4,59 (1,287)	4,39 (1,426)	
Week 16:			
Adjusted Mean Change (SE)	0,67 (0,152)	0,75 (0,164)	-0,08 [-0,418; 0,257] 0,639
Week 24:			
Adjusted Mean Change (SE)	0,80 (0,154)	0,77 (0,166)	0,03 [-0,309; 0,379] 0,843

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Gender = Female			
N'	130	148	
Baseline Mean (SD)	4,14 (1,377)	4,34 (1,419)	
Week 16:			
Adjusted Mean Change (SE)	0,68 (0,148)	0,63 (0,139)	0,05 [-0,226; 0,322] 0,731
Week 24:			
Adjusted Mean Change (SE)	0,76 (0,150)	0,68 (0,140)	0,08 [-0,199; 0,362] 0,570

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + gender + gender * treatment + gender * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 5.5 AQLQ-S - Change from Baseline by Region (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,482		
Region = Asia			
N'	69	71	
Baseline Mean (SD)	4,39 (0,790)	4,38 (0,991)	
Week 16:			
Adjusted Mean Change (SE)	0,74 (0,100)	0,59 (0,099)	0,15 [-0,126; 0,423] 0,288
Week 24:			
Adjusted Mean Change (SE)	0,86 (0,103)	0,58 (0,102)	0,27 [-0,008; 0,557] 0,057
Region = Europe			
N'	80	83	
Baseline Mean (SD)	5,05 (0,814)	4,97 (0,721)	
Week 16:			
Adjusted Mean Change (SE)	0,74 (0,093)	0,71 (0,091)	0,03 [-0,222; 0,286] 0,806
Week 24:			
Adjusted Mean Change (SE)	0,81 (0,096)	0,85 (0,094)	-0,04 [-0,299; 0,224] 0,779
Region = Latin America			
N'	61	73	
Baseline Mean (SD)	4,58 (0,819)	4,61 (0,878)	
Week 16:			
Adjusted Mean Change (SE)	0,92 (0,106)	0,94 (0,097)	-0,03 [-0,308; 0,254] 0,853
Week 24:			
Adjusted Mean Change (SE)	0,98 (0,109)	0,90 (0,100)	0,08 [-0,208; 0,371] 0,582

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Region = Others			
N'	16	8	
Baseline Mean (SD)	4,42 (0,966)	4,23 (1,079)	
Week 16:			
Adjusted Mean Change (SE)	0,89 (0,206)	1,27 (0,291)	-0,39 [-1,087; 0,311] 0,276
Week 24:			
Adjusted Mean Change (SE)	1,34 (0,212)	1,43 (0,300)	-0,09 [-0,809; 0,633] 0,810
Symptoms score			
Interaction Test	0,427		
Region = Asia			
N'	69	71	
Baseline Mean (SD)	4,35 (0,854)	4,41 (0,973)	
Week 16:			
Adjusted Mean Change (SE)	0,84 (0,105)	0,64 (0,104)	0,21 [-0,080; 0,494] 0,158
Week 24:			
Adjusted Mean Change (SE)	0,98 (0,107)	0,69 (0,106)	0,29 [-0,004; 0,584] 0,053
Region = Europe			
N'	80	83	
Baseline Mean (SD)	5,03 (0,808)	4,95 (0,770)	
Week 16:			
Adjusted Mean Change (SE)	0,83 (0,097)	0,79 (0,095)	0,04 [-0,225; 0,307] 0,763
Week 24:			
Adjusted Mean Change (SE)	0,86 (0,100)	0,94 (0,097)	-0,07 [-0,344; 0,200] 0,604
Region = Latin America			
N'	61	73	
Baseline Mean (SD)	4,78 (0,833)	4,83 (0,802)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 16:			
Adjusted Mean Change (SE)	1,04 (0,111)	0,95 (0,101)	0,09 [-0,206; 0,383] 0,554
Week 24:			
Adjusted Mean Change (SE)	1,14 (0,113)	0,95 (0,104)	0,19 [-0,110; 0,492] 0,213
Region = Others			
N'	16	8	
Baseline Mean (SD)	4,38 (1,009)	4,47 (0,984)	
Week 16:			
Adjusted Mean Change (SE)	0,95 (0,216)	1,29 (0,305)	-0,34 [-1,069; 0,394] 0,366
Week 24:			
Adjusted Mean Change (SE)	1,31 (0,221)	1,35 (0,312)	-0,04 [-0,785; 0,715] 0,927
Activity limitation score			
Interaction Test	0,327		
Region = Asia			
N'	69	71	
Baseline Mean (SD)	4,43 (0,807)	4,35 (0,965)	
Week 16:			
Adjusted Mean Change (SE)	0,72 (0,107)	0,56 (0,106)	0,16 [-0,138; 0,450] 0,297
Week 24:			
Adjusted Mean Change (SE)	0,80 (0,106)	0,50 (0,105)	0,30 [0,010; 0,593] 0,043 *
Region = Europe			
N'	80	83	
Baseline Mean (SD)	4,99 (0,897)	4,87 (0,782)	
Week 16:			
Adjusted Mean Change (SE)	0,68 (0,100)	0,70 (0,098)	-0,01 [-0,284; 0,260] 0,929

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	0,84 (0,099)	0,81 (0,096)	0,03 [-0,244; 0,296] 0,849
Region = Latin America			
N'	61	73	
Baseline Mean (SD)	4,49 (0,832)	4,60 (0,916)	
Week 16:			
Adjusted Mean Change (SE)	0,80 (0,113)	0,91 (0,103)	-0,11 [-0,412; 0,190] 0,468
Week 24:			
Adjusted Mean Change (SE)	0,87 (0,112)	0,92 (0,103)	-0,05 [-0,352; 0,245] 0,725
Region = Others			
N'	16	8	
Baseline Mean (SD)	4,52 (1,096)	4,33 (0,998)	
Week 16:			
Adjusted Mean Change (SE)	0,83 (0,220)	1,25 (0,311)	-0,43 [-1,173; 0,322] 0,264
Week 24:			
Adjusted Mean Change (SE)	1,33 (0,219)	1,39 (0,310)	-0,05 [-0,799; 0,690] 0,885
Emotional function score			
Interaction Test	0,852		
Region = Asia			
N'	69	71	
Baseline Mean (SD)	4,58 (1,249)	4,59 (1,443)	
Week 16:			
Adjusted Mean Change (SE)	0,57 (0,121)	0,59 (0,119)	-0,01 [-0,346; 0,317] 0,931
Week 24:			
Adjusted Mean Change (SE)	0,69 (0,132)	0,56 (0,131)	0,13 [-0,235; 0,492] 0,488

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Region = Europe			
N'	80	83	
Baseline Mean (SD)	5,49 (1,188)	5,41 (1,036)	
Week 16:			
Adjusted Mean Change (SE)	0,79 (0,113)	0,74 (0,111)	0,04 [-0,263; 0,352] 0,775
Week 24:			
Adjusted Mean Change (SE)	0,80 (0,124)	0,79 (0,121)	0,01 [-0,329; 0,343] 0,969
Region = Latin America			
N'	61	73	
Baseline Mean (SD)	4,74 (1,277)	4,44 (1,322)	
Week 16:			
Adjusted Mean Change (SE)	0,90 (0,128)	0,86 (0,118)	0,04 [-0,304; 0,376] 0,835
Week 24:			
Adjusted Mean Change (SE)	0,91 (0,140)	0,75 (0,129)	0,16 [-0,214; 0,531] 0,404
Region = Others			
N'	16	8	
Baseline Mean (SD)	4,36 (1,031)	4,10 (1,474)	
Week 16:			
Adjusted Mean Change (SE)	0,77 (0,249)	1,15 (0,352)	-0,39 [-1,230; 0,460] 0,371
Week 24:			
Adjusted Mean Change (SE)	1,25 (0,273)	1,44 (0,386)	-0,19 [-1,121; 0,734] 0,682
Environmental stimuli score			
Interaction Test	0,490		
Region = Asia			
N'	69	71	
Baseline Mean (SD)	4,16 (1,176)	4,15 (1,480)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 16:			
Adjusted Mean Change (SE)	0,60 (0,139)	0,45 (0,138)	0,14 [-0,242; 0,524] 0,470
Week 24:			
Adjusted Mean Change (SE)	0,75 (0,142)	0,43 (0,141)	0,32 [-0,070; 0,713] 0,107
Region = Europe			
N'	80	83	
Baseline Mean (SD)	4,69 (1,429)	4,78 (1,163)	
Week 16:			
Adjusted Mean Change (SE)	0,64 (0,129)	0,52 (0,127)	0,13 [-0,229; 0,481] 0,486
Week 24:			
Adjusted Mean Change (SE)	0,66 (0,132)	0,80 (0,130)	-0,15 [-0,509; 0,215] 0,426
Region = Latin America			
N'	61	73	
Baseline Mean (SD)	4,05 (1,442)	4,18 (1,500)	
Week 16:			
Adjusted Mean Change (SE)	0,88 (0,148)	1,10 (0,135)	-0,22 [-0,613; 0,172] 0,271
Week 24:			
Adjusted Mean Change (SE)	0,93 (0,151)	0,88 (0,138)	0,05 [-0,348; 0,453] 0,797
Region = Others			
N'	16	8	
Baseline Mean (SD)	4,33 (1,036)	3,44 (1,591)	
Week 16:			
Adjusted Mean Change (SE)	0,91 (0,287)	1,35 (0,407)	-0,45 [-1,425; 0,528] 0,368

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	1,42 (0,294)	1,66 (0,416)	-0,23 [-1,233; 0,767] 0,647

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 5.6 AQLQ-S - Change from Baseline by History of Asthma Exacerbation (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,995		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	193	194	
Baseline Mean (SD)	4,70 (0,819)	4,71 (0,928)	
Week 16:			
Adjusted Mean Change (SE)	0,81 (0,094)	0,77 (0,096)	0,04 [-0,120; 0,204] 0,612
Week 24:			
Adjusted Mean Change (SE)	0,89 (0,096)	0,81 (0,097)	0,08 [-0,090; 0,248] 0,359
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	4,56 (1,086)	4,42 (0,728)	
Week 16:			
Adjusted Mean Change (SE)	0,53 (0,163)	0,60 (0,149)	-0,07 [-0,448; 0,309] 0,718
Week 24:			
Adjusted Mean Change (SE)	0,84 (0,168)	0,65 (0,151)	0,19 [-0,200; 0,577] 0,342
Symptoms score			
Interaction Test	0,924		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	193	194	
Baseline Mean (SD)	4,73 (0,834)	4,78 (0,886)	
Week 16:			
Adjusted Mean Change (SE)	0,94 (0,098)	0,85 (0,100)	0,09 [-0,081; 0,259] 0,304

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	1,02 (0,099)	0,91 (0,101)	0,11 [-0,069; 0,280] 0,235
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	4,61 (1,159)	4,52 (0,818)	
Week 16:			
Adjusted Mean Change (SE)	0,69 (0,171)	0,64 (0,156)	0,04 [-0,352; 0,439] 0,830
Week 24:			
Adjusted Mean Change (SE)	0,96 (0,174)	0,77 (0,156)	0,19 [-0,211; 0,591] 0,353
Activity limitation score			
Interaction Test	0,959		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	193	194	
Baseline Mean (SD)	4,67 (0,869)	4,65 (0,937)	
Week 16:			
Adjusted Mean Change (SE)	0,74 (0,100)	0,74 (0,101)	0,01 [-0,168; 0,182] 0,936
Week 24:			
Adjusted Mean Change (SE)	0,85 (0,100)	0,78 (0,101)	0,07 [-0,104; 0,247] 0,425
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	4,56 (1,067)	4,41 (0,750)	
Week 16:			
Adjusted Mean Change (SE)	0,46 (0,174)	0,59 (0,159)	-0,13 [-0,534; 0,281] 0,542
Week 24:			
Adjusted Mean Change (SE)	0,78 (0,175)	0,60 (0,156)	0,18 [-0,220; 0,588] 0,372

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Emotional function score			
Interaction Test	0,822		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	193	194	
Baseline Mean (SD)	5,00 (1,226)	4,91 (1,366)	
Week 16:			
Adjusted Mean Change (SE)	0,67 (0,114)	0,66 (0,116)	0,01 [-0,188; 0,204] 0,935
Week 24:			
Adjusted Mean Change (SE)	0,70 (0,119)	0,64 (0,121)	0,06 [-0,157; 0,275] 0,593
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	4,50 (1,548)	4,39 (1,148)	
Week 16:			
Adjusted Mean Change (SE)	0,41 (0,198)	0,48 (0,181)	-0,07 [-0,529; 0,384] 0,755
Week 24:			
Adjusted Mean Change (SE)	0,77 (0,213)	0,53 (0,191)	0,25 [-0,249; 0,744] 0,329
Environmental stimuli score			
Interaction Test	0,782		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	193	194	
Baseline Mean (SD)	4,30 (1,318)	4,39 (1,433)	
Week 16:			
Adjusted Mean Change (SE)	0,74 (0,131)	0,70 (0,133)	0,03 [-0,198; 0,263] 0,782
Week 24:			
Adjusted Mean Change (SE)	0,80 (0,132)	0,76 (0,134)	0,04 [-0,194; 0,279] 0,725

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	4,51 (1,564)	4,20 (1,355)	
Week 16:			
Adjusted Mean Change (SE)	0,32 (0,229)	0,54 (0,209)	-0,22 [-0,757; 0,316] 0,420
Week 24:			
Adjusted Mean Change (SE)	0,62 (0,234)	0,48 (0,209)	0,15 [-0,397; 0,690] 0,596

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

6. AQLQ-S - Responder Analysis

Table 6.1a AQLQ-S - Responder Analysis (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	226	235			
AQLQ-S response, n (%)	172 (76,1)	164 (69,8)	1,35 [0,96; 1,91] 0,085	1,11 [0,98; 1,25] 0,088	0,06 [-0,02; 0,14] 0,126

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.1b AQLQ-S - Responder Analysis (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
AQLQ-S response, n (%)	173 (75,2)	167 (69,6)	1,32 [0,94; 1,85] 0,110	1,10 [0,98; 1,24] 0,111	0,06 [-0,02; 0,14] 0,171

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.2a AQLQ-S - Responder Analysis by Age (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,649				
Age = 18-39 years					
N'	43	40			
AQLQ-S response, n (%)	35 (81,4)	33 (82,5)	1,00 [0,45; 2,21] 0,993	0,99 [0,80; 1,24] 0,961	-0,01 [-0,18; 0,15] 0,896
Age = 40-64 years					
N'	141	152			
AQLQ-S response, n (%)	104 (73,8)	103 (67,8)	1,35 [0,87; 2,10] 0,182	1,12 [0,96; 1,31] 0,165	0,06 [-0,04; 0,16] 0,258
Age = ≥65 years					
N'	42	43			
AQLQ-S response, n (%)	33 (78,6)	28 (65,1)	1,69 [0,77; 3,70] 0,190	1,23 [0,91; 1,65] 0,174	0,13 [-0,05; 0,32] 0,163

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.2b AQLQ-S - Responder Analysis by Age (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,608				
Age = 18-39 years					
N'	44	40			
AQLQ-S response, n (%)	36 (81,8)	33 (82,5)	0,99 [0,45; 2,20] 0,987	1,00 [0,80; 1,24] 0,983	-0,01 [-0,17; 0,16] 0,935
Age = 40-64 years					
N'	144	155			
AQLQ-S response, n (%)	104 (72,2)	105 (67,7)	1,28 [0,83; 1,96] 0,262	1,10 [0,94; 1,29] 0,244	0,04 [-0,06; 0,15] 0,397
Age = ≥65 years					
N'	42	45			
AQLQ-S response, n (%)	33 (78,6)	29 (64,4)	1,74 [0,80; 3,78] 0,160	1,25 [0,93; 1,68] 0,143	0,14 [-0,05; 0,33] 0,139

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + age + age * treatment + age * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.3a AQLQ-S - Responder Analysis by Gender (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,409				
Gender = Male					
N'	96	87			
AQLQ-S response, n (%)	73 (76,0)	66 (75,9)	1,60 [0,93; 2,76] 0,092	1,17 [0,98; 1,39] 0,079	0,00 [-0,12; 0,13] 0,977
Gender = Female					
N'	130	148			
AQLQ-S response, n (%)	99 (76,2)	98 (66,2)	1,19 [0,76; 1,86] 0,452	1,06 [0,90; 1,25] 0,469	0,10 [-0,01; 0,21] 0,065

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.3b AQLQ-S - Responder Analysis by Gender (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,465				
Gender = Male					
N'	97	88			
AQLQ-S response, n (%)	73 (75,3)	66 (75,0)	1,52 [0,89; 2,58] 0,125	1,16 [0,97; 1,38] 0,104	0,00 [-0,12; 0,13] 0,968
Gender = Female					
N'	133	152			
AQLQ-S response, n (%)	100 (75,2)	101 (66,4)	1,17 [0,76; 1,82] 0,477	1,06 [0,90; 1,24] 0,500	0,09 [-0,02; 0,19] 0,103

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + gender + gender * treatment + gender * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.4a AQLQ-S - Responder Analysis by Region (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,149				
Region = Asia					
N'	69	71			
AQLQ-S response, n (%)	51 (73,9)	44 (62,0)	2,28 [1,21; 4,30] 0,011 *	1,37 [1,09; 1,74] 0,008 *	0,12 [-0,03; 0,27] 0,127
Region = Europe					
N'	80	83			
AQLQ-S response, n (%)	53 (66,3)	56 (67,5)	0,87 [0,48; 1,57] 0,639	0,94 [0,74; 1,19] 0,606	-0,01 [-0,16; 0,13] 0,869
Region = Latin America					
N'	61	73			
AQLQ-S response, n (%)	53 (86,9)	57 (78,1)	1,54 [0,81; 2,91] 0,184	1,13 [0,95; 1,34] 0,174	0,09 [-0,04; 0,22] 0,175
Region = Others					
N'	16	8			
AQLQ-S response, n (%)	15 (93,8)	7 (87,5)	0,69 [0,08; 5,76] 0,735	0,97 [0,61; 1,54] 0,893	0,06 [-0,20; 0,32] 0,635

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.4b AQLQ-S - Responder Analysis by Region (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,169				
Region = Asia					
N'	70	72			
AQLQ-S response, n (%)	51 (72,9)	45 (62,5)	2,15 [1,16; 3,99] 0,016 *	1,35 [1,07; 1,71] 0,012 *	0,10 [-0,05; 0,26] 0,184
Region = Europe					
N'	83	85			
AQLQ-S response, n (%)	54 (65,1)	57 (67,1)	0,86 [0,49; 1,53] 0,608	0,94 [0,74; 1,19] 0,586	-0,02 [-0,16; 0,12] 0,784
Region = Latin America					
N'	61	75			
AQLQ-S response, n (%)	53 (86,9)	58 (77,3)	1,50 [0,80; 2,81] 0,205	1,12 [0,94; 1,34] 0,201	0,10 [-0,03; 0,22] 0,141
Region = Others					
N'	16	8			
AQLQ-S response, n (%)	15 (93,8)	7 (87,5)	0,69 [0,09; 5,57] 0,726	0,97 [0,61; 1,53] 0,885	0,06 [-0,20; 0,32] 0,635

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + baseline-by-visit interaction + treatment-by-visit-interaction + region + region * treatment + region * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.5a AQLQ-S - Responder Analysis by History of Asthma Exacerbation (as observed) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,442				
Asthma exacerbations in the 12 months prior to screening = 1					
N'	193	194			
AQLQ-S response, n (%)	148 (76,7)	135 (69,6)	1,42 [0,98; 2,07] 0,066	1,13 [1,00; 1,29] 0,054	0,07 [-0,02; 0,16] 0,114
Asthma exacerbations in the 12 months prior to screening = ≥2					
N'	33	41			
AQLQ-S response, n (%)	24 (72,7)	29 (70,7)	0,97 [0,39; 2,40] 0,943	0,97 [0,70; 1,34] 0,843	0,02 [-0,19; 0,23] 0,850

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 6.5b AQLQ-S - Responder Analysis by History of Asthma Exacerbation (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,423				
Asthma exacerbations in the 12 months prior to screening = 1					
N'	196	198			
AQLQ-S response, n (%)	149 (76,0)	137 (69,2)	1,38 [0,96; 2,00] 0,083	1,13 [0,99; 1,28] 0,068	0,07 [-0,02; 0,16] 0,127
Asthma exacerbations in the 12 months prior to screening = ≥2					
N'	34	42			
AQLQ-S response, n (%)	24 (70,6)	30 (71,4)	0,94 [0,39; 2,26] 0,883	0,96 [0,69; 1,33] 0,801	-0,01 [-0,21; 0,20] 0,936

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit
If it was not possible to fit the minimal model, the OR is not given.

Applied model for RR: log(proportion) = treatment + baseline + visit + region + baseline-by-visit interaction + treatment-by-visit-interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

7. SGRQ - Return Rate / Change from Baseline

Table 7.1 SGRQ - Return Rate (FAS)

	Treatment groups		
Patient Reported Outcome - Return Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Return Rate*, n (%)			
Baseline Returns	230 (100,0)	238 (99,2)	468 (99,6)
Week 24 Returns	224 (97,4)	227 (94,6)	451 (96,0)

* The return rate is the proportion of patients with non-missing data for the total score at given visit on the whole study population.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.2a SGRQ - Change from Baseline (as observed) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
N'	224	225	
Baseline Mean (SD)	39,26 (17,548)	40,29 (18,688)	
Week 24:			
Adjusted Mean Change (SE)	-16,67 (1,813)	-14,16 (1,817)	-2,51 [-5,330; 0,319] 0,082
Symptoms score			
N'	224	225	
Baseline Mean (SD)	52,93 (20,223)	51,56 (18,534)	
Week 24:			
Adjusted Mean Change (SE)	-20,07 (2,347)	-17,27 (2,344)	-2,79 [-6,457; 0,870] 0,135
Activity score			
N'	224	225	
Baseline Mean (SD)	51,42 (21,971)	53,00 (21,913)	
Week 24:			
Adjusted Mean Change (SE)	-17,99 (2,496)	-15,80 (2,501)	-2,19 [-6,091; 1,707] 0,270
Impacts score			
N'	224	225	
Baseline Mean (SD)	28,22 (19,022)	29,65 (21,096)	
Week 24:			
Adjusted Mean Change (SE)	-14,25 (1,774)	-11,51 (1,779)	-2,75 [-5,511; 0,019] 0,052

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.2b SGRQ - Change from Baseline (LOCF) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
N'	230	238	
Baseline Mean (SD)	39,08 (17,537)	40,04 (18,861)	
Week 24:			
Adjusted Mean Change (SE)	-16,44 (1,826)	-13,65 (1,823)	-2,79 [-5,590; 0,013] 0,051
Symptoms score			
N'	230	238	
Baseline Mean (SD)	52,71 (20,140)	51,35 (18,676)	
Week 24:			
Adjusted Mean Change (SE)	-19,69 (2,352)	-16,73 (2,339)	-2,97 [-6,581; 0,646] 0,107
Activity score			
N'	230	238	
Baseline Mean (SD)	51,21 (22,009)	52,60 (21,909)	
Week 24:			
Adjusted Mean Change (SE)	-17,80 (2,493)	-15,18 (2,488)	-2,62 [-6,456; 1,211] 0,180
Impacts score			
N'	230	238	
Baseline Mean (SD)	28,06 (18,948)	29,48 (21,364)	
Week 24:			
Adjusted Mean Change (SE)	-14,06 (1,797)	-11,13 (1,795)	-2,93 [-5,690; -0,176] 0,037 *

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.
Imputation method: LOCF

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.3a SGRQ - Change from Baseline by Age (as observed) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,447		
Age = 18-39 years			
N'	42	36	
Baseline Mean (SD)	30,36 (18,514)	35,70 (16,368)	
Week 24:			
Adjusted Mean Change (SE)	-19,99 (2,810)	-20,92 (2,988)	0,93 [-5,805; 7,669] 0,786
Age = 40-64 years			
N'	140	148	
Baseline Mean (SD)	40,97 (17,494)	40,61 (19,909)	
Week 24:			
Adjusted Mean Change (SE)	-16,08 (1,920)	-13,57 (1,913)	-2,51 [-6,004; 0,976] 0,158
Age = ≥65 years			
N'	42	41	
Baseline Mean (SD)	42,47 (13,891)	43,16 (15,390)	
Week 24:			
Adjusted Mean Change (SE)	-15,51 (2,839)	-10,42 (2,838)	-5,10 [-11,593; 1,397] 0,124
Symptoms score			
Interaction Test	0,535		
Age = 18-39 years			
N'	42	36	
Baseline Mean (SD)	44,76 (21,943)	49,71 (18,863)	
Week 24:			
Adjusted Mean Change (SE)	-22,62 (3,674)	-22,47 (3,909)	-0,15 [-8,963; 8,663] 0,973

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Age = 40-64 years			
N'	140	148	
Baseline Mean (SD)	54,70 (19,494)	51,16 (18,313)	
Week 24:			
Adjusted Mean Change (SE)	-20,65 (2,509)	-16,38 (2,487)	-4,27 [-8,846; 0,301] 0,067
Age = ≥65 years			
N'	42	41	
Baseline Mean (SD)	55,19 (19,236)	54,63 (19,145)	
Week 24:			
Adjusted Mean Change (SE)	-15,53 (3,695)	-15,83 (3,696)	0,30 [-8,196; 8,793] 0,945
Activity score			
Interaction Test	0,180		
Age = 18-39 years			
N'	42	36	
Baseline Mean (SD)	39,92 (24,486)	47,92 (20,093)	
Week 24:			
Adjusted Mean Change (SE)	-24,42 (3,846)	-30,02 (4,084)	5,60 [-3,618; 14,817] 0,233
Age = 40-64 years			
N'	140	148	
Baseline Mean (SD)	52,87 (20,833)	52,46 (23,329)	
Week 24:			
Adjusted Mean Change (SE)	-16,74 (2,618)	-13,86 (2,607)	-2,88 [-7,655; 1,887] 0,236
Age = ≥65 years			
N'	42	41	
Baseline Mean (SD)	58,04 (19,156)	59,42 (16,406)	
Week 24:			
Adjusted Mean Change (SE)	-17,14 (3,882)	-11,39 (3,886)	-5,75 [-14,629; 3,130] 0,204

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Impacts score			
Interaction Test	0,498		
Age = 18-39 years			
N'	42	36	
Baseline Mean (SD)	20,91 (18,270)	24,52 (18,849)	
Week 24:			
Adjusted Mean Change (SE)	-17,02 (2,766)	-15,00 (2,942)	-2,01 [-8,643; 4,616] 0,551
Age = 40-64 years			
N'	140	148	
Baseline Mean (SD)	29,94 (19,857)	30,68 (22,411)	
Week 24:			
Adjusted Mean Change (SE)	-13,66 (1,890)	-11,78 (1,887)	-1,87 [-5,309; 1,569] 0,286
Age = ≥65 years			
N'	42	41	
Baseline Mean (SD)	29,76 (15,170)	30,42 (17,532)	
Week 24:			
Adjusted Mean Change (SE)	-13,45 (2,790)	-7,28 (2,790)	-6,16 [-12,562; 0,233] 0,059

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value + age + age * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.3b SGRQ - Change from Baseline by Age (LOCF) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,628		
Age = 18-39 years			
N'	44	40	
Baseline Mean (SD)	30,53 (18,094)	37,51 (17,930)	
Week 24:			
Adjusted Mean Change (SE)	-19,63 (2,800)	-18,06 (2,910)	-1,57 [-8,158; 5,013] 0,639
Age = 40-64 years			
N'	144	154	
Baseline Mean (SD)	40,71 (17,612)	40,34 (19,702)	
Week 24:			
Adjusted Mean Change (SE)	-15,72 (1,939)	-13,52 (1,928)	-2,20 [-5,685; 1,283] 0,215
Age = ≥65 years			
N'	42	44	
Baseline Mean (SD)	42,47 (13,891)	41,28 (16,738)	
Week 24:			
Adjusted Mean Change (SE)	-15,40 (2,878)	-9,86 (2,804)	-5,54 [-12,020; 0,942] 0,094
Symptoms score			
Interaction Test	0,817		
Age = 18-39 years			
N'	44	40	
Baseline Mean (SD)	45,09 (21,512)	50,58 (18,816)	
Week 24:			
Adjusted Mean Change (SE)	-22,66 (3,632)	-20,14 (3,776)	-2,51 [-11,057; 6,027] 0,563

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Age = 40-64 years			
N'	144	154	
Baseline Mean (SD)	54,31 (19,546)	51,33 (18,054)	
Week 24:			
Adjusted Mean Change (SE)	-19,98 (2,512)	-16,33 (2,488)	-3,65 [-8,180; 0,873] 0,113
Age = ≥65 years			
N'	42	44	
Baseline Mean (SD)	55,19 (19,236)	52,12 (20,985)	
Week 24:			
Adjusted Mean Change (SE)	-15,21 (3,718)	-14,62 (3,625)	-0,59 [-9,002; 7,818] 0,890
Activity score			
Interaction Test	0,425		
Age = 18-39 years			
N'	44	40	
Baseline Mean (SD)	40,17 (23,942)	49,31 (20,202)	
Week 24:			
Adjusted Mean Change (SE)	-24,00 (3,805)	-25,98 (3,949)	1,98 [-6,964; 10,928] 0,664
Age = 40-64 years			
N'	144	154	
Baseline Mean (SD)	52,59 (21,094)	52,09 (23,100)	
Week 24:			
Adjusted Mean Change (SE)	-16,34 (2,626)	-13,80 (2,609)	-2,54 [-7,272; 2,188] 0,292
Age = ≥65 years			
N'	42	44	
Baseline Mean (SD)	58,04 (19,156)	57,39 (18,497)	
Week 24:			
Adjusted Mean Change (SE)	-17,02 (3,910)	-10,65 (3,814)	-6,37 [-15,167; 2,429] 0,156

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Impacts score			
Interaction Test	0,437		
Age = 18-39 years			
N'	44	40	
Baseline Mean (SD)	20,89 (17,846)	26,87 (21,781)	
Week 24:			
Adjusted Mean Change (SE)	-16,56 (2,769)	-12,50 (2,878)	-4,06 [-10,568; 2,447] 0,221
Age = 40-64 years			
N'	144	154	
Baseline Mean (SD)	29,75 (19,840)	30,35 (22,170)	
Week 24:			
Adjusted Mean Change (SE)	-13,41 (1,917)	-11,80 (1,910)	-1,61 [-5,060; 1,835] 0,359
Age = ≥65 years			
N'	42	44	
Baseline Mean (SD)	29,76 (15,170)	28,82 (18,084)	
Week 24:			
Adjusted Mean Change (SE)	-13,36 (2,842)	-7,19 (2,770)	-6,17 [-12,582; 0,240] 0,059

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value + age + age * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.
Imputation method: LOCF

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.4a SGRQ - Change from Baseline by Gender (as observed) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,542		
Gender = Male			
N'	96	85	
Baseline Mean (SD)	37,29 (18,087)	37,00 (17,504)	
Week 24:			
Adjusted Mean Change (SE)	-18,06 (2,095)	-14,56 (2,276)	-3,49 [-7,965; 0,975] 0,125
Gender = Female			
N'	128	140	
Baseline Mean (SD)	40,74 (17,053)	42,28 (19,158)	
Week 24:			
Adjusted Mean Change (SE)	-15,31 (2,084)	-13,62 (1,970)	-1,70 [-5,362; 1,972] 0,364
Symptoms score			
Interaction Test	0,384		
Gender = Male			
N'	96	85	
Baseline Mean (SD)	51,72 (21,720)	51,18 (20,016)	
Week 24:			
Adjusted Mean Change (SE)	-22,57 (2,714)	-17,95 (2,948)	-4,62 [-10,406; 1,175] 0,118
Gender = Female			
N'	128	140	
Baseline Mean (SD)	53,84 (19,059)	51,79 (17,644)	
Week 24:			
Adjusted Mean Change (SE)	-17,71 (2,690)	-16,43 (2,529)	-1,28 [-6,035; 3,471] 0,596

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Activity score			
Interaction Test	0,370		
Gender = Male			
N'	96	85	
Baseline Mean (SD)	47,30 (21,599)	48,09 (21,522)	
Week 24:			
Adjusted Mean Change (SE)	-20,84 (2,879)	-16,63 (3,128)	-4,20 [-10,352; 1,948] 0,180
Gender = Female			
N'	128	140	
Baseline Mean (SD)	54,50 (21,823)	55,98 (21,684)	
Week 24:			
Adjusted Mean Change (SE)	-15,19 (2,864)	-14,63 (2,706)	-0,56 [-5,607; 4,483] 0,827
Impacts score			
Interaction Test	0,969		
Gender = Male			
N'	96	85	
Baseline Mean (SD)	27,23 (19,457)	26,38 (18,551)	
Week 24:			
Adjusted Mean Change (SE)	-14,62 (2,055)	-11,83 (2,232)	-2,78 [-7,165; 1,598] 0,213
Gender = Female			
N'	128	140	
Baseline Mean (SD)	28,96 (18,732)	31,64 (22,333)	
Week 24:			
Adjusted Mean Change (SE)	-13,92 (2,039)	-11,25 (1,931)	-2,67 [-6,267; 0,926] 0,145

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value + gender + gender * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.4b SGRQ - Change from Baseline by Gender (LOCF) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,755		
Gender = Male			
N'	97	88	
Baseline Mean (SD)	37,07 (18,116)	36,58 (17,390)	
Week 24:			
Adjusted Mean Change (SE)	-17,96 (2,114)	-14,73 (2,282)	-3,22 [-7,697; 1,249] 0,157
Gender = Female			
N'	133	150	
Baseline Mean (SD)	40,55 (17,021)	42,07 (19,444)	
Week 24:			
Adjusted Mean Change (SE)	-15,08 (2,087)	-12,77 (1,964)	-2,31 [-5,924; 1,307] 0,210
Symptoms score			
Interaction Test	0,528		
Gender = Male			
N'	97	88	
Baseline Mean (SD)	51,47 (21,747)	50,74 (19,918)	
Week 24:			
Adjusted Mean Change (SE)	-22,39 (2,723)	-18,19 (2,938)	-4,20 [-9,963; 1,557] 0,152
Gender = Female			
N'	133	150	
Baseline Mean (SD)	53,61 (18,915)	51,71 (17,966)	
Week 24:			
Adjusted Mean Change (SE)	-17,31 (2,680)	-15,49 (2,508)	-1,81 [-6,471; 2,844] 0,445

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Activity score			
Interaction Test	0,604		
Gender = Male			
N'	97	88	
Baseline Mean (SD)	47,19 (21,514)	47,72 (21,422)	
Week 24:			
Adjusted Mean Change (SE)	-20,70 (2,882)	-17,02 (3,111)	-3,67 [-9,775; 2,432] 0,238
Gender = Female			
N'	133	150	
Baseline Mean (SD)	54,14 (21,981)	55,47 (21,753)	
Week 24:			
Adjusted Mean Change (SE)	-15,16 (2,845)	-13,57 (2,675)	-1,59 [-6,526; 3,339] 0,526
Impacts score			
Interaction Test	0,911		
Gender = Male			
N'	97	88	
Baseline Mean (SD)	26,96 (19,529)	25,95 (18,391)	
Week 24:			
Adjusted Mean Change (SE)	-14,61 (2,085)	-11,93 (2,250)	-2,68 [-7,090; 1,728] 0,233
Gender = Female			
N'	133	150	
Baseline Mean (SD)	28,85 (18,546)	31,56 (22,733)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	-13,62 (2,054)	-10,61 (1,936)	-3,00 [-6,570; 0,561] 0,099

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value + gender + gender * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.
Imputation method: LOCF

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.5a SGRQ - Change from Baseline by Region (as observed) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,818		
Region = Asia			
N'	68	69	
Baseline Mean (SD)	46,46 (17,997)	48,90 (21,206)	
Week 24:			
Adjusted Mean Change (SE)	-13,70 (1,917)	-9,11 (1,916)	-4,59 [-9,846; 0,675] 0,087
Region = Europe			
N'	79	78	
Baseline Mean (SD)	34,85 (15,798)	35,36 (15,986)	
Week 24:			
Adjusted Mean Change (SE)	-11,95 (1,770)	-10,69 (1,780)	-1,25 [-6,164; 3,659] 0,617
Region = Latin America			
N'	61	70	
Baseline Mean (SD)	36,17 (15,455)	38,06 (15,174)	
Week 24:			
Adjusted Mean Change (SE)	-18,32 (2,009)	-16,28 (1,873)	-2,05 [-7,437; 3,345] 0,456
Region = Others			
N'	16	8	
Baseline Mean (SD)	42,21 (22,197)	33,46 (24,928)	
Week 24:			
Adjusted Mean Change (SE)	-19,88 (3,919)	-15,76 (5,544)	-4,13 [-17,463; 9,210] 0,544

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Symptoms score			
Interaction Test	0,167		
Region = Asia			
N'	68	69	
Baseline Mean (SD)	58,56 (18,145)	58,11 (18,923)	
Week 24:			
Adjusted Mean Change (SE)	-19,05 (2,429)	-17,52 (2,409)	-1,53 [-8,215; 5,146] 0,652
Region = Europe			
N'	79	78	
Baseline Mean (SD)	50,91 (20,627)	48,31 (17,068)	
Week 24:			
Adjusted Mean Change (SE)	-17,00 (2,241)	-18,34 (2,260)	1,34 [-4,901; 7,587] 0,673
Region = Latin America			
N'	61	70	
Baseline Mean (SD)	50,72 (18,889)	49,91 (17,716)	
Week 24:			
Adjusted Mean Change (SE)	-29,45 (2,550)	-20,38 (2,382)	-9,07 [-15,921; -2,225] 0,009 *
Region = Others			
N'	16	8	
Baseline Mean (SD)	47,41 (27,420)	41,23 (22,928)	
Week 24:			
Adjusted Mean Change (SE)	-30,39 (4,981)	-28,31 (7,054)	-2,08 [-19,017; 14,856] 0,809
Activity score			
Interaction Test	0,318		
Region = Asia			
N'	68	69	
Baseline Mean (SD)	59,48 (19,396)	60,84 (23,074)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	-13,89 (2,578)	-7,01 (2,567)	-6,87 [-13,957; 0,208] 0,057
Region = Europe			
N'	79	78	
Baseline Mean (SD)	46,44 (20,619)	49,36 (20,186)	
Week 24:			
Adjusted Mean Change (SE)	-13,52 (2,383)	-12,48 (2,391)	-1,04 [-7,662; 5,576] 0,757
Region = Latin America			
N'	61	70	
Baseline Mean (SD)	46,50 (21,273)	50,62 (20,057)	
Week 24:			
Adjusted Mean Change (SE)	-19,43 (2,709)	-21,54 (2,523)	2,11 [-5,154; 9,378] 0,568
Region = Others			
N'	16	8	
Baseline Mean (SD)	60,45 (29,410)	41,62 (28,066)	
Week 24:			
Adjusted Mean Change (SE)	-26,41 (5,288)	-18,58 (7,472)	-7,83 [-25,829; 10,177] 0,394
Impacts score			
Interaction Test	0,910		
Region = Asia			
N'	68	69	
Baseline Mean (SD)	35,31 (21,592)	39,19 (25,309)	
Week 24:			
Adjusted Mean Change (SE)	-11,30 (1,884)	-6,75 (1,888)	-4,55 [-9,736; 0,633] 0,085
Region = Europe			
N'	79	78	
Baseline Mean (SD)	23,43 (16,443)	23,61 (17,510)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	-10,07 (1,744)	-8,08 (1,755)	-1,99 [-6,826; 2,850] 0,420
Region = Latin America			
N'	61	70	
Baseline Mean (SD)	26,03 (16,035)	27,35 (15,714)	
Week 24:			
Adjusted Mean Change (SE)	-14,81 (1,978)	-12,10 (1,845)	-2,71 [-8,024; 2,595] 0,316
Region = Others			
N'	16	8	
Baseline Mean (SD)	30,02 (22,155)	26,35 (29,083)	
Week 24:			
Adjusted Mean Change (SE)	-12,94 (3,859)	-10,74 (5,458)	-2,20 [-15,324; 10,928] 0,742

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + baseline value + region + region * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.5b SGRQ - Change from Baseline by Region (LOCF) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,657		
Region = Asia			
N'	70	72	
Baseline Mean (SD)	45,84 (18,154)	49,21 (21,462)	
Week 24:			
Adjusted Mean Change (SE)	-14,09 (1,898)	-8,82 (1,890)	-5,26 [-10,467; -0,060] 0,047 *
Region = Europe			
N'	83	84	
Baseline Mean (SD)	34,92 (15,870)	35,10 (15,697)	
Week 24:			
Adjusted Mean Change (SE)	-11,39 (1,738)	-10,63 (1,727)	-0,76 [-5,553; 4,033] 0,756
Region = Latin America			
N'	61	74	
Baseline Mean (SD)	36,17 (15,455)	37,44 (15,639)	
Week 24:			
Adjusted Mean Change (SE)	-18,26 (2,023)	-15,48 (1,835)	-2,79 [-8,143; 2,570] 0,307
Region = Others			
N'	16	8	
Baseline Mean (SD)	42,21 (22,197)	33,46 (24,928)	
Week 24:			
Adjusted Mean Change (SE)	-19,96 (3,945)	-15,64 (5,580)	-4,32 [-17,749; 9,099] 0,527

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Symptoms score			
Interaction Test	0,081		
Region = Asia			
N'	70	72	
Baseline Mean (SD)	57,95 (18,312)	58,11 (18,610)	
Week 24:			
Adjusted Mean Change (SE)	-19,18 (2,399)	-17,53 (2,367)	-1,65 [-8,238; 4,931] 0,622
Region = Europe			
N'	83	84	
Baseline Mean (SD)	50,77 (20,403)	48,23 (16,900)	
Week 24:			
Adjusted Mean Change (SE)	-16,42 (2,194)	-18,22 (2,186)	1,81 [-4,270; 7,880] 0,560
Region = Latin America			
N'	61	74	
Baseline Mean (SD)	50,72 (18,889)	49,42 (18,684)	
Week 24:			
Adjusted Mean Change (SE)	-29,44 (2,559)	-19,37 (2,325)	-10,07 [-16,857; -3,287] 0,004 *
Region = Others			
N'	16	8	
Baseline Mean (SD)	47,41 (27,420)	41,23 (22,928)	
Week 24:			
Adjusted Mean Change (SE)	-30,36 (4,998)	-28,26 (7,077)	-2,11 [-19,099; 14,888] 0,808
Activity score			
Interaction Test	0,294		
Region = Asia			
N'	70	72	
Baseline Mean (SD)	58,98 (19,357)	60,81 (22,907)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	-14,32 (2,548)	-6,64 (2,522)	-7,68 [-14,661; -0,697] 0,031 *
Region = Europe			
N'	83	84	
Baseline Mean (SD)	46,33 (20,959)	48,91 (19,859)	
Week 24:			
Adjusted Mean Change (SE)	-12,84 (2,333)	-12,31 (2,313)	-0,53 [-6,973; 5,906] 0,871
Region = Latin America			
N'	61	74	
Baseline Mean (SD)	46,50 (21,273)	50,00 (20,536)	
Week 24:			
Adjusted Mean Change (SE)	-19,31 (2,718)	-20,24 (2,463)	0,94 [-6,259; 8,135] 0,798
Region = Others			
N'	16	8	
Baseline Mean (SD)	60,45 (29,410)	41,62 (28,066)	
Week 24:			
Adjusted Mean Change (SE)	-26,47 (5,307)	-18,40 (7,498)	-8,07 [-26,135; 9,991] 0,381
Impacts score			
Interaction Test	0,743		
Region = Asia			
N'	70	72	
Baseline Mean (SD)	34,59 (21,742)	39,80 (26,027)	
Week 24:			
Adjusted Mean Change (SE)	-11,80 (1,871)	-6,42 (1,867)	-5,38 [-10,526; -0,237] 0,040 *
Region = Europe			
N'	83	84	
Baseline Mean (SD)	23,66 (16,343)	23,41 (17,087)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	-9,56 (1,717)	-8,12 (1,708)	-1,44 [-6,176; 3,294] 0,550
Region = Latin America			
N'	61	74	
Baseline Mean (SD)	26,03 (16,035)	26,68 (15,923)	
Week 24:			
Adjusted Mean Change (SE)	-14,79 (1,997)	-11,73 (1,812)	-3,06 [-8,351; 2,230] 0,256
Region = Others			
N'	16	8	
Baseline Mean (SD)	30,02 (22,155)	26,35 (29,083)	
Week 24:			
Adjusted Mean Change (SE)	-13,06 (3,895)	-10,73 (5,509)	-2,33 [-15,575; 10,923] 0,730

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + baseline value + region + region * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.
Imputation method: LOCF

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.6a SGRQ - Change from Baseline by History of Asthma Exacerbation (as observed) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,705		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	191	184	
Baseline Mean (SD)	38,36 (17,428)	38,51 (18,535)	
Week 24:			
Adjusted Mean Change (SE)	-16,59 (1,844)	-13,81 (1,886)	-2,78 [-5,866; 0,302] 0,077
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	44,47 (17,590)	48,27 (17,442)	
Week 24:			
Adjusted Mean Change (SE)	-16,76 (3,132)	-15,46 (2,817)	-1,31 [-8,313; 5,699] 0,714
Symptoms score			
Interaction Test	0,547		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	191	184	
Baseline Mean (SD)	53,06 (20,434)	49,48 (18,320)	
Week 24:			
Adjusted Mean Change (SE)	-19,70 (2,384)	-17,38 (2,433)	-2,31 [-6,311; 1,683] 0,256
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	52,20 (19,237)	60,90 (16,702)	
Week 24:			
Adjusted Mean Change (SE)	-22,41 (4,023)	-17,04 (3,618)	-5,37 [-14,440; 3,707] 0,246

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Activity score			
Interaction Test	0,859		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	191	184	
Baseline Mean (SD)	50,57 (21,930)	51,49 (22,168)	
Week 24:			
Adjusted Mean Change (SE)	-18,50 (2,542)	-16,25 (2,601)	-2,25 [-6,508; 2,005] 0,299
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	56,29 (21,905)	59,79 (19,571)	
Week 24:			
Adjusted Mean Change (SE)	-14,65 (4,307)	-13,36 (3,857)	-1,29 [-10,959; 8,372] 0,793
Impacts score			
Interaction Test	0,548		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	191	184	
Baseline Mean (SD)	26,97 (18,737)	27,82 (20,733)	
Week 24:			
Adjusted Mean Change (SE)	-14,08 (1,805)	-10,89 (1,848)	-3,19 [-6,211; -0,171] 0,038 *
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	33	41	
Baseline Mean (SD)	35,43 (19,339)	37,85 (21,011)	
Week 24:			
Adjusted Mean Change (SE)	-15,01 (3,070)	-14,12 (2,756)	-0,90 [-7,752; 5,962] 0,798

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value + history of asthma exacerbation + history of asthma exacerbation * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 7.6b SGRQ - Change from Baseline by History of Asthma Exacerbation (LOCF) (FAS)

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Total score			
Interaction Test	0,600		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	196	
Baseline Mean (SD)	38,20 (17,451)	38,29 (18,775)	
Week 24:			
Adjusted Mean Change (SE)	-16,36 (1,858)	-13,21 (1,888)	-3,15 [-6,208; -0,102] 0,043 *
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Baseline Mean (SD)	44,16 (17,418)	48,19 (17,235)	
Week 24:			
Adjusted Mean Change (SE)	-16,54 (3,131)	-15,42 (2,824)	-1,11 [-8,108; 5,884] 0,755
Symptoms score			
Interaction Test	0,587		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	196	
Baseline Mean (SD)	52,79 (20,385)	49,29 (18,505)	
Week 24:			
Adjusted Mean Change (SE)	-19,37 (2,390)	-16,82 (2,423)	-2,55 [-6,483; 1,392] 0,205
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Baseline Mean (SD)	52,23 (18,944)	60,97 (16,505)	
Week 24:			
Adjusted Mean Change (SE)	-21,79 (4,003)	-16,52 (3,612)	-5,27 [-14,289; 3,742] 0,251

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Activity score			
Interaction Test	0,772		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	196	
Baseline Mean (SD)	50,43 (21,996)	51,09 (22,173)	
Week 24:			
Adjusted Mean Change (SE)	-18,28 (2,539)	-15,48 (2,582)	-2,81 [-6,985; 1,373] 0,188
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Baseline Mean (SD)	55,68 (21,864)	59,66 (19,348)	
Week 24:			
Adjusted Mean Change (SE)	-14,59 (4,270)	-13,32 (3,836)	-1,26 [-10,837; 8,307] 0,795
Impacts score			
Interaction Test	0,459		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	196	
Baseline Mean (SD)	26,82 (18,695)	27,71 (21,123)	
Week 24:			
Adjusted Mean Change (SE)	-13,87 (1,828)	-10,41 (1,859)	-3,46 [-6,462; -0,449] 0,024 *
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Baseline Mean (SD)	35,17 (19,103)	37,76 (20,762)	

	Treatment groups		Comparison
Patient Reported Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**
Week 24:			
Adjusted Mean Change (SE)	-14,87 (3,085)	-14,26 (2,778)	-0,62 [-7,501; 6,267] 0,860

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + region + baseline value + history of asthma exacerbation + history of asthma exacerbation * treatment
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.
Imputation method: LOCF

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

8. SGRQ - Responder Analysis

Table 8.1 SGRQ - Responder Analysis (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	238			
SGRQ Response, n (%)	168 (73,0)	162 (68,1)	1,30 [0,87; 1,96] 0,205	1,07 [0,95; 1,21] 0,238	0,05 [-0,03; 0,13] 0,237

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + region
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 8.2 SGRQ - Responder Analysis by Age (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,310				
Age = 18-39 years					
N'	44	40			
SGRQ Responder, n (%)	30 (68,2)	32 (80,0)	0,68 [0,24; 1,89] 0,455	0,85 [0,66; 1,10] 0,218	-0,12 [-0,30; 0,07] 0,211
Age = 40-64 years					
N'	144	154			
SGRQ Responder, n (%)	107 (74,3)	104 (67,5)	1,34 [0,80; 2,26] 0,265	1,10 [0,95; 1,27] 0,198	0,07 [-0,04; 0,17] 0,196
Age = ≥65 years					
N'	42	44			
SGRQ Responder, n (%)	31 (73,8)	26 (59,1)	1,97 [0,78; 5,02] 0,154	1,25 [0,92; 1,69] 0,153	0,15 [-0,05; 0,34] 0,143

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + region + age + age * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 8.3 SGRQ - Responder Analysis by Gender (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,486				
Gender = Male					
N'	97	88			
SGRQ Response, n (%)	74 (76,3)	65 (73,9)	1,06 [0,53; 2,10] 0,868	1,03 [0,87; 1,22] 0,704	0,02 [-0,10; 0,15] 0,703
Gender = Female					
N'	133	150			
SGRQ Response, n (%)	94 (70,7)	97 (64,7)	1,44 [0,86; 2,42] 0,170	1,09 [0,93; 1,28] 0,280	0,06 [-0,05; 0,17] 0,279

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + region + gender + gender * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 8.4 SGRQ - Responder Analysis by Region (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,430				
Region = Asia					
N'	70	72			
SGRQ Response, n (%)	52 (74,3)	46 (63,9)	1,81 [0,86; 3,80] 0,117	1,16 [0,93; 1,45] 0,183	0,10 [-0,05; 0,25] 0,177
Region = Europe					
N'	83	84			
SGRQ Response, n (%)	52 (62,7)	55 (65,5)	0,88 [0,46; 1,68] 0,708	0,96 [0,76; 1,20] 0,704	-0,03 [-0,17; 0,12] 0,703
Region = Latin America					
N'	61	74			
SGRQ Response, n (%)	51 (83,6)	56 (75,7)	1,72 [0,72; 4,12] 0,224	1,10 [0,93; 1,31] 0,252	0,08 [-0,06; 0,21] 0,249
Region = Others					
N'	16	8			
SGRQ Response, n (%)	13 (81,3)	5 (62,5)	2,14 [0,30; 15,37] 0,448	1,30 [0,72; 2,34] 0,380	0,19 [-0,20; 0,57] 0,341

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + region + region * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 8.5 SGRQ - Responder Analysis by History of Asthma Exacerbation (LOCF) (FAS)

	Treatment groups		Comparison		
Binary Efficacy Outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Interaction Test:	p=0,212				
Asthma exacerbations in the 12 months prior to screening = 1					
N'	196	196			
SGRQ Response, n (%)	142 (72,4)	127 (64,8)	1,45 [0,94; 2,26] 0,096	1,12 [0,98; 1,28] 0,104	0,08 [-0,02; 0,17] 0,101
Asthma exacerbations in the 12 months prior to screening = ≥2					
N'	34	42			
SGRQ Response, n (%)	26 (76,5)	35 (83,3)	0,66 [0,21; 2,11] 0,480	0,92 [0,73; 1,16] 0,465	-0,07 [-0,25; 0,11] 0,459

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + baseline + region + history of asthma exacerbation + history of asthma exacerbation * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

9. E-Diary - Symptoms

Table 9.1 Symptoms - Documentation Rate (FAS)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
No symptoms on rising - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	208 (90,4)	214 (89,2)	422 (89,8)
	50%-<70%	16 (7,0)	18 (7,5)	34 (7,2)
	<50%	6 (2,6)	8 (3,3)	14 (3,0)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	13 (5,7)	16 (6,7)	29 (6,2)
	<50%	9 (3,9)	7 (2,9)	16 (3,4)
Week 9 to Week 16	70%-100%	199 (86,5)	206 (85,8)	405 (86,2)
	50%-<70%	23 (10,0)	19 (7,9)	42 (8,9)
	<50%	8 (3,5)	15 (6,3)	23 (4,9)
Week 17 to Week 24	70%-100%	196 (85,2)	212 (88,3)	408 (86,8)
	50%-<70%	22 (9,6)	6 (2,5)	28 (6,0)
	<50%	12 (5,2)	22 (9,2)	34 (7,2)
Baseline to Week 24	70%-100%	206 (89,6)	208 (86,7)	414 (88,1)
	50%-<70%	15 (6,5)	17 (7,1)	32 (6,8)
	<50%	9 (3,9)	15 (6,3)	24 (5,1)
No day-time symptoms - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)
No night-time awakenings - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	208 (90,4)	214 (89,2)	422 (89,8)
	50%-<70%	16 (7,0)	18 (7,5)	34 (7,2)
	<50%	6 (2,6)	8 (3,3)	14 (3,0)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	13 (5,7)	16 (6,7)	29 (6,2)
	<50%	9 (3,9)	7 (2,9)	16 (3,4)
Week 9 to Week 16	70%-100%	199 (86,5)	206 (85,8)	405 (86,2)
	50%-<70%	23 (10,0)	19 (7,9)	42 (8,9)
	<50%	8 (3,5)	15 (6,3)	23 (4,9)
Week 17 to Week 24	70%-100%	196 (85,2)	212 (88,3)	408 (86,8)
	50%-<70%	22 (9,6)	6 (2,5)	28 (6,0)
	<50%	12 (5,2)	22 (9,2)	34 (7,2)
Baseline to Week 24	70%-100%	206 (89,6)	208 (86,7)	414 (88,1)
	50%-<70%	15 (6,5)	17 (7,1)	32 (6,8)
	<50%	9 (3,9)	15 (6,3)	24 (5,1)
Days with no asthma symptoms - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	194 (84,3)	198 (82,5)	392 (83,4)
	50%-<70%	25 (10,9)	24 (10,0)	49 (10,4)
	<50%	11 (4,8)	18 (7,5)	29 (6,2)
Baseline to Week 8	70%-100%	182 (79,1)	197 (82,1)	379 (80,6)
	50%-<70%	27 (11,7)	23 (9,6)	50 (10,6)
	<50%	21 (9,1)	20 (8,3)	41 (8,7)
Week 9 to Week 16	70%-100%	167 (72,6)	182 (75,8)	349 (74,3)
	50%-<70%	43 (18,7)	26 (10,8)	69 (14,7)
	<50%	20 (8,7)	32 (13,3)	52 (11,1)
Week 17 to Week 24	70%-100%	162 (70,4)	181 (75,4)	343 (73,0)
	50%-<70%	38 (16,5)	26 (10,8)	64 (13,6)
	<50%	30 (13,0)	33 (13,8)	63 (13,4)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	174 (75,7)	182 (75,8)	356 (75,7)
	50%-<70%	37 (16,1)	29 (12,1)	66 (14,0)
	<50%	19 (8,3)	29 (12,1)	48 (10,2)
Mean total daily symptom score - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	194 (84,3)	198 (82,5)	392 (83,4)
	50%-<70%	25 (10,9)	24 (10,0)	49 (10,4)
	<50%	11 (4,8)	18 (7,5)	29 (6,2)
Baseline to Week 8	70%-100%	182 (79,1)	197 (82,1)	379 (80,6)
	50%-<70%	27 (11,7)	23 (9,6)	50 (10,6)
	<50%	21 (9,1)	20 (8,3)	41 (8,7)
Week 9 to Week 16	70%-100%	167 (72,6)	182 (75,8)	349 (74,3)
	50%-<70%	43 (18,7)	26 (10,8)	69 (14,7)
	<50%	20 (8,7)	32 (13,3)	52 (11,1)
Week 17 to Week 24	70%-100%	162 (70,4)	181 (75,4)	343 (73,0)
	50%-<70%	38 (16,5)	26 (10,8)	64 (13,6)
	<50%	30 (13,0)	33 (13,8)	63 (13,4)
Baseline to Week 24	70%-100%	174 (75,7)	182 (75,8)	356 (75,7)
	50%-<70%	37 (16,1)	29 (12,1)	66 (14,0)
	<50%	19 (8,3)	29 (12,1)	48 (10,2)
Mean day-time symptom score - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)
Mean night-time symptom score - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	208 (90,4)	214 (89,2)	422 (89,8)
	50%-<70%	16 (7,0)	18 (7,5)	34 (7,2)
	<50%	6 (2,6)	8 (3,3)	14 (3,0)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	13 (5,7)	16 (6,7)	29 (6,2)
	<50%	9 (3,9)	7 (2,9)	16 (3,4)
Week 9 to Week 16	70%-100%	199 (86,5)	206 (85,8)	405 (86,2)
	50%-<70%	23 (10,0)	19 (7,9)	42 (8,9)
	<50%	8 (3,5)	15 (6,3)	23 (4,9)
Week 17 to Week 24	70%-100%	196 (85,2)	212 (88,3)	408 (86,8)
	50%-<70%	22 (9,6)	6 (2,5)	28 (6,0)
	<50%	12 (5,2)	22 (9,2)	34 (7,2)
Baseline to Week 24	70%-100%	206 (89,6)	208 (86,7)	414 (88,1)
	50%-<70%	15 (6,5)	17 (7,1)	32 (6,8)
	<50%	9 (3,9)	15 (6,3)	24 (5,1)
How did you sleep last night? - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	208 (90,4)	214 (89,2)	422 (89,8)
	50%-<70%	16 (7,0)	18 (7,5)	34 (7,2)
	<50%	6 (2,6)	8 (3,3)	14 (3,0)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	13 (5,7)	16 (6,7)	29 (6,2)
	<50%	9 (3,9)	7 (2,9)	16 (3,4)
Week 9 to Week 16	70%-100%	199 (86,5)	206 (85,8)	405 (86,2)
	50%-<70%	23 (10,0)	19 (7,9)	42 (8,9)
	<50%	8 (3,5)	15 (6,3)	23 (4,9)
Week 17 to Week 24	70%-100%	196 (85,2)	212 (88,3)	408 (86,8)
	50%-<70%	22 (9,6)	6 (2,5)	28 (6,0)
	<50%	12 (5,2)	22 (9,2)	34 (7,2)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	206 (89,6)	208 (86,7)	414 (88,1)
	50%-<70%	15 (6,5)	17 (7,1)	32 (6,8)
	<50%	9 (3,9)	15 (6,3)	24 (5,1)
Did you have asthma symptoms upon awakening in the morning? - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	208 (90,4)	214 (89,2)	422 (89,8)
	50%-<70%	16 (7,0)	18 (7,5)	34 (7,2)
	<50%	6 (2,6)	8 (3,3)	14 (3,0)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	13 (5,7)	16 (6,7)	29 (6,2)
	<50%	9 (3,9)	7 (2,9)	16 (3,4)
Week 9 to Week 16	70%-100%	199 (86,5)	206 (85,8)	405 (86,2)
	50%-<70%	23 (10,0)	19 (7,9)	42 (8,9)
	<50%	8 (3,5)	15 (6,3)	23 (4,9)
Week 17 to Week 24	70%-100%	196 (85,2)	212 (88,3)	408 (86,8)
	50%-<70%	22 (9,6)	6 (2,5)	28 (6,0)
	<50%	12 (5,2)	22 (9,2)	34 (7,2)
Baseline to Week 24	70%-100%	206 (89,6)	208 (86,7)	414 (88,1)
	50%-<70%	15 (6,5)	17 (7,1)	32 (6,8)
	<50%	9 (3,9)	15 (6,3)	24 (5,1)
Did your respiratory symptoms stop you from performing your usual daily activities? - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)
How severe was your shortness of breath today? - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)
How was your wheeze during the past 12 hours? - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)
How was your cough during the past 12 hours? - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)
Did you have chest tightness during the past 12 hours? - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)

* For each time period and patient the documentation rate is calculated as the number of documented days divided by the number of days of the whole time period.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 9.2 Symptoms - Change from Baseline (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Percentage of mornings with no symptoms on rising				
N'	221	232		
Baseline Mean (SD)	36,58 (38,192)	36,07 (37,607)		
Week 8:				
Adjusted Mean Change (SE)	9,70 (3,182)	6,95 (3,164)	2,75 [-2,231; 7,739] 0,278	0,058 [-0,128; 0,245]
Week 16:				
Adjusted Mean Change (SE)	16,31 (3,427)	12,81 (3,399)	3,50 [-2,582; 9,579] 0,259	0,068 [-0,117; 0,253]
Week 24:				
Adjusted Mean Change (SE)	17,89 (3,491)	15,51 (3,465)	2,38 [-3,984; 8,735] 0,464	0,046 [-0,141; 0,232]
Percentage of days with no day-time symptoms				
N'	222	233		
Baseline Mean (SD)	18,84 (31,383)	15,72 (29,422)		
Week 8:				
Adjusted Mean Change (SE)	8,81 (2,717)	7,89 (2,745)	0,91 [-3,355; 5,179] 0,675	0,022 [-0,164; 0,208]
Week 16:				
Adjusted Mean Change (SE)	19,01 (3,070)	13,78 (3,077)	5,23 [-0,555; 11,025] 0,076	0,113 [-0,071; 0,297]
Week 24:				
Adjusted Mean Change (SE)	20,55 (3,183)	16,58 (3,187)	3,97 [-2,270; 10,206] 0,212	0,083 [-0,102; 0,269]
Percentage of days with no night-time awakenings				
N'	221	232		
Baseline Mean (SD)	60,46 (37,154)	57,90 (38,217)		
Week 8:				
Adjusted Mean Change (SE)	7,92 (2,988)	6,92 (2,973)	1,00 [-3,680; 5,686] 0,674	0,023 [-0,164; 0,209]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 16:				
Adjusted Mean Change (SE)	13,91 (3,100)	10,51 (3,080)	3,40 [-1,799; 8,601] 0,200	0,073 [-0,112; 0,258]
Week 24:				
Adjusted Mean Change (SE)	15,56 (3,160)	12,40 (3,141)	3,15 [-2,319; 8,626] 0,258	0,067 [-0,119; 0,254]
Percentage of days with no asthma symptoms				
N'	215	221		
Baseline Mean (SD)	16,43 (31,027)	13,91 (28,016)		
Week 8:				
Adjusted Mean Change (SE)	9,98 (3,091)	9,37 (3,138)	0,62 [-3,857; 5,091] 0,787	0,014 [-0,179; 0,207]
Week 16:				
Adjusted Mean Change (SE)	19,73 (3,397)	16,00 (3,435)	3,73 [-2,198; 9,654] 0,217	0,074 [-0,115; 0,263]
Week 24:				
Adjusted Mean Change (SE)	21,53 (3,505)	17,94 (3,542)	3,59 [-2,808; 9,979] 0,271	0,070 [-0,120; 0,260]
Mean total daily symptom score				
N'	215	221		
Baseline Mean (SD)	2,16 (1,471)	2,26 (1,523)		
Week 8:				
Adjusted Mean Change (SE)	-0,47 (0,113)	-0,52 (0,115)	0,05 [-0,117; 0,210] 0,577	0,028 [-0,165; 0,221]
Week 16:				
Adjusted Mean Change (SE)	-0,72 (0,119)	-0,71 (0,120)	-0,01 [-0,198; 0,181] 0,929	-0,005 [-0,194; 0,184]
Week 24:				
Adjusted Mean Change (SE)	-0,76 (0,121)	-0,75 (0,123)	-0,01 [-0,210; 0,192] 0,927	-0,005 [-0,195; 0,185]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Mean day-time symptom score				
N'	222	233		
Baseline Mean (SD)	0,85 (0,576)	0,89 (0,573)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,039)	-0,19 (0,039)	0,03 [-0,031; 0,091] 0,333	0,051 [-0,135; 0,238]
Week 16:				
Adjusted Mean Change (SE)	-0,28 (0,041)	-0,27 (0,042)	-0,01 [-0,077; 0,066] 0,881	-0,009 [-0,193; 0,175]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,043)	-0,28 (0,043)	-0,00 [-0,082; 0,075] 0,932	-0,005 [-0,191; 0,180]
Mean night-time symptom score				
N'	221	232		
Baseline Mean (SD)	0,65 (0,479)	0,70 (0,514)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,035)	-0,16 (0,035)	0,00 [-0,051; 0,058] 0,890	0,007 [-0,179; 0,194]
Week 16:				
Adjusted Mean Change (SE)	-0,23 (0,036)	-0,22 (0,036)	-0,01 [-0,068; 0,056] 0,848	-0,011 [-0,196; 0,174]
Week 24:				
Adjusted Mean Change (SE)	-0,25 (0,037)	-0,24 (0,037)	-0,01 [-0,073; 0,057] 0,814	-0,014 [-0,201; 0,172]
Mean of: How did you sleep last night?				
N'	221	232		
Baseline Mean (SD)	0,48 (0,472)	0,54 (0,532)		
Week 8:				
Adjusted Mean Change (SE)	-0,14 (0,035)	-0,14 (0,035)	-0,00 [-0,057; 0,056] 0,993	-0,000 [-0,187; 0,186]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 16:				
Adjusted Mean Change (SE)	-0,21 (0,036)	-0,19 (0,036)	-0,02 [-0,080; 0,042] 0,537	-0,035 [-0,220; 0,150]
Week 24:				
Adjusted Mean Change (SE)	-0,23 (0,037)	-0,22 (0,037)	-0,01 [-0,076; 0,047] 0,648	-0,026 [-0,213; 0,160]
Mean of: Did you have asthma symptoms upon awakening in the morning?				
N'	221	232		
Baseline Mean (SD)	0,82 (0,588)	0,85 (0,598)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,043)	-0,17 (0,043)	0,00 [-0,064; 0,069] 0,941	0,004 [-0,183; 0,190]
Week 16:				
Adjusted Mean Change (SE)	-0,25 (0,045)	-0,25 (0,045)	0,00 [-0,077; 0,081] 0,964	0,003 [-0,182; 0,188]
Week 24:				
Adjusted Mean Change (SE)	-0,27 (0,047)	-0,26 (0,046)	-0,01 [-0,092; 0,078] 0,871	-0,010 [-0,197; 0,176]
Mean of: Did your respiratory symptoms stop you from performing your usual daily activities?				
N'	222	233		
Baseline Mean (SD)	0,85 (0,664)	0,90 (0,671)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,044)	-0,20 (0,045)	0,04 [-0,033; 0,106] 0,301	0,055 [-0,131; 0,241]
Week 16:				
Adjusted Mean Change (SE)	-0,28 (0,047)	-0,29 (0,047)	0,01 [-0,070; 0,092] 0,782	0,016 [-0,168; 0,200]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,048)	-0,31 (0,049)	0,02 [-0,068; 0,108] 0,661	0,027 [-0,159; 0,213]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Mean of: How severe was your shortness of breath today?				
N'	222	233		
Baseline Mean (SD)	0,99 (0,633)	1,04 (0,647)		
Week 8:				
Adjusted Mean Change (SE)	-0,21 (0,046)	-0,23 (0,046)	0,01 [-0,057; 0,087] 0,681	0,022 [-0,164; 0,208]
Week 16:				
Adjusted Mean Change (SE)	-0,33 (0,049)	-0,32 (0,049)	-0,02 [-0,100; 0,069] 0,718	-0,021 [-0,205; 0,163]
Week 24:				
Adjusted Mean Change (SE)	-0,36 (0,050)	-0,33 (0,051)	-0,03 [-0,122; 0,061] 0,509	-0,041 [-0,226; 0,145]
Mean of: How was your wheeze during the past 12 hours?				
N'	222	233		
Baseline Mean (SD)	0,85 (0,651)	0,89 (0,633)		
Week 8:				
Adjusted Mean Change (SE)	-0,21 (0,046)	-0,27 (0,047)	0,07 [-0,007; 0,137] 0,078	0,094 [-0,092; 0,280]
Week 16:				
Adjusted Mean Change (SE)	-0,31 (0,049)	-0,33 (0,049)	0,02 [-0,068; 0,100] 0,708	0,022 [-0,162; 0,206]
Week 24:				
Adjusted Mean Change (SE)	-0,33 (0,050)	-0,34 (0,050)	0,01 [-0,076; 0,104] 0,753	0,019 [-0,166; 0,205]
Mean of: How was your cough during the past 12 hours?				
N'	222	233		
Baseline Mean (SD)	0,91 (0,699)	0,92 (0,667)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,050)	-0,15 (0,051)	-0,00 [-0,082; 0,076] 0,941	-0,004 [-0,190; 0,182]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,053)	-0,25 (0,054)	-0,04 [-0,135; 0,049] 0,360	-0,053 [-0,238; 0,131]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,055)	-0,27 (0,055)	-0,02 [-0,121; 0,079] 0,675	-0,026 [-0,212; 0,160]
Did you have chest tightness during the past 12 hours?				
N'	222	233		
Baseline Mean (SD)	0,63 (0,606)	0,70 (0,658)		
Week 8:				
Adjusted Mean Change (SE)	-0,09 (0,044)	-0,12 (0,044)	0,03 [-0,035; 0,101] 0,344	0,050 [-0,136; 0,237]
Week 16:				
Adjusted Mean Change (SE)	-0,17 (0,046)	-0,17 (0,046)	-0,00 [-0,081; 0,078] 0,968	-0,002 [-0,186; 0,182]
Week 24:				
Adjusted Mean Change (SE)	-0,18 (0,047)	-0,18 (0,047)	-0,01 [-0,090; 0,079] 0,896	-0,008 [-0,194; 0,178]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 9.3 Symptoms - Change from Baseline by Age (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Percentage of mornings with no symptoms on rising				
Interaction Test	0,026 *			
Age = 18-39 years				
N'	43	40		
Baseline Mean (SD)	42,40 (38,099)	48,50 (39,193)		
Week 8:				
Adjusted Mean Change (SE)	20,29 (4,949)	3,97 (5,105)	16,32 [4,666; 27,970] 0,006 *	0,513 [0,067; 0,959]
Week 16:				
Adjusted Mean Change (SE)	28,21 (5,704)	10,67 (5,881)	17,54 [3,420; 31,661] 0,015 *	0,470 [0,034; 0,907]
Week 24:				
Adjusted Mean Change (SE)	29,75 (5,919)	13,64 (6,109)	16,11 [1,293; 30,924] 0,033 *	0,426 [-0,020; 0,873]
Age = 40-64 years				
N'	136	149		
Baseline Mean (SD)	36,68 (39,580)	34,07 (37,138)		
Week 8:				
Adjusted Mean Change (SE)	7,84 (3,406)	7,27 (3,374)	0,57 [-5,706; 6,843] 0,859	0,014 [-0,221; 0,250]
Week 16:				
Adjusted Mean Change (SE)	15,06 (3,764)	12,88 (3,705)	2,18 [-5,452; 9,803] 0,576	0,049 [-0,184; 0,282]
Week 24:				
Adjusted Mean Change (SE)	16,66 (3,853)	14,47 (3,794)	2,19 [-5,772; 10,149] 0,590	0,048 [-0,186; 0,282]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	30,31 (33,254)	31,44 (36,174)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	6,50 (5,003)	10,30 (4,938)	-3,79 [-15,221; 7,636] 0,515	-0,118 [-0,546; 0,310]
Week 16:				
Adjusted Mean Change (SE)	9,86 (5,780)	16,24 (5,702)	-6,37 [-20,309; 7,564] 0,370	-0,171 [-0,600; 0,257]
Week 24:				
Adjusted Mean Change (SE)	11,49 (5,969)	22,87 (5,927)	-11,38 [-25,961; 3,208] 0,126	-0,299 [-0,734; 0,137]
Percentage of days with no day-time symptoms				
Interaction Test	0,055			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	22,45 (32,682)	28,28 (36,258)		
Week 8:				
Adjusted Mean Change (SE)	20,68 (4,281)	10,02 (4,339)	10,66 [0,623; 20,691] 0,037 *	0,399 [-0,053; 0,850]
Week 16:				
Adjusted Mean Change (SE)	34,05 (5,361)	17,67 (5,438)	16,38 [2,907; 29,860] 0,017 *	0,477 [0,035; 0,919]
Week 24:				
Adjusted Mean Change (SE)	35,89 (5,726)	18,89 (5,793)	17,01 [2,434; 31,581] 0,022 *	0,473 [0,023; 0,923]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	20,35 (32,392)	14,51 (28,219)		
Week 8:				
Adjusted Mean Change (SE)	7,07 (2,873)	6,90 (2,909)	0,17 [-5,125; 5,462] 0,950	0,005 [-0,229; 0,238]
Week 16:				
Adjusted Mean Change (SE)	17,57 (3,375)	13,73 (3,368)	3,84 [-3,319; 10,992] 0,293	0,095 [-0,137; 0,326]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	19,69 (3,532)	15,95 (3,518)	3,73 [-3,976; 11,441] 0,342	0,089 [-0,144; 0,321]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	10,29 (25,289)	8,25 (22,881)		
Week 8:				
Adjusted Mean Change (SE)	4,11 (4,238)	10,31 (4,186)	-6,20 [-15,868; 3,468] 0,208	-0,226 [-0,652; 0,201]
Week 16:				
Adjusted Mean Change (SE)	10,31 (5,325)	11,35 (5,263)	-1,04 [-14,173; 12,091] 0,876	-0,030 [-0,455; 0,395]
Week 24:				
Adjusted Mean Change (SE)	9,59 (5,650)	17,75 (5,620)	-8,16 [-22,337; 6,016] 0,259	-0,225 [-0,656; 0,207]
Percentage of days with no night-time awakenings				
Interaction Test	0,140			
Age = 18-39 years				
N'	43	40		
Baseline Mean (SD)	68,89 (35,040)	69,62 (36,394)		
Week 8:				
Adjusted Mean Change (SE)	15,68 (4,666)	7,66 (4,814)	8,01 [-2,959; 18,986] 0,152	0,267 [-0,173; 0,708]
Week 16:				
Adjusted Mean Change (SE)	20,92 (5,023)	14,07 (5,173)	6,85 [-5,288; 18,994] 0,268	0,209 [-0,223; 0,640]
Week 24:				
Adjusted Mean Change (SE)	21,54 (5,228)	12,11 (5,388)	9,43 [-3,386; 22,240] 0,149	0,283 [-0,161; 0,726]
Age = 40-64 years				
N'	136	149		
Baseline Mean (SD)	58,04 (37,503)	54,96 (36,915)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	7,35 (3,212)	5,67 (3,183)	1,69 [-4,228; 7,598] 0,576	0,045 [-0,191; 0,280]
Week 16:				
Adjusted Mean Change (SE)	13,06 (3,378)	8,30 (3,338)	4,76 [-1,799; 11,322] 0,155	0,119 [-0,114; 0,353]
Week 24:				
Adjusted Mean Change (SE)	14,68 (3,464)	10,50 (3,422)	4,18 [-2,714; 11,068] 0,234	0,102 [-0,132; 0,336]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	59,68 (37,733)	57,19 (42,888)		
Week 8:				
Adjusted Mean Change (SE)	3,17 (4,710)	11,82 (4,650)	-8,65 [-19,426; 2,117] 0,115	-0,285 [-0,715; 0,145]
Week 16:				
Adjusted Mean Change (SE)	10,78 (5,081)	16,15 (5,013)	-5,37 [-17,349; 6,614] 0,379	-0,164 [-0,593; 0,264]
Week 24:				
Adjusted Mean Change (SE)	13,52 (5,265)	20,68 (5,223)	-7,16 [-19,777; 5,456] 0,266	-0,213 [-0,647; 0,221]
Percentage of days with no asthma symptoms				
Interaction Test	0,240			
Age = 18-39 years				
N'	39	36		
Baseline Mean (SD)	19,10 (32,101)	24,41 (32,683)		
Week 8:				
Adjusted Mean Change (SE)	20,71 (4,701)	12,31 (4,821)	8,40 [-2,361; 19,161] 0,126	0,298 [-0,173; 0,770]
Week 16:				
Adjusted Mean Change (SE)	34,20 (5,679)	22,69 (5,892)	11,50 [-2,595; 25,595] 0,110	0,327 [-0,132; 0,786]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	38,01 (6,018)	23,58 (6,287)	14,43 [-0,814; 29,675] 0,064	0,394 [-0,077; 0,865]
Age = 40-64 years				
N'	134	145		
Baseline Mean (SD)	18,03 (32,538)	13,21 (27,668)		
Week 8:				
Adjusted Mean Change (SE)	8,60 (3,249)	8,63 (3,305)	-0,03 [-5,621; 5,552] 0,990	-0,001 [-0,244; 0,242]
Week 16:				
Adjusted Mean Change (SE)	18,56 (3,683)	16,16 (3,702)	2,41 [-4,904; 9,715] 0,518	0,055 [-0,181; 0,292]
Week 24:				
Adjusted Mean Change (SE)	20,90 (3,832)	18,01 (3,840)	2,89 [-4,972; 10,746] 0,471	0,064 [-0,173; 0,301]
Age = ≥65 years				
N'	42	40		
Baseline Mean (SD)	8,86 (23,695)	6,99 (22,128)		
Week 8:				
Adjusted Mean Change (SE)	5,73 (4,577)	10,46 (4,640)	-4,73 [-14,852; 5,389] 0,359	-0,160 [-0,594; 0,273]
Week 16:				
Adjusted Mean Change (SE)	11,46 (5,547)	10,78 (5,654)	0,68 [-12,748; 14,105] 0,921	0,019 [-0,417; 0,455]
Week 24:				
Adjusted Mean Change (SE)	9,73 (5,854)	14,06 (5,998)	-4,33 [-18,788; 10,127] 0,557	-0,116 [-0,555; 0,324]
Mean total daily symptom score				
Interaction Test	0,042 *			
Age = 18-39 years				
N'	39	36		
Baseline Mean (SD)	1,78 (1,247)	1,66 (1,494)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,84 (0,172)	-0,51 (0,177)	-0,33 [-0,723; 0,064] 0,101	-0,319 [-0,791; 0,153]
Week 16:				
Adjusted Mean Change (SE)	-1,09 (0,190)	-0,82 (0,196)	-0,27 [-0,725; 0,182] 0,241	-0,231 [-0,689; 0,226]
Week 24:				
Adjusted Mean Change (SE)	-1,13 (0,198)	-0,81 (0,206)	-0,32 [-0,801; 0,165] 0,197	-0,264 [-0,732; 0,204]
Age = 40-64 years				
N'	134	145		
Baseline Mean (SD)	2,21 (1,570)	2,32 (1,493)		
Week 8:				
Adjusted Mean Change (SE)	-0,44 (0,119)	-0,49 (0,121)	0,04 [-0,161; 0,248] 0,674	0,032 [-0,211; 0,275]
Week 16:				
Adjusted Mean Change (SE)	-0,73 (0,127)	-0,67 (0,128)	-0,06 [-0,293; 0,178] 0,632	-0,038 [-0,274; 0,198]
Week 24:				
Adjusted Mean Change (SE)	-0,76 (0,130)	-0,71 (0,132)	-0,05 [-0,296; 0,203] 0,714	-0,030 [-0,267; 0,207]
Age = ≥65 years				
N'	42	40		
Baseline Mean (SD)	2,33 (1,299)	2,58 (1,553)		
Week 8:				
Adjusted Mean Change (SE)	-0,26 (0,168)	-0,68 (0,170)	0,42 [0,045; 0,788] 0,028 *	0,384 [-0,053; 0,821]
Week 16:				
Adjusted Mean Change (SE)	-0,39 (0,185)	-0,80 (0,189)	0,41 [-0,019; 0,846] 0,061	0,347 [-0,092; 0,786]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,48 (0,193)	-0,90 (0,197)	0,42 [-0,037; 0,880] 0,072	0,342 [-0,100; 0,784]
Mean day-time symptom score				
Interaction Test	0,023 *			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	0,71 (0,518)	0,65 (0,563)		
Week 8:				
Adjusted Mean Change (SE)	-0,32 (0,062)	-0,19 (0,062)	-0,13 [-0,272; 0,016] 0,081	-0,333 [-0,783; 0,117]
Week 16:				
Adjusted Mean Change (SE)	-0,42 (0,069)	-0,29 (0,070)	-0,13 [-0,296; 0,040] 0,134	-0,290 [-0,728; 0,148]
Week 24:				
Adjusted Mean Change (SE)	-0,42 (0,074)	-0,28 (0,075)	-0,14 [-0,324; 0,043] 0,134	-0,302 [-0,748; 0,145]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	0,85 (0,600)	0,93 (0,557)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,041)	-0,19 (0,042)	0,04 [-0,039; 0,113] 0,338	0,075 [-0,159; 0,308]
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,045)	-0,26 (0,045)	-0,02 [-0,114; 0,065] 0,588	-0,046 [-0,277; 0,186]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,047)	-0,28 (0,047)	-0,01 [-0,111; 0,084] 0,782	-0,024 [-0,257; 0,208]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,96 (0,532)	0,99 (0,589)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,07 (0,061)	-0,23 (0,060)	0,16 [0,020; 0,298] 0,025 *	0,403 [-0,026; 0,833]
Week 16:				
Adjusted Mean Change (SE)	-0,10 (0,069)	-0,28 (0,068)	0,18 [0,014; 0,341] 0,033 *	0,400 [-0,030; 0,829]
Week 24:				
Adjusted Mean Change (SE)	-0,14 (0,073)	-0,31 (0,073)	0,16 [-0,014; 0,343] 0,071	0,350 [-0,084; 0,784]
Mean night-time symptom score				
Interaction Test	0,033 *			
Age = 18-39 years				
N'	43	40		
Baseline Mean (SD)	0,53 (0,408)	0,52 (0,483)		
Week 8:				
Adjusted Mean Change (SE)	-0,27 (0,054)	-0,14 (0,056)	-0,12 [-0,249; 0,005] 0,060	-0,351 [-0,793; 0,091]
Week 16:				
Adjusted Mean Change (SE)	-0,34 (0,059)	-0,24 (0,061)	-0,10 [-0,245; 0,043] 0,167	-0,262 [-0,694; 0,170]
Week 24:				
Adjusted Mean Change (SE)	-0,36 (0,062)	-0,23 (0,063)	-0,12 [-0,273; 0,030] 0,115	-0,310 [-0,754; 0,134]
Age = 40-64 years				
N'	136	149		
Baseline Mean (SD)	0,68 (0,511)	0,72 (0,513)		
Week 8:				
Adjusted Mean Change (SE)	-0,14 (0,037)	-0,15 (0,037)	0,01 [-0,059; 0,078] 0,789	0,021 [-0,214; 0,257]
Week 16:				
Adjusted Mean Change (SE)	-0,23 (0,040)	-0,21 (0,039)	-0,02 [-0,095; 0,061] 0,667	-0,036 [-0,270; 0,197]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,24 (0,041)	-0,23 (0,040)	-0,02 [-0,099; 0,064] 0,681	-0,036 [-0,270; 0,198]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,69 (0,423)	0,76 (0,523)		
Week 8:				
Adjusted Mean Change (SE)	-0,09 (0,055)	-0,21 (0,054)	0,12 [-0,010; 0,240] 0,071	0,327 [-0,103; 0,758]
Week 16:				
Adjusted Mean Change (SE)	-0,14 (0,060)	-0,27 (0,059)	0,13 [-0,011; 0,273] 0,070	0,340 [-0,091; 0,771]
Week 24:				
Adjusted Mean Change (SE)	-0,18 (0,062)	-0,32 (0,062)	0,14 [-0,006; 0,293] 0,059	0,363 [-0,074; 0,799]
Mean of: How did you sleep last night?				
Interaction Test	0,150			
Age = 18-39 years				
N'	43	40		
Baseline Mean (SD)	0,37 (0,407)	0,37 (0,440)		
Week 8:				
Adjusted Mean Change (SE)	-0,23 (0,056)	-0,16 (0,057)	-0,07 [-0,202; 0,062] 0,296	-0,196 [-0,636; 0,244]
Week 16:				
Adjusted Mean Change (SE)	-0,30 (0,059)	-0,24 (0,060)	-0,05 [-0,196; 0,086] 0,446	-0,143 [-0,574; 0,288]
Week 24:				
Adjusted Mean Change (SE)	-0,31 (0,060)	-0,23 (0,061)	-0,08 [-0,228; 0,061] 0,256	-0,220 [-0,663; 0,223]
Age = 40-64 years				
N'	136	149		
Baseline Mean (SD)	0,52 (0,497)	0,59 (0,544)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,13 (0,038)	-0,12 (0,038)	-0,01 [-0,082; 0,060] 0,761	-0,024 [-0,260; 0,211]
Week 16:				
Adjusted Mean Change (SE)	-0,20 (0,040)	-0,16 (0,039)	-0,04 [-0,114; 0,039] 0,342	-0,079 [-0,312; 0,155]
Week 24:				
Adjusted Mean Change (SE)	-0,22 (0,040)	-0,19 (0,040)	-0,03 [-0,104; 0,052] 0,514	-0,055 [-0,289; 0,179]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,47 (0,443)	0,52 (0,544)		
Week 8:				
Adjusted Mean Change (SE)	-0,08 (0,056)	-0,19 (0,056)	0,11 [-0,018; 0,240] 0,091	0,307 [-0,123; 0,738]
Week 16:				
Adjusted Mean Change (SE)	-0,16 (0,059)	-0,25 (0,059)	0,09 [-0,054; 0,225] 0,227	0,225 [-0,204; 0,654]
Week 24:				
Adjusted Mean Change (SE)	-0,20 (0,060)	-0,30 (0,060)	0,10 [-0,041; 0,244] 0,163	0,264 [-0,170; 0,699]
Mean of: Did you have asthma symptoms upon awakening in the morning?				
Interaction Test	0,025 *			
Age = 18-39 years				
N'	43	40		
Baseline Mean (SD)	0,69 (0,519)	0,67 (0,589)		
Week 8:				
Adjusted Mean Change (SE)	-0,30 (0,067)	-0,13 (0,069)	-0,17 [-0,328; -0,015] 0,032 *	-0,401 [-0,845; 0,042]
Week 16:				
Adjusted Mean Change (SE)	-0,39 (0,075)	-0,24 (0,077)	-0,15 [-0,330; 0,038] 0,119	-0,299 [-0,732; 0,134]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,40 (0,079)	-0,24 (0,082)	-0,16 [-0,357; 0,038] 0,113	-0,316 [-0,760; 0,128]
Age = 40-64 years				
N'	136	149		
Baseline Mean (SD)	0,84 (0,618)	0,85 (0,580)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,046)	-0,17 (0,045)	0,02 [-0,064; 0,104] 0,637	0,038 [-0,198; 0,273]
Week 16:				
Adjusted Mean Change (SE)	-0,25 (0,050)	-0,25 (0,049)	-0,01 [-0,106; 0,092] 0,893	-0,012 [-0,245; 0,222]
Week 24:				
Adjusted Mean Change (SE)	-0,27 (0,052)	-0,25 (0,051)	-0,02 [-0,125; 0,087] 0,723	-0,032 [-0,266; 0,202]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,91 (0,545)	1,00 (0,634)		
Week 8:				
Adjusted Mean Change (SE)	-0,11 (0,067)	-0,23 (0,066)	0,12 [-0,033; 0,274] 0,123	0,278 [-0,151; 0,708]
Week 16:				
Adjusted Mean Change (SE)	-0,12 (0,076)	-0,31 (0,075)	0,18 [-0,001; 0,363] 0,051	0,370 [-0,061; 0,802]
Week 24:				
Adjusted Mean Change (SE)	-0,16 (0,080)	-0,35 (0,079)	0,19 [-0,002; 0,386] 0,053	0,377 [-0,060; 0,814]
Mean of: Did your respiratory symptoms stop you from performing your usual daily activities?				
Interaction Test	0,244			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	0,64 (0,536)	0,61 (0,585)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,31 (0,070)	-0,21 (0,071)	-0,10 [-0,269; 0,060] 0,212	-0,238 [-0,687; 0,210]
Week 16:				
Adjusted Mean Change (SE)	-0,41 (0,078)	-0,33 (0,079)	-0,08 [-0,269; 0,112] 0,417	-0,157 [-0,593; 0,279]
Week 24:				
Adjusted Mean Change (SE)	-0,40 (0,084)	-0,31 (0,085)	-0,09 [-0,293; 0,122] 0,419	-0,162 [-0,607; 0,282]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	0,84 (0,693)	0,94 (0,667)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,047)	-0,20 (0,048)	0,05 [-0,038; 0,135] 0,275	0,086 [-0,148; 0,319]
Week 16:				
Adjusted Mean Change (SE)	-0,30 (0,051)	-0,30 (0,051)	0,00 [-0,098; 0,104] 0,950	0,005 [-0,226; 0,236]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,053)	-0,32 (0,053)	0,03 [-0,084; 0,135] 0,650	0,040 [-0,192; 0,272]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	1,07 (0,623)	1,04 (0,698)		
Week 8:				
Adjusted Mean Change (SE)	-0,08 (0,070)	-0,21 (0,069)	0,13 [-0,027; 0,290] 0,105	0,291 [-0,136; 0,719]
Week 16:				
Adjusted Mean Change (SE)	-0,11 (0,078)	-0,23 (0,077)	0,12 [-0,063; 0,308] 0,196	0,243 [-0,184; 0,669]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,17 (0,083)	-0,27 (0,082)	0,10 [-0,101; 0,303] 0,328	0,189 [-0,242; 0,621]
Mean of: How severe was your shortness of breath today?				
Interaction Test	0,052			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	0,85 (0,552)	0,71 (0,619)		
Week 8:				
Adjusted Mean Change (SE)	-0,38 (0,073)	-0,22 (0,074)	-0,16 [-0,331; 0,009] 0,063	-0,355 [-0,805; 0,095]
Week 16:				
Adjusted Mean Change (SE)	-0,49 (0,081)	-0,33 (0,082)	-0,16 [-0,357; 0,038] 0,114	-0,306 [-0,744; 0,132]
Week 24:				
Adjusted Mean Change (SE)	-0,50 (0,087)	-0,30 (0,088)	-0,20 [-0,415; 0,016] 0,069	-0,366 [-0,813; 0,082]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	0,97 (0,661)	1,08 (0,629)		
Week 8:				
Adjusted Mean Change (SE)	-0,19 (0,049)	-0,22 (0,049)	0,03 [-0,056; 0,123] 0,468	0,057 [-0,177; 0,290]
Week 16:				
Adjusted Mean Change (SE)	-0,34 (0,053)	-0,31 (0,053)	-0,03 [-0,134; 0,076] 0,584	-0,046 [-0,277; 0,185]
Week 24:				
Adjusted Mean Change (SE)	-0,36 (0,055)	-0,33 (0,055)	-0,03 [-0,142; 0,086] 0,631	-0,042 [-0,275; 0,190]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	1,19 (0,574)	1,20 (0,647)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,14 (0,072)	-0,27 (0,071)	0,13 [-0,038; 0,289] 0,133	0,269 [-0,158; 0,696]
Week 16:				
Adjusted Mean Change (SE)	-0,17 (0,081)	-0,34 (0,080)	0,17 [-0,023; 0,362] 0,084	0,324 [-0,104; 0,752]
Week 24:				
Adjusted Mean Change (SE)	-0,23 (0,086)	-0,36 (0,085)	0,12 [-0,086; 0,332] 0,249	0,223 [-0,209; 0,655]
Mean of: How was your wheeze during the past 12 hours?				
Interaction Test	0,012 *			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	0,66 (0,537)	0,68 (0,606)		
Week 8:				
Adjusted Mean Change (SE)	-0,38 (0,073)	-0,28 (0,074)	-0,10 [-0,271; 0,071] 0,252	-0,219 [-0,667; 0,229]
Week 16:				
Adjusted Mean Change (SE)	-0,46 (0,081)	-0,36 (0,082)	-0,09 [-0,291; 0,103] 0,351	-0,181 [-0,617; 0,256]
Week 24:				
Adjusted Mean Change (SE)	-0,47 (0,086)	-0,38 (0,087)	-0,10 [-0,308; 0,117] 0,379	-0,176 [-0,621; 0,269]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	0,91 (0,685)	0,93 (0,632)		
Week 8:				
Adjusted Mean Change (SE)	-0,19 (0,049)	-0,25 (0,050)	0,06 [-0,030; 0,150] 0,190	0,103 [-0,131; 0,336]
Week 16:				
Adjusted Mean Change (SE)	-0,33 (0,053)	-0,30 (0,053)	-0,03 [-0,134; 0,075] 0,577	-0,047 [-0,278; 0,184]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,34 (0,055)	-0,31 (0,055)	-0,02 [-0,137; 0,088] 0,673	-0,037 [-0,269; 0,196]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,85 (0,612)	0,96 (0,637)		
Week 8:				
Adjusted Mean Change (SE)	-0,08 (0,072)	-0,32 (0,071)	0,24 [0,076; 0,406] 0,004 *	0,515 [0,083; 0,947]
Week 16:				
Adjusted Mean Change (SE)	-0,10 (0,081)	-0,38 (0,080)	0,28 [0,086; 0,471] 0,005 *	0,533 [0,101; 0,966]
Week 24:				
Adjusted Mean Change (SE)	-0,15 (0,085)	-0,41 (0,084)	0,25 [0,048; 0,462] 0,016 *	0,466 [0,030; 0,902]
Mean of: How was your cough during the past 12 hours?				
Interaction Test	0,114			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	0,81 (0,726)	0,77 (0,705)		
Week 8:				
Adjusted Mean Change (SE)	-0,30 (0,080)	-0,16 (0,081)	-0,15 [-0,335; 0,041] 0,124	-0,295 [-0,744; 0,154]
Week 16:				
Adjusted Mean Change (SE)	-0,45 (0,089)	-0,30 (0,090)	-0,15 [-0,370; 0,062] 0,162	-0,271 [-0,709; 0,166]
Week 24:				
Adjusted Mean Change (SE)	-0,45 (0,095)	-0,32 (0,096)	-0,13 [-0,367; 0,103] 0,270	-0,222 [-0,667; 0,223]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	0,92 (0,715)	0,96 (0,647)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,14 (0,054)	-0,14 (0,054)	-0,00 [-0,104; 0,094] 0,922	-0,008 [-0,241; 0,226]
Week 16:				
Adjusted Mean Change (SE)	-0,30 (0,058)	-0,24 (0,058)	-0,06 [-0,177; 0,052] 0,283	-0,090 [-0,322; 0,141]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,060)	-0,26 (0,060)	-0,04 [-0,160; 0,088] 0,568	-0,050 [-0,282; 0,182]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	1,00 (0,620)	0,94 (0,697)		
Week 8:				
Adjusted Mean Change (SE)	-0,06 (0,079)	-0,20 (0,078)	0,14 [-0,038; 0,324] 0,121	0,279 [-0,148; 0,706]
Week 16:				
Adjusted Mean Change (SE)	-0,12 (0,088)	-0,25 (0,087)	0,13 [-0,077; 0,344] 0,214	0,234 [-0,193; 0,660]
Week 24:				
Adjusted Mean Change (SE)	-0,11 (0,093)	-0,25 (0,093)	0,14 [-0,092; 0,364] 0,242	0,227 [-0,205; 0,658]
Did you have chest tightness during the past 12 hours?				
Interaction Test	0,017 *			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	0,58 (0,559)	0,47 (0,586)		
Week 8:				
Adjusted Mean Change (SE)	-0,24 (0,069)	-0,11 (0,070)	-0,13 [-0,289; 0,035] 0,123	-0,294 [-0,744; 0,155]
Week 16:				
Adjusted Mean Change (SE)	-0,33 (0,077)	-0,17 (0,078)	-0,16 [-0,345; 0,027] 0,093	-0,324 [-0,763; 0,114]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,33 (0,081)	-0,14 (0,082)	-0,19 [-0,393; 0,005] 0,056	-0,382 [-0,830; 0,066]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	0,62 (0,614)	0,73 (0,653)		
Week 8:				
Adjusted Mean Change (SE)	-0,07 (0,046)	-0,12 (0,047)	0,04 [-0,044; 0,127] 0,338	0,075 [-0,159; 0,309]
Week 16:				
Adjusted Mean Change (SE)	-0,17 (0,050)	-0,15 (0,050)	-0,01 [-0,111; 0,087] 0,812	-0,020 [-0,251; 0,211]
Week 24:				
Adjusted Mean Change (SE)	-0,18 (0,052)	-0,16 (0,052)	-0,01 [-0,120; 0,091] 0,791	-0,023 [-0,255; 0,209]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,70 (0,632)	0,79 (0,706)		
Week 8:				
Adjusted Mean Change (SE)	0,01 (0,068)	-0,15 (0,068)	0,16 [0,003; 0,315] 0,046 *	0,358 [-0,071; 0,787]
Week 16:				
Adjusted Mean Change (SE)	-0,02 (0,076)	-0,21 (0,075)	0,19 [0,007; 0,369] 0,042 *	0,381 [-0,048; 0,810]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,05 (0,080)	-0,26 (0,079)	0,21 [0,016; 0,403] 0,034 *	0,408 [-0,027; 0,843]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + age + age * treatment + age * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 9.4 Symptoms - Change from Baseline by Gender (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Percentage of mornings with no symptoms on rising				
Interaction Test	0,153			
Gender = Male				
N'	93	84		
Baseline Mean (SD)	39,24 (39,766)	29,61 (35,883)		
Week 8:				
Adjusted Mean Change (SE)	9,15 (3,721)	9,59 (4,047)	-0,45 [-8,477; 7,586] 0,913	-0,012 [-0,311; 0,286]
Week 16:				
Adjusted Mean Change (SE)	14,14 (4,209)	15,60 (4,544)	-1,46 [-11,249; 8,334] 0,770	-0,036 [-0,332; 0,261]
Week 24:				
Adjusted Mean Change (SE)	15,85 (4,334)	20,36 (4,678)	-4,51 [-14,748; 5,725] 0,387	-0,108 [-0,408; 0,191]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	34,65 (37,043)	39,74 (38,184)		
Week 8:				
Adjusted Mean Change (SE)	10,55 (3,655)	5,86 (3,397)	4,69 [-1,740; 11,120] 0,153	0,115 [-0,125; 0,355]
Week 16:				
Adjusted Mean Change (SE)	18,32 (4,016)	11,63 (3,735)	6,69 [-1,136; 14,521] 0,094	0,148 [-0,090; 0,385]
Week 24:				
Adjusted Mean Change (SE)	19,81 (4,107)	13,19 (3,827)	6,63 [-1,549; 14,802] 0,112	0,144 [-0,095; 0,383]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Percentage of days with no day-time symptoms				
Interaction Test	0,742			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	20,51 (32,900)	14,36 (28,238)		
Week 8:				
Adjusted Mean Change (SE)	10,19 (3,176)	7,09 (3,455)	3,10 [-3,751; 9,955] 0,374	0,101 [-0,197; 0,399]
Week 16:				
Adjusted Mean Change (SE)	18,38 (3,868)	11,22 (4,147)	7,16 [-2,123; 16,434] 0,130	0,190 [-0,105; 0,484]
Week 24:				
Adjusted Mean Change (SE)	20,01 (4,081)	16,96 (4,369)	3,05 [-6,947; 13,053] 0,549	0,077 [-0,219; 0,374]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	17,61 (30,293)	16,51 (30,148)		
Week 8:				
Adjusted Mean Change (SE)	7,44 (3,125)	8,06 (2,964)	-0,63 [-6,124; 4,869] 0,823	-0,018 [-0,257; 0,222]
Week 16:				
Adjusted Mean Change (SE)	19,14 (3,644)	14,94 (3,443)	4,20 [-3,257; 11,653] 0,269	0,101 [-0,136; 0,338]
Week 24:				
Adjusted Mean Change (SE)	20,60 (3,808)	16,05 (3,598)	4,55 [-3,483; 12,578] 0,267	0,106 [-0,133; 0,344]
Percentage of days with no night-time awakenings				
Interaction Test	0,816			
Gender = Male				
N'	93	84		
Baseline Mean (SD)	61,03 (37,087)	58,98 (37,800)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	8,76 (3,496)	7,08 (3,786)	1,68 [-5,846; 9,204] 0,662	0,050 [-0,249; 0,348]
Week 16:				
Adjusted Mean Change (SE)	13,32 (3,722)	12,01 (4,015)	1,31 [-7,044; 9,663] 0,758	0,036 [-0,260; 0,333]
Week 24:				
Adjusted Mean Change (SE)	14,42 (3,844)	12,05 (4,143)	2,37 [-6,425; 11,167] 0,597	0,064 [-0,235; 0,364]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	60,05 (37,343)	57,29 (38,566)		
Week 8:				
Adjusted Mean Change (SE)	7,27 (3,428)	6,80 (3,196)	0,47 [-5,561; 6,504] 0,878	0,012 [-0,227; 0,252]
Week 16:				
Adjusted Mean Change (SE)	14,30 (3,593)	9,65 (3,351)	4,65 [-2,036; 11,339] 0,172	0,114 [-0,123; 0,352]
Week 24:				
Adjusted Mean Change (SE)	16,33 (3,681)	12,58 (3,439)	3,75 [-3,282; 10,792] 0,295	0,091 [-0,148; 0,330]
Percentage of days with no asthma symptoms				
Interaction Test	0,842			
Gender = Male				
N'	89	79		
Baseline Mean (SD)	18,67 (33,488)	12,77 (27,518)		
Week 8:				
Adjusted Mean Change (SE)	10,74 (3,522)	8,20 (3,878)	2,54 [-4,725; 9,804] 0,493	0,077 [-0,234; 0,388]
Week 16:				
Adjusted Mean Change (SE)	17,94 (4,156)	13,36 (4,527)	4,57 [-5,048; 14,193] 0,351	0,117 [-0,191; 0,424]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	20,45 (4,368)	17,38 (4,750)	3,06 [-7,305; 13,433] 0,562	0,074 [-0,233; 0,381]
Gender = Female				
N'	126	142		
Baseline Mean (SD)	14,85 (29,198)	14,54 (28,365)		
Week 8:				
Adjusted Mean Change (SE)	9,08 (3,507)	9,72 (3,340)	-0,64 [-6,375; 5,088] 0,826	-0,017 [-0,264; 0,231]
Week 16:				
Adjusted Mean Change (SE)	20,67 (3,952)	17,14 (3,765)	3,53 [-4,034; 11,099] 0,360	0,079 [-0,161; 0,320]
Week 24:				
Adjusted Mean Change (SE)	21,96 (4,110)	17,95 (3,919)	4,01 [-4,160; 12,177] 0,336	0,087 [-0,156; 0,331]
Mean total daily symptom score				
Interaction Test	0,559			
Gender = Male				
N'	89	79		
Baseline Mean (SD)	2,00 (1,452)	2,25 (1,424)		
Week 8:				
Adjusted Mean Change (SE)	-0,50 (0,129)	-0,56 (0,142)	0,06 [-0,202; 0,329] 0,639	0,052 [-0,258; 0,363]
Week 16:				
Adjusted Mean Change (SE)	-0,64 (0,140)	-0,73 (0,153)	0,09 [-0,220; 0,397] 0,573	0,067 [-0,240; 0,374]
Week 24:				
Adjusted Mean Change (SE)	-0,72 (0,145)	-0,80 (0,159)	0,08 [-0,248; 0,405] 0,636	0,057 [-0,250; 0,364]
Gender = Female				
N'	126	142		
Baseline Mean (SD)	2,27 (1,481)	2,26 (1,581)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,44 (0,129)	-0,49 (0,123)	0,04 [-0,164; 0,254] 0,674	0,032 [-0,216; 0,279]
Week 16:				
Adjusted Mean Change (SE)	-0,77 (0,136)	-0,69 (0,130)	-0,07 [-0,316; 0,170] 0,555	-0,048 [-0,288; 0,193]
Week 24:				
Adjusted Mean Change (SE)	-0,79 (0,140)	-0,72 (0,133)	-0,06 [-0,320; 0,194] 0,630	-0,040 [-0,283; 0,203]
Mean day-time symptom score				
Interaction Test	0,728			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	0,79 (0,579)	0,85 (0,519)		
Week 8:				
Adjusted Mean Change (SE)	-0,19 (0,046)	-0,21 (0,049)	0,02 [-0,080; 0,115] 0,727	0,039 [-0,259; 0,337]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,050)	-0,28 (0,054)	0,03 [-0,086; 0,144] 0,619	0,059 [-0,235; 0,353]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,053)	-0,31 (0,057)	0,02 [-0,103; 0,148] 0,728	0,043 [-0,254; 0,340]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,89 (0,572)	0,92 (0,602)		
Week 8:				
Adjusted Mean Change (SE)	-0,14 (0,045)	-0,18 (0,043)	0,04 [-0,036; 0,121] 0,288	0,084 [-0,156; 0,323]
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,048)	-0,26 (0,046)	-0,03 [-0,120; 0,065] 0,554	-0,050 [-0,287; 0,186]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,28 (0,051)	-0,26 (0,048)	-0,02 [-0,119; 0,083] 0,728	-0,031 [-0,270; 0,207]
Mean night-time symptom score				
Interaction Test	0,596			
Gender = Male				
N'	93	84		
Baseline Mean (SD)	0,61 (0,464)	0,70 (0,479)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,041)	-0,16 (0,044)	0,00 [-0,085; 0,090] 0,952	0,007 [-0,292; 0,305]
Week 16:				
Adjusted Mean Change (SE)	-0,21 (0,044)	-0,24 (0,047)	0,03 [-0,072; 0,127] 0,589	0,064 [-0,233; 0,361]
Week 24:				
Adjusted Mean Change (SE)	-0,24 (0,045)	-0,25 (0,049)	0,02 [-0,087; 0,122] 0,738	0,041 [-0,259; 0,340]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,68 (0,489)	0,69 (0,535)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,040)	-0,16 (0,037)	0,01 [-0,065; 0,075] 0,882	0,012 [-0,228; 0,252]
Week 16:				
Adjusted Mean Change (SE)	-0,24 (0,042)	-0,22 (0,039)	-0,03 [-0,107; 0,052] 0,495	-0,058 [-0,295; 0,179]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,043)	-0,24 (0,040)	-0,02 [-0,108; 0,059] 0,566	-0,050 [-0,289; 0,189]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Mean of: How did you sleep last night?				
Interaction Test	0,834			
Gender = Male				
N'	93	84		
Baseline Mean (SD)	0,45 (0,437)	0,51 (0,521)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,042)	-0,13 (0,045)	-0,02 [-0,113; 0,068] 0,621	-0,056 [-0,355; 0,242]
Week 16:				
Adjusted Mean Change (SE)	-0,22 (0,044)	-0,20 (0,047)	-0,01 [-0,110; 0,085] 0,804	-0,029 [-0,326; 0,268]
Week 24:				
Adjusted Mean Change (SE)	-0,23 (0,044)	-0,21 (0,048)	-0,02 [-0,119; 0,080] 0,704	-0,045 [-0,345; 0,254]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,50 (0,497)	0,56 (0,538)		
Week 8:				
Adjusted Mean Change (SE)	-0,13 (0,041)	-0,14 (0,038)	0,02 [-0,057; 0,088] 0,677	0,034 [-0,206; 0,273]
Week 16:				
Adjusted Mean Change (SE)	-0,20 (0,042)	-0,18 (0,039)	-0,02 [-0,099; 0,057] 0,592	-0,045 [-0,282; 0,193]
Week 24:				
Adjusted Mean Change (SE)	-0,23 (0,043)	-0,22 (0,040)	-0,01 [-0,091; 0,068] 0,773	-0,025 [-0,264; 0,214]
Mean of: Did you have asthma symptoms upon awakening in the morning?				
Interaction Test	0,224			
Gender = Male				
N'	93	84		
Baseline Mean (SD)	0,77 (0,593)	0,89 (0,550)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,050)	-0,19 (0,054)	0,03 [-0,078; 0,137] 0,590	0,061 [-0,237; 0,360]
Week 16:				
Adjusted Mean Change (SE)	-0,21 (0,055)	-0,28 (0,060)	0,07 [-0,055; 0,200] 0,264	0,135 [-0,162; 0,432]
Week 24:				
Adjusted Mean Change (SE)	-0,24 (0,058)	-0,30 (0,062)	0,06 [-0,074; 0,198] 0,370	0,112 [-0,188; 0,411]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,86 (0,584)	0,82 (0,624)		
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,049)	-0,17 (0,046)	-0,01 [-0,100; 0,072] 0,748	-0,026 [-0,265; 0,214]
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,053)	-0,24 (0,049)	-0,05 [-0,147; 0,056] 0,379	-0,076 [-0,313; 0,161]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,055)	-0,24 (0,051)	-0,05 [-0,160; 0,058] 0,359	-0,083 [-0,322; 0,156]
Mean of: Did your respiratory symptoms stop you from performing your usual daily activities?				
Interaction Test	0,861			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	0,78 (0,677)	0,86 (0,616)		
Week 8:				
Adjusted Mean Change (SE)	-0,22 (0,052)	-0,22 (0,056)	-0,00 [-0,111; 0,111] 1,000	-0,000 [-0,298; 0,298]
Week 16:				
Adjusted Mean Change (SE)	-0,28 (0,057)	-0,32 (0,061)	0,03 [-0,095; 0,164] 0,601	0,062 [-0,232; 0,356]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,32 (0,060)	-0,33 (0,064)	0,02 [-0,124; 0,158] 0,816	0,029 [-0,268; 0,325]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,89 (0,653)	0,93 (0,701)		
Week 8:				
Adjusted Mean Change (SE)	-0,12 (0,051)	-0,19 (0,048)	0,07 [-0,022; 0,155] 0,143	0,116 [-0,124; 0,355]
Week 16:				
Adjusted Mean Change (SE)	-0,27 (0,055)	-0,27 (0,052)	-0,00 [-0,105; 0,104] 0,989	-0,001 [-0,238; 0,235]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,057)	-0,28 (0,054)	0,03 [-0,087; 0,140] 0,648	0,041 [-0,198; 0,279]
Mean of: How severe was your shortness of breath today?				
Interaction Test	0,639			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	0,94 (0,624)	1,01 (0,587)		
Week 8:				
Adjusted Mean Change (SE)	-0,25 (0,053)	-0,25 (0,058)	0,01 [-0,106; 0,123] 0,887	0,016 [-0,282; 0,314]
Week 16:				
Adjusted Mean Change (SE)	-0,33 (0,059)	-0,36 (0,064)	0,03 [-0,103; 0,166] 0,647	0,055 [-0,240; 0,349]
Week 24:				
Adjusted Mean Change (SE)	-0,36 (0,062)	-0,36 (0,067)	0,00 [-0,141; 0,151] 0,947	0,008 [-0,289; 0,305]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	1,03 (0,639)	1,06 (0,681)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,053)	-0,21 (0,050)	0,03 [-0,067; 0,117] 0,594	0,042 [-0,197; 0,281]
Week 16:				
Adjusted Mean Change (SE)	-0,34 (0,057)	-0,29 (0,054)	-0,04 [-0,152; 0,065] 0,433	-0,067 [-0,303; 0,170]
Week 24:				
Adjusted Mean Change (SE)	-0,35 (0,059)	-0,30 (0,056)	-0,05 [-0,168; 0,067] 0,400	-0,075 [-0,314; 0,163]
Mean of: How was your wheeze during the past 12 hours?				
Interaction Test	0,983			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	0,80 (0,655)	0,84 (0,606)		
Week 8:				
Adjusted Mean Change (SE)	-0,24 (0,054)	-0,27 (0,059)	0,03 [-0,090; 0,142] 0,657	0,050 [-0,248; 0,348]
Week 16:				
Adjusted Mean Change (SE)	-0,28 (0,059)	-0,33 (0,064)	0,05 [-0,087; 0,182] 0,488	0,082 [-0,212; 0,377]
Week 24:				
Adjusted Mean Change (SE)	-0,33 (0,062)	-0,35 (0,066)	0,03 [-0,117; 0,171] 0,715	0,045 [-0,252; 0,342]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,89 (0,648)	0,93 (0,648)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,053)	-0,27 (0,050)	0,09 [0,001; 0,187] 0,048 *	0,157 [-0,083; 0,397]
Week 16:				
Adjusted Mean Change (SE)	-0,33 (0,057)	-0,32 (0,054)	-0,01 [-0,114; 0,102] 0,915	-0,009 [-0,246; 0,228]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,32 (0,059)	-0,33 (0,056)	0,01 [-0,109; 0,123] 0,900	0,011 [-0,227; 0,250]
Mean of: How was your cough during the past 12 hours?				
Interaction Test	0,736			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	0,81 (0,680)	0,90 (0,645)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,059)	-0,17 (0,064)	-0,00 [-0,128; 0,126] 0,992	-0,001 [-0,299; 0,297]
Week 16:				
Adjusted Mean Change (SE)	-0,28 (0,065)	-0,25 (0,070)	-0,02 [-0,170; 0,126] 0,769	-0,035 [-0,329; 0,259]
Week 24:				
Adjusted Mean Change (SE)	-0,30 (0,068)	-0,32 (0,073)	0,01 [-0,147; 0,174] 0,871	0,020 [-0,277; 0,317]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,99 (0,707)	0,94 (0,681)		
Week 8:				
Adjusted Mean Change (SE)	-0,14 (0,058)	-0,14 (0,055)	-0,00 [-0,103; 0,101] 0,980	-0,002 [-0,241; 0,237]
Week 16:				
Adjusted Mean Change (SE)	-0,30 (0,062)	-0,24 (0,059)	-0,06 [-0,176; 0,062] 0,345	-0,081 [-0,317; 0,156]
Week 24:				
Adjusted Mean Change (SE)	-0,27 (0,065)	-0,23 (0,061)	-0,04 [-0,168; 0,090] 0,555	-0,053 [-0,291; 0,186]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Did you have chest tightness during the past 12 hours?				
Interaction Test	0,502			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	0,60 (0,618)	0,64 (0,612)		
Week 8:				
Adjusted Mean Change (SE)	-0,10 (0,051)	-0,15 (0,055)	0,04 [-0,067; 0,152] 0,444	0,086 [-0,212; 0,384]
Week 16:				
Adjusted Mean Change (SE)	-0,13 (0,056)	-0,18 (0,060)	0,04 [-0,085; 0,169] 0,516	0,077 [-0,217; 0,371]
Week 24:				
Adjusted Mean Change (SE)	-0,15 (0,058)	-0,19 (0,062)	0,03 [-0,101; 0,170] 0,618	0,061 [-0,236; 0,358]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,65 (0,599)	0,74 (0,683)		
Week 8:				
Adjusted Mean Change (SE)	-0,08 (0,050)	-0,11 (0,048)	0,03 [-0,058; 0,118] 0,499	0,053 [-0,186; 0,293]
Week 16:				
Adjusted Mean Change (SE)	-0,19 (0,054)	-0,16 (0,051)	-0,03 [-0,133; 0,071] 0,546	-0,051 [-0,288; 0,185]
Week 24:				
Adjusted Mean Change (SE)	-0,20 (0,055)	-0,17 (0,053)	-0,03 [-0,141; 0,076] 0,556	-0,052 [-0,291; 0,187]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + gender + gender * treatment + gender * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 9.5 Symptoms - Change from Baseline by Region (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Percentage of mornings with no symptoms on rising				
Interaction Test	0,554			
Region = Asia				
N'	68	70		
Baseline Mean (SD)	20,44 (30,694)	26,62 (34,583)		
Week 8:				
Adjusted Mean Change (SE)	10,37 (3,306)	11,15 (3,246)	-0,78 [-9,816; 8,249] 0,865	-0,029 [-0,367; 0,308]
Week 16:				
Adjusted Mean Change (SE)	17,79 (4,038)	12,35 (3,944)	5,43 [-5,569; 16,438] 0,333	0,165 [-0,171; 0,500]
Week 24:				
Adjusted Mean Change (SE)	17,81 (4,234)	16,13 (4,129)	1,68 [-9,850; 13,207] 0,775	0,049 [-0,287; 0,384]
Region = Europe				
N'	79	82		
Baseline Mean (SD)	31,22 (35,875)	36,95 (36,643)		
Week 8:				
Adjusted Mean Change (SE)	11,47 (3,044)	10,32 (2,970)	1,15 [-7,199; 9,503] 0,787	0,043 [-0,268; 0,354]
Week 16:				
Adjusted Mean Change (SE)	15,55 (3,702)	18,32 (3,631)	-2,76 [-12,944; 7,416] 0,594	-0,084 [-0,394; 0,226]
Week 24:				
Adjusted Mean Change (SE)	16,81 (3,882)	21,14 (3,828)	-4,33 [-15,035; 6,371] 0,427	-0,128 [-0,443; 0,188]
Region = Latin America				
N'	58	72		
Baseline Mean (SD)	58,60 (39,647)	42,53 (40,147)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	11,89 (3,621)	7,82 (3,197)	4,07 [-5,374; 13,520] 0,398	0,153 [-0,202; 0,507]
Week 16:				
Adjusted Mean Change (SE)	21,57 (4,387)	14,62 (3,875)	6,95 [-4,497; 18,398] 0,234	0,211 [-0,138; 0,559]
Week 24:				
Adjusted Mean Change (SE)	27,15 (4,592)	16,40 (4,078)	10,75 [-1,260; 22,769] 0,079	0,314 [-0,039; 0,667]
Region = Others				
N'	16	8		
Baseline Mean (SD)	51,82 (32,614)	51,62 (37,258)		
Week 8:				
Adjusted Mean Change (SE)	28,57 (6,737)	10,19 (9,519)	18,38 [-4,488; 41,253] 0,115	0,682 [-0,188; 1,553]
Week 16:				
Adjusted Mean Change (SE)	33,27 (8,226)	25,94 (11,623)	7,33 [-20,595; 35,257] 0,606	0,223 [-0,628; 1,074]
Week 24:				
Adjusted Mean Change (SE)	28,83 (8,614)	25,90 (12,170)	2,93 [-26,314; 32,165] 0,844	0,085 [-0,764; 0,934]
Percentage of days with no day-time symptoms				
Interaction Test	N.E.			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	10,05 (25,876)	8,49 (20,677)		
Week 8:				
Adjusted Mean Change (SE)	8,98 (2,762)	8,81 (2,750)	0,16 [-7,521; 7,850] 0,966	0,007 [-0,333; 0,347]
Week 16:				
Adjusted Mean Change (SE)	19,52 (3,928)	13,95 (3,913)	5,57 [-5,366; 16,498] 0,317	0,173 [-0,165; 0,511]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	19,48 (4,160)	15,67 (4,140)	3,81 [-7,758; 15,386] 0,517	0,112 [-0,226; 0,450]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	14,88 (26,517)	12,49 (26,282)		
Week 8:				
Adjusted Mean Change (SE)	6,89 (2,450)	11,56 (2,363)	-4,68 [-11,384; 2,029] 0,171	-0,216 [-0,525; 0,093]
Week 16:				
Adjusted Mean Change (SE)	13,03 (3,388)	17,27 (3,267)	-4,24 [-13,518; 5,029] 0,368	-0,142 [-0,450; 0,167]
Week 24:				
Adjusted Mean Change (SE)	14,54 (3,794)	23,22 (3,680)	-8,69 [-19,101; 1,728] 0,102	-0,262 [-0,577; 0,052]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	31,34 (37,604)	24,72 (36,078)		
Week 8:				
Adjusted Mean Change (SE)	12,08 (3,039)	8,77 (2,746)	3,32 [-4,763; 11,394] 0,419	0,145 [-0,206; 0,496]
Week 16:				
Adjusted Mean Change (SE)	26,79 (3,908)	15,77 (3,523)	11,02 [0,640; 21,403] 0,038 *	0,365 [0,021; 0,710]
Week 24:				
Adjusted Mean Change (SE)	31,81 (4,179)	16,31 (3,774)	15,49 [4,381; 26,605] 0,007 *	0,485 [0,135; 0,835]
Region = Others				
N'	16	8		
Baseline Mean (SD)	28,61 (34,492)	29,11 (36,573)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	32,81 (7,227)	14,08 (10,312)	18,73 [-6,887; 44,347] 0,146	0,658 [-0,250; 1,567]
Week 16:				
Adjusted Mean Change (SE)	45,81 (8,743)	20,08 (12,335)	25,73 [-5,029; 56,497] 0,098	0,736 [-0,138; 1,610]
Week 24:				
Adjusted Mean Change (SE)	41,43 (8,632)	20,52 (12,178)	20,91 [-9,463; 51,280] 0,170	0,606 [-0,260; 1,472]
Percentage of days with no night-time awakenings				
Interaction Test	0,288			
Region = Asia				
N'	68	70		
Baseline Mean (SD)	45,40 (36,746)	45,59 (39,063)		
Week 8:				
Adjusted Mean Change (SE)	10,88 (3,412)	14,07 (3,368)	-3,19 [-12,527; 6,151] 0,503	-0,114 [-0,452; 0,223]
Week 16:				
Adjusted Mean Change (SE)	20,65 (3,414)	15,79 (3,357)	4,86 [-4,467; 14,182] 0,307	0,173 [-0,162; 0,509]
Week 24:				
Adjusted Mean Change (SE)	21,73 (3,414)	20,27 (3,357)	1,46 [-7,864; 10,784] 0,759	0,052 [-0,283; 0,387]
Region = Europe				
N'	79	82		
Baseline Mean (SD)	62,65 (37,630)	63,79 (35,568)		
Week 8:				
Adjusted Mean Change (SE)	12,65 (3,147)	13,36 (3,080)	-0,71 [-9,347; 7,927] 0,872	-0,026 [-0,337; 0,285]
Week 16:				
Adjusted Mean Change (SE)	15,60 (3,137)	19,03 (3,085)	-3,43 [-12,064; 5,195] 0,435	-0,123 [-0,434; 0,187]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	17,27 (3,142)	19,73 (3,105)	-2,47 [-11,134; 6,196] 0,576	-0,090 [-0,405; 0,225]
Region = Latin America				
N'	58	72		
Baseline Mean (SD)	70,43 (33,188)	63,79 (38,058)		
Week 8:				
Adjusted Mean Change (SE)	17,11 (3,700)	9,75 (3,306)	7,36 [-2,361; 17,084] 0,138	0,268 [-0,088; 0,624]
Week 16:				
Adjusted Mean Change (SE)	22,95 (3,684)	13,24 (3,287)	9,71 [0,036; 19,381] 0,049 *	0,349 [-0,002; 0,699]
Week 24:				
Adjusted Mean Change (SE)	25,38 (3,682)	13,65 (3,306)	11,73 [2,036; 21,427] 0,018 *	0,425 [0,070; 0,780]
Region = Others				
N'	16	8		
Baseline Mean (SD)	77,53 (30,291)	52,35 (38,921)		
Week 8:				
Adjusted Mean Change (SE)	15,44 (6,988)	12,96 (9,854)	2,48 [-21,253; 26,208] 0,838	0,089 [-0,760; 0,938]
Week 16:				
Adjusted Mean Change (SE)	20,81 (6,988)	14,77 (9,854)	6,04 [-17,686; 29,775] 0,617	0,216 [-0,634; 1,067]
Week 24:				
Adjusted Mean Change (SE)	21,80 (6,988)	17,93 (9,854)	3,87 [-19,864; 27,597] 0,749	0,138 [-0,711; 0,988]
Percentage of days with no asthma symptoms				
Interaction Test	0,087			
Region = Asia				
N'	66	65		
Baseline Mean (SD)	8,62 (25,807)	8,34 (20,756)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	8,63 (3,704)	7,09 (3,700)	1,54 [-8,707; 11,785] 0,768	0,052 [-0,297; 0,402]
Week 16:				
Adjusted Mean Change (SE)	17,14 (3,673)	12,13 (3,690)	5,00 [-5,191; 15,192] 0,336	0,168 [-0,176; 0,513]
Week 24:				
Adjusted Mean Change (SE)	16,53 (3,685)	13,53 (3,690)	3,00 [-7,204; 13,211] 0,564	0,101 [-0,244; 0,447]
Region = Europe				
N'	77	82		
Baseline Mean (SD)	12,82 (26,676)	10,45 (24,692)		
Week 8:				
Adjusted Mean Change (SE)	6,75 (3,397)	11,08 (3,281)	-4,33 [-13,590; 4,938] 0,360	-0,146 [-0,460; 0,167]
Week 16:				
Adjusted Mean Change (SE)	13,91 (3,382)	17,61 (3,296)	-3,71 [-12,969; 5,558] 0,433	-0,125 [-0,438; 0,188]
Week 24:				
Adjusted Mean Change (SE)	14,34 (3,390)	21,91 (3,320)	-7,57 [-16,872; 1,736] 0,111	-0,258 [-0,576; 0,060]
Region = Latin America				
N'	56	66		
Baseline Mean (SD)	28,26 (38,051)	22,62 (35,254)		
Week 8:				
Adjusted Mean Change (SE)	12,74 (4,071)	12,08 (3,736)	0,66 [-10,109; 11,431] 0,904	0,023 [-0,351; 0,396]
Week 16:				
Adjusted Mean Change (SE)	26,36 (4,022)	20,16 (3,679)	6,20 [-4,426; 16,827] 0,252	0,209 [-0,152; 0,569]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	33,73 (4,006)	20,18 (3,697)	13,55 [2,916; 24,180] 0,013 *	0,457 [0,092; 0,822]
Region = Others				
N'	16	8		
Baseline Mean (SD)	24,65 (31,689)	22,67 (30,003)		
Week 8:				
Adjusted Mean Change (SE)	35,88 (7,608)	10,87 (11,515)	25,00 [-2,036; 52,044] 0,070	0,898 [-0,163; 1,958]
Week 16:				
Adjusted Mean Change (SE)	49,11 (7,429)	27,37 (10,495)	21,74 [-3,477; 46,952] 0,091	0,732 [-0,142; 1,605]
Week 24:				
Adjusted Mean Change (SE)	46,81 (7,429)	27,37 (10,495)	19,43 [-5,783; 44,646] 0,131	0,654 [-0,215; 1,523]
Mean total daily symptom score				
Interaction Test	0,485			
Region = Asia				
N'	66	65		
Baseline Mean (SD)	2,88 (1,511)	2,84 (1,551)		
Week 8:				
Adjusted Mean Change (SE)	-0,43 (0,108)	-0,66 (0,108)	0,23 [-0,068; 0,528] 0,129	0,267 [-0,084; 0,618]
Week 16:				
Adjusted Mean Change (SE)	-0,73 (0,126)	-0,68 (0,126)	-0,04 [-0,390; 0,301] 0,800	-0,044 [-0,388; 0,300]
Week 24:				
Adjusted Mean Change (SE)	-0,74 (0,134)	-0,81 (0,134)	0,07 [-0,294; 0,439] 0,698	0,068 [-0,278; 0,413]
Region = Europe				
N'	77	82		
Baseline Mean (SD)	2,17 (1,291)	2,06 (1,234)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,55 (0,099)	-0,61 (0,095)	0,07 [-0,203; 0,336] 0,628	0,077 [-0,236; 0,391]
Week 16:				
Adjusted Mean Change (SE)	-0,70 (0,115)	-0,87 (0,111)	0,17 [-0,141; 0,486] 0,280	0,173 [-0,141; 0,486]
Week 24:				
Adjusted Mean Change (SE)	-0,74 (0,122)	-0,90 (0,119)	0,16 [-0,172; 0,495] 0,343	0,154 [-0,164; 0,471]
Region = Latin America				
N'	56	66		
Baseline Mean (SD)	1,44 (1,291)	1,97 (1,701)		
Week 8:				
Adjusted Mean Change (SE)	-0,60 (0,118)	-0,54 (0,108)	-0,06 [-0,374; 0,253] 0,704	-0,072 [-0,446; 0,301]
Week 16:				
Adjusted Mean Change (SE)	-0,94 (0,136)	-0,81 (0,124)	-0,13 [-0,486; 0,235] 0,494	-0,125 [-0,484; 0,235]
Week 24:				
Adjusted Mean Change (SE)	-1,05 (0,144)	-0,78 (0,132)	-0,26 [-0,647; 0,118] 0,175	-0,249 [-0,610; 0,112]
Region = Others				
N'	16	8		
Baseline Mean (SD)	1,63 (1,401)	1,89 (1,371)		
Week 8:				
Adjusted Mean Change (SE)	-0,95 (0,221)	-0,51 (0,330)	-0,43 [-1,214; 0,344] 0,273	-0,540 [-1,575; 0,496]
Week 16:				
Adjusted Mean Change (SE)	-1,14 (0,252)	-0,82 (0,355)	-0,32 [-1,171; 0,538] 0,468	-0,314 [-1,168; 0,539]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-1,13 (0,267)	-0,95 (0,377)	-0,18 [-1,084; 0,729] 0,701	-0,166 [-1,016; 0,684]
Mean day-time symptom score				
Interaction Test	0,221			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	1,11 (0,613)	1,12 (0,581)		
Week 8:				
Adjusted Mean Change (SE)	-0,12 (0,047)	-0,24 (0,047)	0,12 [-0,011; 0,247] 0,074	0,307 [-0,035; 0,649]
Week 16:				
Adjusted Mean Change (SE)	-0,27 (0,047)	-0,26 (0,047)	-0,01 [-0,134; 0,123] 0,936	-0,014 [-0,351; 0,324]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,047)	-0,29 (0,047)	0,03 [-0,098; 0,159] 0,642	0,079 [-0,258; 0,417]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	0,85 (0,502)	0,85 (0,470)		
Week 8:				
Adjusted Mean Change (SE)	-0,19 (0,043)	-0,23 (0,042)	0,04 [-0,075; 0,161] 0,473	0,113 [-0,196; 0,421]
Week 16:				
Adjusted Mean Change (SE)	-0,25 (0,043)	-0,33 (0,042)	0,08 [-0,038; 0,197] 0,187	0,208 [-0,101; 0,517]
Week 24:				
Adjusted Mean Change (SE)	-0,27 (0,043)	-0,35 (0,042)	0,08 [-0,036; 0,201] 0,171	0,219 [-0,095; 0,532]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	0,58 (0,520)	0,75 (0,627)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,21 (0,050)	-0,18 (0,045)	-0,03 [-0,161; 0,103] 0,666	-0,077 [-0,428; 0,274]
Week 16:				
Adjusted Mean Change (SE)	-0,35 (0,050)	-0,29 (0,045)	-0,06 [-0,191; 0,071] 0,368	-0,156 [-0,498; 0,186]
Week 24:				
Adjusted Mean Change (SE)	-0,38 (0,050)	-0,28 (0,045)	-0,10 [-0,230; 0,032] 0,140	-0,259 [-0,606; 0,087]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,68 (0,475)	0,69 (0,453)		
Week 8:				
Adjusted Mean Change (SE)	-0,38 (0,096)	-0,24 (0,138)	-0,13 [-0,463; 0,194] 0,422	-0,357 [-1,251; 0,538]
Week 16:				
Adjusted Mean Change (SE)	-0,50 (0,096)	-0,28 (0,135)	-0,22 [-0,545; 0,104] 0,182	-0,578 [-1,442; 0,286]
Week 24:				
Adjusted Mean Change (SE)	-0,48 (0,096)	-0,28 (0,135)	-0,19 [-0,519; 0,130] 0,240	-0,509 [-1,369; 0,352]
Mean night-time symptom score				
Interaction Test	0,467			
Region = Asia				
N'	68	70		
Baseline Mean (SD)	0,88 (0,478)	0,89 (0,536)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,036)	-0,21 (0,036)	0,05 [-0,049; 0,149] 0,319	0,170 [-0,168; 0,508]
Week 16:				
Adjusted Mean Change (SE)	-0,24 (0,041)	-0,23 (0,041)	-0,01 [-0,124; 0,100] 0,836	-0,035 [-0,370; 0,300]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,043)	-0,28 (0,043)	0,02 [-0,102; 0,134] 0,785	0,046 [-0,289; 0,381]
Region = Europe				
N'	79	82		
Baseline Mean (SD)	0,65 (0,425)	0,61 (0,432)		
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,033)	-0,20 (0,033)	0,02 [-0,069; 0,114] 0,635	0,075 [-0,236; 0,386]
Week 16:				
Adjusted Mean Change (SE)	-0,23 (0,038)	-0,29 (0,037)	0,06 [-0,046; 0,162] 0,276	0,172 [-0,138; 0,483]
Week 24:				
Adjusted Mean Change (SE)	-0,24 (0,040)	-0,29 (0,039)	0,04 [-0,067; 0,153] 0,441	0,124 [-0,191; 0,439]
Region = Latin America				
N'	58	72		
Baseline Mean (SD)	0,42 (0,415)	0,61 (0,544)		
Week 8:				
Adjusted Mean Change (SE)	-0,21 (0,039)	-0,17 (0,035)	-0,04 [-0,148; 0,059] 0,395	-0,153 [-0,508; 0,201]
Week 16:				
Adjusted Mean Change (SE)	-0,31 (0,045)	-0,24 (0,040)	-0,07 [-0,184; 0,050] 0,259	-0,200 [-0,548; 0,148]
Week 24:				
Adjusted Mean Change (SE)	-0,35 (0,047)	-0,25 (0,042)	-0,10 [-0,222; 0,024] 0,113	-0,284 [-0,637; 0,069]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,50 (0,518)	0,64 (0,462)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,29 (0,074)	-0,21 (0,104)	-0,08 [-0,326; 0,175] 0,553	-0,257 [-1,109; 0,595]
Week 16:				
Adjusted Mean Change (SE)	-0,35 (0,084)	-0,31 (0,119)	-0,04 [-0,323; 0,247] 0,795	-0,112 [-0,962; 0,737]
Week 24:				
Adjusted Mean Change (SE)	-0,33 (0,088)	-0,36 (0,125)	0,03 [-0,274; 0,325] 0,867	0,073 [-0,776; 0,922]
Mean of: How did you sleep last night?				
Interaction Test	0,264			
Region = Asia				
N'	68	70		
Baseline Mean (SD)	0,67 (0,492)	0,72 (0,563)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,040)	-0,22 (0,039)	0,06 [-0,051; 0,166] 0,302	0,177 [-0,161; 0,515]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,040)	-0,24 (0,039)	-0,01 [-0,120; 0,097] 0,837	-0,035 [-0,370; 0,300]
Week 24:				
Adjusted Mean Change (SE)	-0,28 (0,040)	-0,30 (0,039)	0,02 [-0,090; 0,127] 0,742	0,056 [-0,279; 0,391]
Region = Europe				
N'	79	82		
Baseline Mean (SD)	0,43 (0,436)	0,45 (0,461)		
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,037)	-0,21 (0,036)	0,02 [-0,078; 0,123] 0,659	0,070 [-0,241; 0,381]
Week 16:				
Adjusted Mean Change (SE)	-0,23 (0,037)	-0,28 (0,036)	0,05 [-0,052; 0,149] 0,341	0,150 [-0,160; 0,461]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,25 (0,037)	-0,29 (0,036)	0,04 [-0,064; 0,137] 0,479	0,114 [-0,201; 0,429]
Region = Latin America				
N'	58	72		
Baseline Mean (SD)	0,36 (0,431)	0,47 (0,537)		
Week 8:				
Adjusted Mean Change (SE)	-0,24 (0,043)	-0,15 (0,038)	-0,08 [-0,196; 0,030] 0,150	-0,260 [-0,616; 0,096]
Week 16:				
Adjusted Mean Change (SE)	-0,30 (0,043)	-0,21 (0,038)	-0,10 [-0,208; 0,017] 0,095	-0,296 [-0,645; 0,054]
Week 24:				
Adjusted Mean Change (SE)	-0,33 (0,043)	-0,22 (0,038)	-0,11 [-0,221; 0,004] 0,059	-0,338 [-0,691; 0,015]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,33 (0,496)	0,68 (0,550)		
Week 8:				
Adjusted Mean Change (SE)	-0,21 (0,081)	-0,17 (0,115)	-0,04 [-0,318; 0,234] 0,765	-0,130 [-0,979; 0,720]
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,081)	-0,17 (0,115)	-0,11 [-0,389; 0,163] 0,422	-0,348 [-1,203; 0,506]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,081)	-0,27 (0,115)	-0,03 [-0,304; 0,248] 0,843	-0,086 [-0,935; 0,763]
Mean of: Did you have asthma symptoms upon awakening in the morning?				
Interaction Test	0,902			
Region = Asia				
N'	68	70		
Baseline Mean (SD)	1,10 (0,576)	1,05 (0,621)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,051)	-0,20 (0,051)	0,04 [-0,105; 0,176] 0,619	0,085 [-0,253; 0,422]
Week 16:				
Adjusted Mean Change (SE)	-0,24 (0,051)	-0,22 (0,050)	-0,02 [-0,162; 0,117] 0,753	-0,053 [-0,388; 0,282]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,051)	-0,26 (0,050)	0,00 [-0,138; 0,142] 0,978	0,005 [-0,330; 0,340]
Region = Europe				
N'	79	82		
Baseline Mean (SD)	0,87 (0,541)	0,78 (0,519)		
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,047)	-0,20 (0,046)	0,01 [-0,116; 0,144] 0,831	0,034 [-0,277; 0,345]
Week 16:				
Adjusted Mean Change (SE)	-0,24 (0,047)	-0,30 (0,046)	0,06 [-0,073; 0,185] 0,396	0,134 [-0,176; 0,445]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,047)	-0,29 (0,047)	0,04 [-0,092; 0,168] 0,570	0,091 [-0,224; 0,406]
Region = Latin America				
N'	58	72		
Baseline Mean (SD)	0,48 (0,479)	0,76 (0,631)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,056)	-0,17 (0,050)	0,00 [-0,145; 0,148] 0,983	0,004 [-0,351; 0,358]
Week 16:				
Adjusted Mean Change (SE)	-0,30 (0,056)	-0,28 (0,049)	-0,02 [-0,166; 0,126] 0,788	-0,048 [-0,395; 0,300]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,35 (0,056)	-0,28 (0,050)	-0,07 [-0,213; 0,079] 0,369	-0,161 [-0,512; 0,190]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,68 (0,596)	0,60 (0,474)		
Week 8:				
Adjusted Mean Change (SE)	-0,37 (0,105)	-0,22 (0,148)	-0,15 [-0,507; 0,203] 0,401	-0,364 [-1,218; 0,491]
Week 16:				
Adjusted Mean Change (SE)	-0,42 (0,105)	-0,41 (0,148)	-0,01 [-0,364; 0,346] 0,959	-0,022 [-0,871; 0,826]
Week 24:				
Adjusted Mean Change (SE)	-0,38 (0,105)	-0,41 (0,148)	0,02 [-0,330; 0,380] 0,892	0,059 [-0,790; 0,908]
Mean of: Did your respiratory symptoms stop you from performing your usual daily activities?				
Interaction Test	0,828			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	1,20 (0,646)	1,18 (0,651)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,046)	-0,22 (0,046)	0,06 [-0,070; 0,183] 0,381	0,150 [-0,191; 0,490]
Week 16:				
Adjusted Mean Change (SE)	-0,32 (0,054)	-0,25 (0,054)	-0,07 [-0,221; 0,075] 0,331	-0,165 [-0,503; 0,173]
Week 24:				
Adjusted Mean Change (SE)	-0,31 (0,059)	-0,28 (0,059)	-0,02 [-0,182; 0,140] 0,798	-0,043 [-0,381; 0,294]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	0,89 (0,616)	0,91 (0,582)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,19 (0,042)	-0,22 (0,041)	0,03 [-0,085; 0,146] 0,603	0,082 [-0,227; 0,390]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,050)	-0,36 (0,048)	0,10 [-0,033; 0,238] 0,137	0,234 [-0,075; 0,543]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,054)	-0,37 (0,052)	0,08 [-0,065; 0,231] 0,270	0,176 [-0,137; 0,490]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	0,48 (0,545)	0,68 (0,716)		
Week 8:				
Adjusted Mean Change (SE)	-0,14 (0,050)	-0,19 (0,044)	0,05 [-0,083; 0,176] 0,481	0,125 [-0,226; 0,476]
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,058)	-0,29 (0,052)	0,01 [-0,145; 0,156] 0,947	0,012 [-0,330; 0,353]
Week 24:				
Adjusted Mean Change (SE)	-0,30 (0,063)	-0,29 (0,056)	-0,02 [-0,180; 0,148] 0,850	-0,033 [-0,378; 0,312]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,53 (0,548)	0,54 (0,407)		
Week 8:				
Adjusted Mean Change (SE)	-0,29 (0,094)	-0,32 (0,136)	0,03 [-0,289; 0,358] 0,833	0,093 [-0,795; 0,982]
Week 16:				
Adjusted Mean Change (SE)	-0,39 (0,110)	-0,36 (0,155)	-0,03 [-0,402; 0,344] 0,879	-0,066 [-0,915; 0,783]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,33 (0,120)	-0,39 (0,169)	0,06 [-0,346; 0,466] 0,772	0,125 [-0,724; 0,975]
Mean of: How severe was your shortness of breath today?				
Interaction Test	N.E.			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	1,27 (0,640)	1,31 (0,631)		
Week 8:				
Adjusted Mean Change (SE)	-0,23 (0,054)	-0,33 (0,054)	0,10 [-0,052; 0,249] 0,200	0,223 [-0,118; 0,564]
Week 16:				
Adjusted Mean Change (SE)	-0,40 (0,063)	-0,41 (0,063)	0,00 [-0,175; 0,178] 0,986	0,003 [-0,334; 0,340]
Week 24:				
Adjusted Mean Change (SE)	-0,41 (0,068)	-0,43 (0,067)	0,02 [-0,166; 0,210] 0,818	0,040 [-0,298; 0,377]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	1,02 (0,575)	1,00 (0,540)		
Week 8:				
Adjusted Mean Change (SE)	-0,24 (0,037)	-0,27 (0,036)	0,03 [-0,072; 0,131] 0,562	0,091 [-0,217; 0,399]
Week 16:				
Adjusted Mean Change (SE)	-0,33 (0,047)	-0,39 (0,045)	0,06 [-0,062; 0,192] 0,317	0,157 [-0,151; 0,466]
Week 24:				
Adjusted Mean Change (SE)	-0,36 (0,054)	-0,39 (0,053)	0,03 [-0,123; 0,175] 0,734	0,054 [-0,259; 0,367]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	0,69 (0,573)	0,89 (0,718)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,23 (0,050)	-0,19 (0,045)	-0,04 [-0,171; 0,094] 0,566	-0,103 [-0,454; 0,248]
Week 16:				
Adjusted Mean Change (SE)	-0,36 (0,054)	-0,28 (0,048)	-0,08 [-0,224; 0,062] 0,265	-0,195 [-0,538; 0,147]
Week 24:				
Adjusted Mean Change (SE)	-0,41 (0,056)	-0,29 (0,051)	-0,12 [-0,274; 0,026] 0,104	-0,289 [-0,636; 0,058]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,77 (0,552)	0,68 (0,451)		
Week 8:				
Adjusted Mean Change (SE)	-0,37 (0,110)	-0,14 (0,157)	-0,22 [-0,616; 0,166] 0,250	-0,518 [-1,419; 0,382]
Week 16:				
Adjusted Mean Change (SE)	-0,44 (0,141)	-0,15 (0,198)	-0,30 [-0,793; 0,197] 0,228	-0,531 [-1,393; 0,331]
Week 24:				
Adjusted Mean Change (SE)	-0,39 (0,135)	-0,13 (0,189)	-0,26 [-0,730; 0,219] 0,281	-0,474 [-1,333; 0,385]
Mean of: How was your wheeze during the past 12 hours?				
Interaction Test	0,055			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	1,05 (0,702)	1,07 (0,636)		
Week 8:				
Adjusted Mean Change (SE)	-0,13 (0,048)	-0,32 (0,048)	0,19 [0,056; 0,319] 0,005 *	0,482 [0,137; 0,827]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,055)	-0,32 (0,055)	0,06 [-0,092; 0,214] 0,433	0,134 [-0,203; 0,472]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,25 (0,059)	-0,35 (0,059)	0,10 [-0,060; 0,268] 0,214	0,213 [-0,125; 0,551]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	0,83 (0,583)	0,80 (0,559)		
Week 8:				
Adjusted Mean Change (SE)	-0,22 (0,044)	-0,31 (0,042)	0,09 [-0,034; 0,206] 0,158	0,222 [-0,087; 0,531]
Week 16:				
Adjusted Mean Change (SE)	-0,27 (0,051)	-0,39 (0,049)	0,12 [-0,020; 0,260] 0,093	0,264 [-0,045; 0,574]
Week 24:				
Adjusted Mean Change (SE)	-0,31 (0,055)	-0,39 (0,053)	0,08 [-0,070; 0,231] 0,294	0,168 [-0,146; 0,481]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	0,69 (0,651)	0,84 (0,690)		
Week 8:				
Adjusted Mean Change (SE)	-0,29 (0,051)	-0,26 (0,046)	-0,03 [-0,163; 0,106] 0,680	-0,074 [-0,425; 0,277]
Week 16:				
Adjusted Mean Change (SE)	-0,43 (0,059)	-0,34 (0,053)	-0,09 [-0,248; 0,063] 0,242	-0,204 [-0,547; 0,138]
Week 24:				
Adjusted Mean Change (SE)	-0,44 (0,063)	-0,35 (0,057)	-0,09 [-0,256; 0,077] 0,293	-0,185 [-0,531; 0,161]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,72 (0,574)	0,87 (0,628)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,45 (0,097)	-0,25 (0,141)	-0,20 [-0,534; 0,140] 0,251	-0,512 [-1,413; 0,388]
Week 16:				
Adjusted Mean Change (SE)	-0,59 (0,113)	-0,27 (0,160)	-0,32 [-0,701; 0,069] 0,108	-0,697 [-1,568; 0,174]
Week 24:				
Adjusted Mean Change (SE)	-0,61 (0,121)	-0,27 (0,172)	-0,34 [-0,754; 0,072] 0,105	-0,702 [-1,573; 0,170]
Mean of: How was your cough during the past 12 hours?				
Interaction Test	0,073			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	1,13 (0,673)	1,05 (0,662)		
Week 8:				
Adjusted Mean Change (SE)	-0,08 (0,052)	-0,21 (0,052)	0,13 [-0,014; 0,274] 0,078	0,305 [-0,036; 0,647]
Week 16:				
Adjusted Mean Change (SE)	-0,25 (0,061)	-0,25 (0,061)	-0,00 [-0,170; 0,167] 0,990	-0,002 [-0,340; 0,335]
Week 24:				
Adjusted Mean Change (SE)	-0,25 (0,066)	-0,28 (0,065)	0,03 [-0,154; 0,209] 0,767	0,051 [-0,287; 0,388]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	0,96 (0,618)	0,92 (0,598)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,048)	-0,18 (0,046)	0,03 [-0,102; 0,161] 0,657	0,070 [-0,238; 0,378]
Week 16:				
Adjusted Mean Change (SE)	-0,24 (0,057)	-0,26 (0,055)	0,03 [-0,129; 0,180] 0,745	0,051 [-0,257; 0,359]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,19 (0,061)	-0,33 (0,059)	0,13 [-0,033; 0,302] 0,115	0,252 [-0,062; 0,566]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	0,65 (0,769)	0,82 (0,737)		
Week 8:				
Adjusted Mean Change (SE)	-0,25 (0,056)	-0,14 (0,050)	-0,11 [-0,262; 0,033] 0,128	-0,272 [-0,624; 0,080]
Week 16:				
Adjusted Mean Change (SE)	-0,41 (0,065)	-0,31 (0,059)	-0,09 [-0,265; 0,077] 0,283	-0,187 [-0,529; 0,155]
Week 24:				
Adjusted Mean Change (SE)	-0,44 (0,070)	-0,26 (0,063)	-0,18 [-0,369; 0,001] 0,052	-0,342 [-0,690; 0,005]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,77 (0,607)	0,86 (0,676)		
Week 8:				
Adjusted Mean Change (SE)	-0,47 (0,106)	-0,22 (0,155)	-0,25 [-0,623; 0,115] 0,177	-0,603 [-1,508; 0,302]
Week 16:				
Adjusted Mean Change (SE)	-0,65 (0,125)	-0,25 (0,177)	-0,40 [-0,822; 0,028] 0,067	-0,795 [-1,673; 0,083]
Week 24:				
Adjusted Mean Change (SE)	-0,64 (0,135)	-0,27 (0,190)	-0,37 [-0,827; 0,089] 0,114	-0,686 [-1,556; 0,185]
Did you have chest tightness during the past 12 hours?				
Interaction Test	0,300			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	0,91 (0,713)	1,01 (0,721)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,03 (0,045)	-0,15 (0,046)	0,12 [-0,004; 0,245] 0,057	0,326 [-0,016; 0,669]
Week 16:				
Adjusted Mean Change (SE)	-0,14 (0,053)	-0,13 (0,053)	-0,00 [-0,149; 0,140] 0,950	-0,011 [-0,348; 0,327]
Week 24:				
Adjusted Mean Change (SE)	-0,13 (0,056)	-0,16 (0,056)	0,03 [-0,122; 0,186] 0,684	0,069 [-0,268; 0,407]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	0,56 (0,510)	0,60 (0,561)		
Week 8:				
Adjusted Mean Change (SE)	-0,11 (0,042)	-0,15 (0,040)	0,05 [-0,068; 0,159] 0,435	0,123 [-0,186; 0,431]
Week 16:				
Adjusted Mean Change (SE)	-0,14 (0,049)	-0,23 (0,047)	0,09 [-0,041; 0,223] 0,177	0,212 [-0,097; 0,521]
Week 24:				
Adjusted Mean Change (SE)	-0,16 (0,052)	-0,24 (0,050)	0,09 [-0,056; 0,227] 0,237	0,189 [-0,125; 0,502]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	0,41 (0,495)	0,54 (0,631)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,048)	-0,11 (0,044)	-0,04 [-0,170; 0,085] 0,511	-0,117 [-0,468; 0,234]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,056)	-0,17 (0,050)	-0,08 [-0,229; 0,064] 0,270	-0,192 [-0,534; 0,151]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,30 (0,059)	-0,16 (0,054)	-0,13 [-0,291; 0,023] 0,094	-0,295 [-0,642; 0,052]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,61 (0,515)	0,53 (0,468)		
Week 8:				
Adjusted Mean Change (SE)	-0,27 (0,092)	-0,22 (0,133)	-0,05 [-0,372; 0,264] 0,738	-0,149 [-1,038; 0,740]
Week 16:				
Adjusted Mean Change (SE)	-0,38 (0,107)	-0,30 (0,151)	-0,08 [-0,448; 0,280] 0,650	-0,197 [-1,047; 0,654]
Week 24:				
Adjusted Mean Change (SE)	-0,34 (0,114)	-0,25 (0,161)	-0,09 [-0,479; 0,296] 0,644	-0,200 [-1,051; 0,650]

N': Number of patients in the analysis
CI: Confidence Interval
N.E.: not estimable
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: unstructured covariance matrix
Exceptional model(s): **Percentage of days with no day-time symptoms**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction [by region], **Percentage of days with no night-time awakenings**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: compound symmetry covariance matrix, **Percentage of days with no asthma symptoms**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: compound symmetry covariance matrix, **Mean day-time symptom score**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: compound symmetry covariance matrix, **Mean of: How did you sleep last night?**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: compound symmetry covariance matrix, **Mean of: Did you have asthma symptoms upon awakening in the morning?**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: compound symmetry covariance matrix, **Mean of: How severe was your shortness of breath today?**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction [by region]
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 9.6 Symptoms - Change from Baseline by History of Asthma Exacerbation (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Percentage of mornings with no symptoms on rising				
Interaction Test	0,129			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	188	191		
Baseline Mean (SD)	35,53 (38,255)	38,06 (38,494)		
Week 8:				
Adjusted Mean Change (SE)	9,63 (3,260)	7,80 (3,301)	1,84 [-3,623; 7,300] 0,509	0,041 [-0,163; 0,245]
Week 16:				
Adjusted Mean Change (SE)	15,49 (3,538)	14,08 (3,571)	1,41 [-5,234; 8,062] 0,676	0,029 [-0,173; 0,231]
Week 24:				
Adjusted Mean Change (SE)	16,72 (3,610)	16,95 (3,647)	-0,22 [-7,174; 6,726] 0,950	-0,005 [-0,209; 0,200]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	41		
Baseline Mean (SD)	42,56 (37,851)	26,79 (31,964)		
Week 8:				
Adjusted Mean Change (SE)	10,98 (5,492)	3,68 (4,932)	7,31 [-5,145; 19,760] 0,250	0,233 [-0,229; 0,696]
Week 16:				
Adjusted Mean Change (SE)	21,75 (6,405)	7,56 (5,749)	14,19 [-1,002; 29,380] 0,067	0,388 [-0,077; 0,853]
Week 24:				
Adjusted Mean Change (SE)	25,27 (6,624)	9,50 (5,951)	15,77 [-0,072; 31,610] 0,051	0,417 [-0,049; 0,883]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Percentage of days with no day-time symptoms				
Interaction Test	0,064			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	18,85 (32,133)	16,39 (29,868)		
Week 8:				
Adjusted Mean Change (SE)	8,39 (2,784)	8,19 (2,870)	0,19 [-4,467; 4,856] 0,935	0,005 [-0,198; 0,208]
Week 16:				
Adjusted Mean Change (SE)	17,24 (3,179)	14,17 (3,245)	3,07 [-3,227; 9,362] 0,339	0,069 [-0,132; 0,270]
Week 24:				
Adjusted Mean Change (SE)	18,73 (3,306)	17,86 (3,370)	0,87 [-5,910; 7,655] 0,801	0,019 [-0,184; 0,222]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	18,79 (27,125)	12,51 (27,293)		
Week 8:				
Adjusted Mean Change (SE)	11,85 (4,701)	6,88 (4,239)	4,96 [-5,740; 15,664] 0,363	0,186 [-0,279; 0,650]
Week 16:				
Adjusted Mean Change (SE)	29,72 (5,970)	12,32 (5,390)	17,40 [2,926; 31,869] 0,019 *	0,509 [0,041; 0,977]
Week 24:				
Adjusted Mean Change (SE)	31,46 (6,342)	10,82 (5,748)	20,64 [5,069; 36,210] 0,009 *	0,571 [0,098; 1,044]
Percentage of days with no night-time awakenings				
Interaction Test	0,044 *			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	188	191		
Baseline Mean (SD)	60,74 (37,709)	60,07 (37,962)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	7,83 (3,037)	8,90 (3,078)	-1,07 [-6,150; 4,016] 0,680	-0,026 [-0,230; 0,178]
Week 16:				
Adjusted Mean Change (SE)	13,43 (3,168)	12,80 (3,205)	0,64 [-5,020; 6,294] 0,825	0,015 [-0,187; 0,216]
Week 24:				
Adjusted Mean Change (SE)	15,61 (3,243)	14,42 (3,282)	1,20 [-4,782; 7,181] 0,694	0,027 [-0,177; 0,231]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	41		
Baseline Mean (SD)	58,86 (34,317)	47,83 (38,249)		
Week 8:				
Adjusted Mean Change (SE)	10,25 (5,121)	-0,95 (4,593)	11,20 [-0,389; 22,784] 0,058	0,383 [-0,082; 0,848]
Week 16:				
Adjusted Mean Change (SE)	18,41 (5,563)	1,19 (4,988)	17,22 [4,299; 30,146] 0,009 *	0,543 [0,074; 1,012]
Week 24:				
Adjusted Mean Change (SE)	17,05 (5,798)	4,41 (5,205)	12,64 [-0,992; 26,273] 0,069	0,382 [-0,083; 0,847]
Percentage of days with no asthma symptoms				
Interaction Test	0,093			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	182	181		
Baseline Mean (SD)	16,51 (31,960)	14,95 (29,124)		
Week 8:				
Adjusted Mean Change (SE)	9,87 (3,158)	9,94 (3,282)	-0,08 [-4,980; 4,830] 0,976	-0,002 [-0,213; 0,209]
Week 16:				
Adjusted Mean Change (SE)	18,47 (3,506)	16,83 (3,623)	1,64 [-4,838; 8,122] 0,619	0,034 [-0,173; 0,241]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	20,07 (3,627)	19,60 (3,745)	0,48 [-6,510; 7,466] 0,893	0,010 [-0,199; 0,218]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	16,00 (25,689)	9,20 (22,018)		
Week 8:				
Adjusted Mean Change (SE)	11,73 (5,041)	7,68 (4,543)	4,05 [-7,037; 15,132] 0,474	0,146 [-0,334; 0,627]
Week 16:				
Adjusted Mean Change (SE)	27,75 (6,168)	13,20 (5,574)	14,55 [0,022; 29,080] 0,050 *	0,415 [-0,054; 0,883]
Week 24:				
Adjusted Mean Change (SE)	30,59 (6,538)	11,28 (5,934)	19,31 [3,648; 34,969] 0,016 *	0,521 [0,047; 0,996]
Mean total daily symptom score				
Interaction Test	0,060			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	182	181		
Baseline Mean (SD)	2,17 (1,475)	2,19 (1,518)		
Week 8:				
Adjusted Mean Change (SE)	-0,48 (0,115)	-0,58 (0,120)	0,10 [-0,074; 0,283] 0,250	0,068 [-0,143; 0,278]
Week 16:				
Adjusted Mean Change (SE)	-0,71 (0,121)	-0,79 (0,126)	0,08 [-0,127; 0,287] 0,449	0,048 [-0,159; 0,255]
Week 24:				
Adjusted Mean Change (SE)	-0,76 (0,124)	-0,83 (0,129)	0,08 [-0,142; 0,297] 0,490	0,046 [-0,162; 0,254]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	2,09 (1,471)	2,58 (1,524)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,52 (0,184)	-0,29 (0,166)	-0,23 [-0,629; 0,177] 0,272	-0,224 [-0,706; 0,257]
Week 16:				
Adjusted Mean Change (SE)	-0,88 (0,204)	-0,44 (0,184)	-0,44 [-0,902; 0,028] 0,065	-0,377 [-0,845; 0,090]
Week 24:				
Adjusted Mean Change (SE)	-0,89 (0,213)	-0,46 (0,193)	-0,42 [-0,917; 0,069] 0,092	-0,353 [-0,823; 0,117]
Mean day-time symptom score				
Interaction Test	0,103			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	0,85 (0,581)	0,88 (0,572)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,040)	-0,21 (0,041)	0,04 [-0,023; 0,110] 0,201	0,078 [-0,125; 0,282]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,043)	-0,29 (0,044)	0,02 [-0,055; 0,101] 0,568	0,038 [-0,163; 0,239]
Week 24:				
Adjusted Mean Change (SE)	-0,28 (0,044)	-0,30 (0,045)	0,03 [-0,058; 0,112] 0,532	0,044 [-0,158; 0,247]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	0,81 (0,552)	0,94 (0,583)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,067)	-0,14 (0,060)	-0,04 [-0,189; 0,116] 0,641	-0,095 [-0,559; 0,369]
Week 16:				
Adjusted Mean Change (SE)	-0,36 (0,076)	-0,21 (0,069)	-0,16 [-0,334; 0,024] 0,090	-0,357 [-0,821; 0,108]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,35 (0,081)	-0,19 (0,074)	-0,16 [-0,357; 0,034] 0,105	-0,349 [-0,816; 0,118]
Mean night-time symptom score				
Interaction Test	0,055			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	188	191		
Baseline Mean (SD)	0,65 (0,479)	0,67 (0,516)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,035)	-0,18 (0,036)	0,02 [-0,036; 0,083] 0,436	0,049 [-0,156; 0,253]
Week 16:				
Adjusted Mean Change (SE)	-0,23 (0,037)	-0,25 (0,038)	0,02 [-0,044; 0,091] 0,499	0,045 [-0,157; 0,247]
Week 24:				
Adjusted Mean Change (SE)	-0,25 (0,038)	-0,27 (0,039)	0,02 [-0,051; 0,091] 0,583	0,038 [-0,166; 0,242]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	41		
Baseline Mean (SD)	0,65 (0,482)	0,83 (0,490)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,060)	-0,07 (0,054)	-0,09 [-0,227; 0,044] 0,186	-0,267 [-0,730; 0,196]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,066)	-0,11 (0,059)	-0,15 [-0,305; 0,003] 0,055	-0,400 [-0,865; 0,066]
Week 24:				
Adjusted Mean Change (SE)	-0,28 (0,069)	-0,13 (0,062)	-0,14 [-0,305; 0,019] 0,083	-0,365 [-0,830; 0,099]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Mean of: How did you sleep last night?				
Interaction Test	0,086			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	188	191		
Baseline Mean (SD)	0,47 (0,478)	0,52 (0,528)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,036)	-0,16 (0,037)	0,02 [-0,043; 0,079] 0,569	0,036 [-0,168; 0,240]
Week 16:				
Adjusted Mean Change (SE)	-0,21 (0,037)	-0,22 (0,038)	0,01 [-0,053; 0,078] 0,710	0,024 [-0,178; 0,226]
Week 24:				
Adjusted Mean Change (SE)	-0,24 (0,038)	-0,24 (0,038)	0,01 [-0,062; 0,073] 0,875	0,011 [-0,194; 0,215]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	41		
Baseline Mean (SD)	0,50 (0,444)	0,67 (0,539)		
Week 8:				
Adjusted Mean Change (SE)	-0,12 (0,061)	-0,03 (0,055)	-0,08 [-0,223; 0,055] 0,236	-0,241 [-0,703; 0,222]
Week 16:				
Adjusted Mean Change (SE)	-0,22 (0,065)	-0,05 (0,058)	-0,17 [-0,323; -0,022] 0,025 *	-0,465 [-0,932; 0,002]
Week 24:				
Adjusted Mean Change (SE)	-0,21 (0,066)	-0,10 (0,059)	-0,11 [-0,259; 0,049] 0,179	-0,279 [-0,742; 0,184]
Mean of: Did you have asthma symptoms upon awakening in the morning?				
Interaction Test	0,098			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	188	191		
Baseline Mean (SD)	0,83 (0,585)	0,82 (0,600)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,044)	-0,19 (0,044)	0,02 [-0,049; 0,097] 0,517	0,040 [-0,164; 0,244]
Week 16:				
Adjusted Mean Change (SE)	-0,25 (0,047)	-0,27 (0,047)	0,03 [-0,058; 0,114] 0,525	0,043 [-0,159; 0,245]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,048)	-0,29 (0,049)	0,03 [-0,065; 0,120] 0,559	0,042 [-0,162; 0,246]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	41		
Baseline Mean (SD)	0,79 (0,616)	0,99 (0,574)		
Week 8:				
Adjusted Mean Change (SE)	-0,20 (0,074)	-0,10 (0,066)	-0,10 [-0,271; 0,063] 0,220	-0,248 [-0,710; 0,215]
Week 16:				
Adjusted Mean Change (SE)	-0,30 (0,084)	-0,17 (0,075)	-0,13 [-0,327; 0,068] 0,199	-0,270 [-0,733; 0,193]
Week 24:				
Adjusted Mean Change (SE)	-0,34 (0,088)	-0,16 (0,079)	-0,18 [-0,391; 0,030] 0,093	-0,358 [-0,823; 0,106]
Mean of: Did your respiratory symptoms stop you from performing your usual daily activities?				
Interaction Test	0,214			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	0,86 (0,662)	0,90 (0,667)		
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,045)	-0,23 (0,047)	0,05 [-0,026; 0,125] 0,197	0,079 [-0,124; 0,283]
Week 16:				
Adjusted Mean Change (SE)	-0,28 (0,048)	-0,32 (0,049)	0,04 [-0,047; 0,129] 0,357	0,061 [-0,139; 0,262]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,050)	-0,33 (0,051)	0,04 [-0,054; 0,138] 0,393	0,060 [-0,142; 0,263]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	0,77 (0,677)	0,89 (0,700)		
Week 8:				
Adjusted Mean Change (SE)	-0,13 (0,076)	-0,11 (0,069)	-0,02 [-0,195; 0,151] 0,801	-0,051 [-0,515; 0,412]
Week 16:				
Adjusted Mean Change (SE)	-0,32 (0,086)	-0,18 (0,077)	-0,14 [-0,342; 0,063] 0,177	-0,284 [-0,747; 0,179]
Week 24:				
Adjusted Mean Change (SE)	-0,30 (0,092)	-0,21 (0,083)	-0,09 [-0,309; 0,131] 0,426	-0,171 [-0,635; 0,293]
Mean of: How severe was your shortness of breath today?				
Interaction Test	0,094			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	0,99 (0,641)	1,02 (0,643)		
Week 8:				
Adjusted Mean Change (SE)	-0,21 (0,047)	-0,24 (0,048)	0,03 [-0,050; 0,106] 0,485	0,043 [-0,161; 0,246]
Week 16:				
Adjusted Mean Change (SE)	-0,32 (0,050)	-0,34 (0,051)	0,02 [-0,070; 0,113] 0,647	0,031 [-0,170; 0,231]
Week 24:				
Adjusted Mean Change (SE)	-0,35 (0,052)	-0,35 (0,053)	0,01 [-0,093; 0,106] 0,897	0,009 [-0,194; 0,212]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	0,99 (0,591)	1,12 (0,671)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,23 (0,079)	-0,18 (0,071)	-0,05 [-0,230; 0,128] 0,577	-0,114 [-0,578; 0,350]
Week 16:				
Adjusted Mean Change (SE)	-0,42 (0,089)	-0,22 (0,080)	-0,21 [-0,418; 0,002] 0,053	-0,407 [-0,873; 0,058]
Week 24:				
Adjusted Mean Change (SE)	-0,43 (0,095)	-0,21 (0,086)	-0,22 [-0,451; 0,005] 0,056	-0,412 [-0,880; 0,057]
Mean of: How was your wheeze during the past 12 hours?				
Interaction Test	0,302			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	0,84 (0,654)	0,87 (0,633)		
Week 8:				
Adjusted Mean Change (SE)	-0,20 (0,047)	-0,27 (0,049)	0,07 [-0,009; 0,149] 0,084	0,107 [-0,097; 0,310]
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,050)	-0,33 (0,051)	0,04 [-0,051; 0,131] 0,390	0,057 [-0,144; 0,258]
Week 24:				
Adjusted Mean Change (SE)	-0,31 (0,052)	-0,35 (0,053)	0,04 [-0,062; 0,134] 0,471	0,050 [-0,152; 0,253]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	0,91 (0,639)	0,99 (0,632)		
Week 8:				
Adjusted Mean Change (SE)	-0,21 (0,080)	-0,25 (0,072)	0,04 [-0,142; 0,220] 0,672	0,086 [-0,377; 0,550]
Week 16:				
Adjusted Mean Change (SE)	-0,43 (0,089)	-0,31 (0,080)	-0,12 [-0,328; 0,092] 0,270	-0,231 [-0,694; 0,231]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,41 (0,094)	-0,31 (0,085)	-0,10 [-0,329; 0,122] 0,367	-0,193 [-0,658; 0,272]
Mean of: How was your cough during the past 12 hours?				
Interaction Test	0,236			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	0,93 (0,710)	0,90 (0,671)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,052)	-0,17 (0,053)	0,01 [-0,075; 0,098] 0,793	0,016 [-0,187; 0,219]
Week 16:				
Adjusted Mean Change (SE)	-0,28 (0,055)	-0,26 (0,056)	-0,02 [-0,125; 0,076] 0,634	-0,032 [-0,233; 0,169]
Week 24:				
Adjusted Mean Change (SE)	-0,28 (0,057)	-0,30 (0,058)	0,01 [-0,096; 0,122] 0,818	0,016 [-0,186; 0,219]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	0,81 (0,632)	1,06 (0,638)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,087)	-0,09 (0,079)	-0,07 [-0,274; 0,124] 0,459	-0,151 [-0,616; 0,313]
Week 16:				
Adjusted Mean Change (SE)	-0,36 (0,098)	-0,22 (0,088)	-0,14 [-0,375; 0,089] 0,226	-0,255 [-0,718; 0,208]
Week 24:				
Adjusted Mean Change (SE)	-0,33 (0,104)	-0,14 (0,094)	-0,19 [-0,443; 0,058] 0,131	-0,325 [-0,791; 0,142]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Did you have chest tightness during the past 12 hours?				
Interaction Test	0,025 *			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	0,64 (0,614)	0,71 (0,654)		
Week 8:				
Adjusted Mean Change (SE)	-0,09 (0,044)	-0,15 (0,046)	0,06 [-0,015; 0,134] 0,115	0,097 [-0,106; 0,300]
Week 16:				
Adjusted Mean Change (SE)	-0,15 (0,047)	-0,19 (0,048)	0,04 [-0,050; 0,122] 0,408	0,055 [-0,146; 0,256]
Week 24:				
Adjusted Mean Change (SE)	-0,17 (0,048)	-0,21 (0,050)	0,04 [-0,052; 0,131] 0,399	0,059 [-0,144; 0,262]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	0,58 (0,567)	0,63 (0,680)		
Week 8:				
Adjusted Mean Change (SE)	-0,12 (0,075)	-0,02 (0,067)	-0,10 [-0,272; 0,068] 0,241	-0,239 [-0,705; 0,226]
Week 16:				
Adjusted Mean Change (SE)	-0,27 (0,084)	-0,07 (0,076)	-0,20 [-0,398; -0,003] 0,046 *	-0,419 [-0,885; 0,047]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,088)	-0,05 (0,080)	-0,24 [-0,450; -0,029] 0,026 *	-0,477 [-0,948; -0,007]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

10. E-Diary - Rescue Medication

Table 10.1 Rescue Medication - Documentation Rate (FAS)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Rescue medication during the night - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	208 (90,4)	214 (89,2)	422 (89,8)
	50%-<70%	16 (7,0)	18 (7,5)	34 (7,2)
	<50%	6 (2,6)	8 (3,3)	14 (3,0)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	13 (5,7)	16 (6,7)	29 (6,2)
	<50%	9 (3,9)	7 (2,9)	16 (3,4)
Week 9 to Week 16	70%-100%	199 (86,5)	206 (85,8)	405 (86,2)
	50%-<70%	23 (10,0)	19 (7,9)	42 (8,9)
	<50%	8 (3,5)	15 (6,3)	23 (4,9)
Week 17 to Week 24	70%-100%	196 (85,2)	212 (88,3)	408 (86,8)
	50%-<70%	22 (9,6)	6 (2,5)	28 (6,0)
	<50%	12 (5,2)	22 (9,2)	34 (7,2)
Baseline to Week 24	70%-100%	206 (89,6)	208 (86,7)	414 (88,1)
	50%-<70%	15 (6,5)	17 (7,1)	32 (6,8)
	<50%	9 (3,9)	15 (6,3)	24 (5,1)
Rescue medication during the day - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	213 (92,6)	209 (87,1)	422 (89,8)
	50%-<70%	12 (5,2)	26 (10,8)	38 (8,1)
	<50%	5 (2,2)	5 (2,1)	10 (2,1)
Baseline to Week 8	70%-100%	208 (90,4)	217 (90,4)	425 (90,4)
	50%-<70%	14 (6,1)	14 (5,8)	28 (6,0)
	<50%	8 (3,5)	9 (3,8)	17 (3,6)
Week 9 to Week 16	70%-100%	206 (89,6)	210 (87,5)	416 (88,5)
	50%-<70%	14 (6,1)	11 (4,6)	25 (5,3)
	<50%	10 (4,3)	19 (7,9)	29 (6,2)
Week 17 to Week 24	70%-100%	193 (83,9)	208 (86,7)	401 (85,3)
	50%-<70%	22 (9,6)	13 (5,4)	35 (7,4)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)

		Treatment groups		
Outcome - Documentation Rate (FAS)		**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Total N=470**
Baseline to Week 24	70%-100%	205 (89,1)	209 (87,1)	414 (88,1)
	50%-<70%	15 (6,5)	15 (6,3)	30 (6,4)
	<50%	10 (4,3)	16 (6,7)	26 (5,5)
Rescue medication free days - Documentation rate in standardized days*, n (%)				
Baseline	70%-100%	205 (89,1)	211 (87,9)	416 (88,5)
	50%-<70%	18 (7,8)	22 (9,2)	40 (8,5)
	<50%	7 (3,0)	7 (2,9)	14 (3,0)
Baseline to Week 8	70%-100%	197 (85,7)	215 (89,6)	412 (87,7)
	50%-<70%	20 (8,7)	18 (7,5)	38 (8,1)
	<50%	13 (5,7)	7 (2,9)	20 (4,3)
Week 9 to Week 16	70%-100%	185 (80,4)	200 (83,3)	385 (81,9)
	50%-<70%	31 (13,5)	16 (6,7)	47 (10,0)
	<50%	14 (6,1)	24 (10,0)	38 (8,1)
Week 17 to Week 24	70%-100%	174 (75,7)	197 (82,1)	371 (78,9)
	50%-<70%	34 (14,8)	20 (8,3)	54 (11,5)
	<50%	22 (9,6)	23 (9,6)	45 (9,6)
Baseline to Week 24	70%-100%	191 (83,0)	203 (84,6)	394 (83,8)
	50%-<70%	24 (10,4)	18 (7,5)	42 (8,9)
	<50%	15 (6,5)	19 (7,9)	34 (7,2)

* For each time period and patient the documentation rate is calculated as the number of documented days divided by the number of days of the whole time period.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 10.2 Rescue Medication - Change from Baseline (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Daily number of puffs of rescue medication during the night				
N'	221	232		
Baseline Mean (SD)	0,58 (0,773)	0,71 (0,912)		
Week 8:				
Adjusted Mean Change (SE)	-0,17 (0,058)	-0,04 (0,058)	-0,13 [-0,225; -0,042] 0,004 *	-0,154 [-0,341; 0,033]
Week 16:				
Adjusted Mean Change (SE)	-0,22 (0,061)	-0,10 (0,061)	-0,12 [-0,225; -0,013] 0,028 *	-0,129 [-0,315; 0,056]
Week 24:				
Adjusted Mean Change (SE)	-0,23 (0,063)	-0,12 (0,063)	-0,11 [-0,219; 0,005] 0,060	-0,115 [-0,302; 0,071]
Daily number of puffs of rescue medication during the day				
N'	222	233		
Baseline Mean (SD)	0,90 (1,149)	1,03 (1,103)		
Week 8:				
Adjusted Mean Change (SE)	-0,26 (0,073)	-0,12 (0,073)	-0,14 [-0,257; -0,030] 0,014 *	-0,132 [-0,318; 0,055]
Week 16:				
Adjusted Mean Change (SE)	-0,37 (0,077)	-0,20 (0,078)	-0,16 [-0,300; -0,030] 0,017 *	-0,141 [-0,325; 0,043]
Week 24:				
Adjusted Mean Change (SE)	-0,38 (0,080)	-0,25 (0,080)	-0,13 [-0,272; 0,020] 0,089	-0,106 [-0,291; 0,080]
Percentage of rescue medication free days				
N'	219	232		
Baseline Mean (SD)	45,24 (41,045)	42,15 (40,992)		
Week 8:				
Adjusted Mean Change (SE)	12,40 (3,088)	8,29 (3,056)	4,11 [-1,048; 9,263] 0,118	0,090 [-0,097; 0,278]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 16:				
Adjusted Mean Change (SE)	19,85 (3,263)	14,53 (3,228)	5,32 [-0,601; 11,231] 0,078	0,109 [-0,076; 0,295]
Week 24:				
Adjusted Mean Change (SE)	21,20 (3,316)	17,91 (3,281)	3,28 [-2,855; 9,420] 0,294	0,067 [-0,120; 0,254]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 10.3 Rescue Medication - Change from Baseline by Age (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Daily number of puffs of rescue medication during the night				
Interaction Test	0,086			
Age = 18-39 years				
N'	43	40		
Baseline Mean (SD)	0,64 (0,822)	0,58 (0,841)		
Week 8:				
Adjusted Mean Change (SE)	-0,26 (0,091)	-0,07 (0,094)	-0,19 [-0,405; 0,025] 0,083	-0,324 [-0,765; 0,118]
Week 16:				
Adjusted Mean Change (SE)	-0,29 (0,101)	-0,20 (0,104)	-0,09 [-0,336; 0,157] 0,477	-0,136 [-0,567; 0,296]
Week 24:				
Adjusted Mean Change (SE)	-0,29 (0,106)	-0,21 (0,109)	-0,08 [-0,343; 0,181] 0,545	-0,120 [-0,562; 0,322]
Age = 40-64 years				
N'	136	149		
Baseline Mean (SD)	0,58 (0,804)	0,73 (0,941)		
Week 8:				
Adjusted Mean Change (SE)	-0,15 (0,063)	0,00 (0,062)	-0,16 [-0,273; -0,041] 0,008 *	-0,212 [-0,448; 0,024]
Week 16:				
Adjusted Mean Change (SE)	-0,24 (0,067)	-0,04 (0,067)	-0,20 [-0,330; -0,063] 0,004 *	-0,246 [-0,480; -0,012]
Week 24:				
Adjusted Mean Change (SE)	-0,25 (0,069)	-0,05 (0,068)	-0,19 [-0,333; -0,051] 0,008 *	-0,235 [-0,470; -0,001]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,51 (0,616)	0,77 (0,879)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,092)	-0,20 (0,091)	0,02 [-0,194; 0,228] 0,871	0,029 [-0,398; 0,457]
Week 16:				
Adjusted Mean Change (SE)	-0,12 (0,102)	-0,25 (0,101)	0,12 [-0,121; 0,367] 0,323	0,186 [-0,242; 0,615]
Week 24:				
Adjusted Mean Change (SE)	-0,16 (0,106)	-0,33 (0,106)	0,17 [-0,089; 0,428] 0,197	0,250 [-0,185; 0,684]
Daily number of puffs of rescue medication during the day				
Interaction Test	0,674			
Age = 18-39 years				
N'	41	40		
Baseline Mean (SD)	0,89 (1,060)	0,70 (0,910)		
Week 8:				
Adjusted Mean Change (SE)	-0,39 (0,116)	-0,17 (0,118)	-0,21 [-0,485; 0,059] 0,125	-0,293 [-0,742; 0,156]
Week 16:				
Adjusted Mean Change (SE)	-0,45 (0,131)	-0,36 (0,133)	-0,09 [-0,413; 0,229] 0,574	-0,109 [-0,545; 0,327]
Week 24:				
Adjusted Mean Change (SE)	-0,47 (0,140)	-0,41 (0,141)	-0,06 [-0,406; 0,288] 0,738	-0,067 [-0,511; 0,377]
Age = 40-64 years				
N'	139	150		
Baseline Mean (SD)	0,92 (1,250)	1,04 (1,090)		
Week 8:				
Adjusted Mean Change (SE)	-0,25 (0,078)	-0,11 (0,079)	-0,15 [-0,289; -0,002] 0,046 *	-0,156 [-0,390; 0,078]
Week 16:				
Adjusted Mean Change (SE)	-0,40 (0,085)	-0,18 (0,085)	-0,22 [-0,388; -0,048] 0,012 *	-0,213 [-0,445; 0,019]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,40 (0,089)	-0,22 (0,089)	-0,18 [-0,365; 0,002] 0,053	-0,171 [-0,404; 0,062]
Age = ≥65 years				
N'	42	43		
Baseline Mean (SD)	0,84 (0,868)	1,28 (1,251)		
Week 8:				
Adjusted Mean Change (SE)	-0,20 (0,115)	-0,13 (0,114)	-0,07 [-0,328; 0,198] 0,626	-0,088 [-0,513; 0,338]
Week 16:				
Adjusted Mean Change (SE)	-0,21 (0,131)	-0,16 (0,129)	-0,05 [-0,364; 0,263] 0,753	-0,059 [-0,485; 0,366]
Week 24:				
Adjusted Mean Change (SE)	-0,22 (0,138)	-0,22 (0,137)	0,00 [-0,337; 0,339] 0,995	0,001 [-0,429; 0,432]
Percentage of rescue medication free days				
Interaction Test	0,790			
Age = 18-39 years				
N'	41	39		
Baseline Mean (SD)	47,48 (41,622)	53,44 (40,021)		
Week 8:				
Adjusted Mean Change (SE)	19,62 (5,101)	9,22 (5,236)	10,40 [-1,981; 22,783] 0,100	0,329 [-0,127; 0,785]
Week 16:				
Adjusted Mean Change (SE)	24,36 (5,642)	21,30 (5,770)	3,06 [-11,020; 17,131] 0,670	0,085 [-0,354; 0,523]
Week 24:				
Adjusted Mean Change (SE)	25,53 (5,822)	24,14 (5,957)	1,39 [-13,252; 16,039] 0,852	0,038 [-0,411; 0,488]
Age = 40-64 years				
N'	136	151		
Baseline Mean (SD)	45,49 (42,288)	41,58 (40,434)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	10,06 (3,372)	7,63 (3,309)	2,43 [-4,062; 8,927] 0,462	0,062 [-0,174; 0,297]
Week 16:				
Adjusted Mean Change (SE)	20,38 (3,626)	12,93 (3,552)	7,45 [0,003; 14,896] 0,050 *	0,174 [-0,059; 0,407]
Week 24:				
Adjusted Mean Change (SE)	21,48 (3,698)	16,27 (3,623)	5,20 [-2,507; 12,916] 0,186	0,120 [-0,114; 0,353]
Age = ≥65 years				
N'	42	42		
Baseline Mean (SD)	42,26 (36,943)	33,74 (42,504)		
Week 8:				
Adjusted Mean Change (SE)	13,93 (5,040)	10,91 (5,014)	3,02 [-8,868; 14,910] 0,618	0,093 [-0,335; 0,521]
Week 16:				
Adjusted Mean Change (SE)	15,08 (5,610)	15,30 (5,599)	-0,22 [-13,957; 13,513] 0,975	-0,006 [-0,436; 0,424]
Week 24:				
Adjusted Mean Change (SE)	17,38 (5,762)	19,38 (5,768)	-2,00 [-16,240; 12,235] 0,782	-0,054 [-0,487; 0,379]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + age + age * treatment + age * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 10.4 Rescue Medication - Change from Baseline by Gender (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Daily number of puffs of rescue medication during the night				
Interaction Test	0,920			
Gender = Male				
N'	93	84		
Baseline Mean (SD)	0,57 (0,893)	0,76 (0,892)		
Week 8:				
Adjusted Mean Change (SE)	-0,19 (0,068)	-0,06 (0,074)	-0,13 [-0,275; 0,019] 0,088	-0,194 [-0,493; 0,105]
Week 16:				
Adjusted Mean Change (SE)	-0,25 (0,075)	-0,14 (0,080)	-0,11 [-0,278; 0,063] 0,215	-0,149 [-0,446; 0,148]
Week 24:				
Adjusted Mean Change (SE)	-0,28 (0,077)	-0,14 (0,083)	-0,13 [-0,313; 0,047] 0,146	-0,179 [-0,479; 0,121]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,59 (0,677)	0,68 (0,925)		
Week 8:				
Adjusted Mean Change (SE)	-0,16 (0,067)	-0,02 (0,062)	-0,13 [-0,251; -0,016] 0,026 *	-0,178 [-0,418; 0,062]
Week 16:				
Adjusted Mean Change (SE)	-0,19 (0,072)	-0,07 (0,067)	-0,12 [-0,256; 0,016] 0,083	-0,148 [-0,386; 0,089]
Week 24:				
Adjusted Mean Change (SE)	-0,19 (0,074)	-0,11 (0,069)	-0,08 [-0,229; 0,059] 0,247	-0,103 [-0,342; 0,136]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Daily number of puffs of rescue medication during the day				
Interaction Test	0,869			
Gender = Male				
N'	94	85		
Baseline Mean (SD)	0,92 (1,438)	0,97 (1,028)		
Week 8:				
Adjusted Mean Change (SE)	-0,28 (0,085)	-0,14 (0,092)	-0,14 [-0,318; 0,046] 0,143	-0,165 [-0,464; 0,133]
Week 16:				
Adjusted Mean Change (SE)	-0,40 (0,094)	-0,23 (0,101)	-0,17 [-0,386; 0,047] 0,125	-0,184 [-0,479; 0,111]
Week 24:				
Adjusted Mean Change (SE)	-0,45 (0,099)	-0,30 (0,106)	-0,16 [-0,388; 0,078] 0,191	-0,162 [-0,459; 0,135]
Gender = Female				
N'	128	148		
Baseline Mean (SD)	0,88 (0,884)	1,06 (1,146)		
Week 8:				
Adjusted Mean Change (SE)	-0,24 (0,083)	-0,09 (0,079)	-0,14 [-0,290; 0,002] 0,054	-0,153 [-0,392; 0,087]
Week 16:				
Adjusted Mean Change (SE)	-0,33 (0,090)	-0,17 (0,086)	-0,16 [-0,330; 0,018] 0,079	-0,151 [-0,388; 0,086]
Week 24:				
Adjusted Mean Change (SE)	-0,31 (0,094)	-0,21 (0,089)	-0,10 [-0,285; 0,090] 0,309	-0,091 [-0,330; 0,147]
Percentage of rescue medication free days				
Interaction Test	0,835			
Gender = Male				
N'	91	85		
Baseline Mean (SD)	49,71 (42,408)	42,89 (43,452)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	14,09 (3,714)	10,03 (3,970)	4,06 [-4,236; 12,347] 0,337	0,115 [-0,186; 0,416]
Week 16:				
Adjusted Mean Change (SE)	22,78 (4,066)	16,64 (4,318)	6,14 [-3,366; 15,653] 0,205	0,157 [-0,141; 0,455]
Week 24:				
Adjusted Mean Change (SE)	24,36 (4,167)	20,32 (4,421)	4,04 [-5,814; 13,895] 0,421	0,101 [-0,197; 0,400]
Gender = Female				
N'	128	147		
Baseline Mean (SD)	42,07 (39,911)	41,73 (39,647)		
Week 8:				
Adjusted Mean Change (SE)	11,01 (3,577)	7,11 (3,324)	3,90 [-2,728; 10,527] 0,248	0,098 [-0,143; 0,339]
Week 16:				
Adjusted Mean Change (SE)	17,58 (3,829)	13,13 (3,573)	4,45 [-3,146; 12,048] 0,250	0,103 [-0,135; 0,341]
Week 24:				
Adjusted Mean Change (SE)	18,76 (3,905)	16,34 (3,649)	2,43 [-5,453; 10,310] 0,545	0,056 [-0,184; 0,296]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + gender + gender * treatment + gender * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 10.5 Rescue Medication - Change from Baseline by Region (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Daily number of puffs of rescue medication during the night				
Interaction Test	N.E.			
Region = Asia				
N'	68	70		
Baseline Mean (SD)	0,67 (0,843)	0,89 (1,062)		
Week 8:				
Adjusted Mean Change (SE)	-0,36 (0,071)	-0,15 (0,071)	-0,21 [-0,411; -0,014] 0,036 *	-0,363 [-0,703; -0,023]
Week 16:				
Adjusted Mean Change (SE)	-0,42 (0,076)	-0,19 (0,074)	-0,24 [-0,446; -0,027] 0,027 *	-0,381 [-0,719; -0,043]
Week 24:				
Adjusted Mean Change (SE)	-0,48 (0,080)	-0,29 (0,079)	-0,19 [-0,410; 0,034] 0,097	-0,286 [-0,623; 0,051]
Region = Europe				
N'	79	82		
Baseline Mean (SD)	0,52 (0,719)	0,52 (0,707)		
Week 8:				
Adjusted Mean Change (SE)	-0,26 (0,041)	-0,23 (0,040)	-0,03 [-0,139; 0,088] 0,663	-0,069 [-0,380; 0,242]
Week 16:				
Adjusted Mean Change (SE)	-0,26 (0,051)	-0,29 (0,050)	0,02 [-0,119; 0,160] 0,771	0,046 [-0,264; 0,356]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,057)	-0,26 (0,056)	-0,00 [-0,159; 0,155] 0,978	-0,005 [-0,319; 0,310]
Region = Latin America				
N'	58	72		
Baseline Mean (SD)	0,50 (0,663)	0,77 (0,955)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,23 (0,068)	-0,08 (0,060)	-0,15 [-0,329; 0,028] 0,098	-0,302 [-0,658; 0,054]
Week 16:				
Adjusted Mean Change (SE)	-0,34 (0,083)	-0,16 (0,074)	-0,18 [-0,402; 0,040] 0,107	-0,288 [-0,637; 0,061]
Week 24:				
Adjusted Mean Change (SE)	-0,34 (0,084)	-0,16 (0,075)	-0,18 [-0,404; 0,042] 0,112	-0,288 [-0,640; 0,065]
Region = Others				
N'	16	8		
Baseline Mean (SD)	0,80 (1,051)	0,57 (0,670)		
Week 8:				
Adjusted Mean Change (SE)	-0,31 (0,104)	-0,27 (0,148)	-0,04 [-0,409; 0,330] 0,830	-0,094 [-0,943; 0,755]
Week 16:				
Adjusted Mean Change (SE)	-0,32 (0,127)	-0,35 (0,181)	0,03 [-0,420; 0,482] 0,889	0,061 [-0,788; 0,910]
Week 24:				
Adjusted Mean Change (SE)	-0,26 (0,137)	-0,32 (0,194)	0,06 [-0,425; 0,543] 0,806	0,108 [-0,742; 0,957]
Daily number of puffs of rescue medication during the day				
Interaction Test	0,182			
Region = Asia				
N'	68	68		
Baseline Mean (SD)	1,08 (1,436)	1,20 (1,277)		
Week 8:				
Adjusted Mean Change (SE)	-0,27 (0,074)	-0,07 (0,074)	-0,20 [-0,404; 0,009] 0,061	-0,325 [-0,667; 0,017]
Week 16:				
Adjusted Mean Change (SE)	-0,39 (0,089)	-0,06 (0,089)	-0,33 [-0,573; -0,081] 0,009 *	-0,448 [-0,790; -0,107]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	-0,43 (0,096)	-0,12 (0,096)	-0,31 [-0,571; -0,041] 0,024 *	-0,389 [-0,730; -0,049]
Region = Europe				
N'	78	84		
Baseline Mean (SD)	0,85 (1,121)	0,90 (0,986)		
Week 8:				
Adjusted Mean Change (SE)	-0,31 (0,069)	-0,30 (0,067)	-0,01 [-0,202; 0,175] 0,886	-0,022 [-0,331; 0,286]
Week 16:				
Adjusted Mean Change (SE)	-0,43 (0,083)	-0,43 (0,080)	0,00 [-0,224; 0,227] 0,989	0,002 [-0,306; 0,310]
Week 24:				
Adjusted Mean Change (SE)	-0,40 (0,089)	-0,49 (0,086)	0,09 [-0,156; 0,331] 0,479	0,113 [-0,200; 0,426]
Region = Latin America				
N'	60	73		
Baseline Mean (SD)	0,71 (0,780)	1,04 (1,085)		
Week 8:				
Adjusted Mean Change (SE)	-0,32 (0,080)	-0,08 (0,072)	-0,24 [-0,450; -0,027] 0,027 *	-0,397 [-0,751; -0,042]
Week 16:				
Adjusted Mean Change (SE)	-0,41 (0,094)	-0,20 (0,085)	-0,21 [-0,464; 0,036] 0,093	-0,293 [-0,637; 0,050]
Week 24:				
Adjusted Mean Change (SE)	-0,45 (0,102)	-0,23 (0,092)	-0,23 [-0,497; 0,043] 0,099	-0,292 [-0,639; 0,056]
Region = Others				
N'	16	8		
Baseline Mean (SD)	1,06 (1,032)	0,69 (0,683)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	-0,43 (0,153)	-0,40 (0,222)	-0,03 [-0,561; 0,496] 0,904	-0,054 [-0,942; 0,835]
Week 16:				
Adjusted Mean Change (SE)	-0,49 (0,182)	-0,50 (0,258)	0,01 [-0,606; 0,635] 0,964	0,019 [-0,829; 0,868]
Week 24:				
Adjusted Mean Change (SE)	-0,43 (0,196)	-0,52 (0,278)	0,09 [-0,581; 0,756] 0,798	0,111 [-0,738; 0,960]
Percentage of rescue medication free days				
Interaction Test	0,405			
Region = Asia				
N'	67	70		
Baseline Mean (SD)	35,28 (40,276)	33,31 (39,161)		
Week 8:				
Adjusted Mean Change (SE)	12,92 (3,815)	12,73 (3,717)	0,19 [-10,238; 10,615] 0,972	0,006 [-0,334; 0,346]
Week 16:				
Adjusted Mean Change (SE)	24,11 (3,798)	13,98 (3,708)	10,13 [-0,257; 20,521] 0,056	0,327 [-0,011; 0,666]
Week 24:				
Adjusted Mean Change (SE)	27,35 (3,798)	18,07 (3,708)	9,27 [-1,117; 19,661] 0,080	0,300 [-0,039; 0,638]
Region = Europe				
N'	77	83		
Baseline Mean (SD)	51,02 (42,393)	47,58 (40,609)		
Week 8:				
Adjusted Mean Change (SE)	17,17 (3,539)	14,75 (3,396)	2,42 [-7,194; 12,037] 0,621	0,078 [-0,233; 0,390]
Week 16:				
Adjusted Mean Change (SE)	22,56 (3,531)	24,53 (3,403)	-1,96 [-11,575; 7,653] 0,689	-0,063 [-0,375; 0,248]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	22,99 (3,539)	29,11 (3,425)	-6,12 [-15,778; 3,531] 0,214	-0,200 [-0,516; 0,116]
Region = Latin America				
N'	59	71		
Baseline Mean (SD)	49,35 (40,653)	43,10 (42,588)		
Week 8:				
Adjusted Mean Change (SE)	16,08 (4,080)	7,07 (3,697)	9,01 [-1,802; 19,812] 0,102	0,296 [-0,061; 0,654]
Week 16:				
Adjusted Mean Change (SE)	22,08 (4,044)	13,80 (3,670)	8,27 [-2,443; 18,992] 0,130	0,268 [-0,080; 0,617]
Week 24:				
Adjusted Mean Change (SE)	23,86 (4,042)	15,57 (3,697)	8,29 [-2,464; 19,039] 0,131	0,271 [-0,081; 0,623]
Region = Others				
N'	16	8		
Baseline Mean (SD)	44,04 (34,170)	54,88 (39,443)		
Week 8:				
Adjusted Mean Change (SE)	25,17 (7,817)	22,00 (11,198)	3,17 [-23,624; 29,973] 0,816	0,106 [-0,792; 1,003]
Week 16:				
Adjusted Mean Change (SE)	31,47 (7,731)	31,35 (10,938)	0,12 [-26,167; 26,404] 0,993	0,004 [-0,845; 0,853]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	27,60 (7,731)	32,18 (10,938)	-4,58 [-30,863; 21,708] 0,733	-0,148 [-0,998; 0,702]

N': Number of patients in the analysis
CI: Confidence Interval
N.E.: not estimable
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: unstructured covariance matrix
Exceptional model(s): **Daily number of puffs of rescue medication during the night**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction [by region], **Percentage of rescue medication free days**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: compound symmetry covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 10.6 Rescue Medication - Change from Baseline by History of Asthma Exacerbation (FAS)

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Daily number of puffs of rescue medication during the night				
Interaction Test	0,870			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	188	191		
Baseline Mean (SD)	0,56 (0,789)	0,68 (0,923)		
Week 8:				
Adjusted Mean Change (SE)	-0,18 (0,060)	-0,05 (0,061)	-0,13 [-0,233; -0,033] 0,009 *	-0,163 [-0,368; 0,041]
Week 16:				
Adjusted Mean Change (SE)	-0,23 (0,063)	-0,11 (0,064)	-0,12 [-0,235; -0,004] 0,042 *	-0,137 [-0,339; 0,065]
Week 24:				
Adjusted Mean Change (SE)	-0,24 (0,065)	-0,13 (0,066)	-0,12 [-0,238; 0,007] 0,065	-0,130 [-0,334; 0,074]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	41		
Baseline Mean (SD)	0,68 (0,680)	0,84 (0,854)		
Week 8:				
Adjusted Mean Change (SE)	-0,11 (0,101)	0,01 (0,090)	-0,13 [-0,356; 0,100] 0,270	-0,223 [-0,686; 0,239]
Week 16:				
Adjusted Mean Change (SE)	-0,17 (0,112)	-0,06 (0,101)	-0,11 [-0,375; 0,151] 0,402	-0,175 [-0,637; 0,286]
Week 24:				
Adjusted Mean Change (SE)	-0,16 (0,118)	-0,10 (0,105)	-0,06 [-0,341; 0,216] 0,660	-0,093 [-0,554; 0,368]

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Daily number of puffs of rescue medication during the day				
Interaction Test	0,531			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	193		
Baseline Mean (SD)	0,87 (1,191)	1,00 (1,097)		
Week 8:				
Adjusted Mean Change (SE)	-0,26 (0,074)	-0,14 (0,077)	-0,12 [-0,243; 0,005] 0,060	-0,116 [-0,319; 0,088]
Week 16:				
Adjusted Mean Change (SE)	-0,36 (0,080)	-0,21 (0,082)	-0,15 [-0,297; -0,001] 0,048 *	-0,133 [-0,335; 0,068]
Week 24:				
Adjusted Mean Change (SE)	-0,37 (0,083)	-0,26 (0,085)	-0,12 [-0,275; 0,044] 0,155	-0,101 [-0,304; 0,102]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	40		
Baseline Mean (SD)	1,03 (0,870)	1,14 (1,139)		
Week 8:				
Adjusted Mean Change (SE)	-0,32 (0,125)	-0,05 (0,113)	-0,27 [-0,554; 0,016] 0,064	-0,378 [-0,846; 0,089]
Week 16:				
Adjusted Mean Change (SE)	-0,42 (0,143)	-0,17 (0,129)	-0,25 [-0,590; 0,089] 0,148	-0,305 [-0,769; 0,158]
Week 24:				
Adjusted Mean Change (SE)	-0,43 (0,152)	-0,25 (0,138)	-0,19 [-0,552; 0,180] 0,319	-0,214 [-0,679; 0,251]
Percentage of rescue medication free days				
Interaction Test	0,723			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	186	191		
Baseline Mean (SD)	47,00 (41,237)	42,56 (41,911)		

	Treatment groups		Comparison	
E-Diary - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	12,50 (3,165)	9,23 (3,190)	3,27 [-2,362; 8,899] 0,255	0,076 [-0,129; 0,282]
Week 16:				
Adjusted Mean Change (SE)	20,21 (3,363)	15,46 (3,385)	4,75 [-1,704; 11,203] 0,149	0,103 [-0,100; 0,305]
Week 24:				
Adjusted Mean Change (SE)	21,34 (3,425)	18,10 (3,449)	3,23 [-3,469; 9,937] 0,344	0,069 [-0,135; 0,274]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	33	41		
Baseline Mean (SD)	35,32 (39,070)	40,24 (36,826)		
Week 8:				
Adjusted Mean Change (SE)	11,72 (5,541)	3,83 (4,905)	7,88 [-4,876; 20,641] 0,226	0,251 [-0,213; 0,715]
Week 16:				
Adjusted Mean Change (SE)	17,73 (6,171)	10,02 (5,509)	7,71 [-6,966; 22,384] 0,303	0,220 [-0,243; 0,682]
Week 24:				
Adjusted Mean Change (SE)	20,28 (6,353)	16,87 (5,675)	3,41 [-11,801; 18,620] 0,660	0,094 [-0,367; 0,555]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11. Exacerbations - Time-to-event Analysis

Table 11.1 Exacerbations - Time-to-event Analysis (FAS)

	Treatment groups		Comparison
Time-to-first outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbation			
N'	230	240	
Number of patients with at least one event, n (%)	44 (19,1)	67 (27,9)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	80,74 [75,62; 85,86]	71,78 [66,05; 77,51]	0,64 [0,44; 0,94] 0,022 *
Severe asthma exacerbation			
N'	230	240	
Number of patients with at least one event, n (%)	21 (9,1)	32 (13,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	90,79 [87,04; 94,55]	86,49 [82,13; 90,84]	0,67 [0,38; 1,15] 0,147
SCS use due to asthma exacerbation (for at least three consecutive days)			
N'	230	240	
Number of patients with at least one event, n (%)	25 (10,9)	33 (13,8)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	89,05 [85,00; 93,10]	86,05 [81,63; 90,47]	0,78 [0,46; 1,31] 0,346
ER visit and/or hospitalization due to asthma exacerbation			
N'	230	240	
Number of patients with at least one event, n (%)	2 (0,9)	2 (0,8)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	99,13 [97,93; 100,00]	99,16 [98,00; 100,00]	1,05 [0,15; 7,43] 0,963

	Treatment groups		Comparison
Time-to-first outcome (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
ER visit due to asthma exacerbation			
N'	230	240	
Number of patients with at least one event, n (%)	1 (0,4)	1 (0,4)	
Median (in weeks)	-	-	
% of outcome-free patients+	99,57 [98,71; 100,00]	99,58 [98,76; 100,00]	1,03 [0,06; 16,51] 0,982
Hospitalization due to asthma exacerbation			
N'	230	240	
Number of patients with at least one event, n (%)	1 (0,4)	1 (0,4)	
Median (in weeks)	-	-	
% of outcome-free patients+	99,57 [98,71; 100,00]	99,58 [98,76; 100,00]	1,06 [0,07; 16,93] 0,968

N': Number of patients in the analysis
CI: Confidence Interval
HR: Hazard Ratio
*: $p < 0,05$
+ K-M estimate (%) of outcome-free patients

Applied model for HR: log(hazard ratio) = treatment + region + history of asthma exacerbation
If it was not possible to fit the minimal model, the HR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 11.2 Exacerbations - Time-to-event Analysis by Age (FAS)

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,784		
Age = 18-39 years			
N'	44	40	
Number of patients with at least one event, n (%)	6 (13,6)	5 (12,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	86,18 [75,91; 96,46]	87,50 [77,25; 97,75]	0,92 [0,28; 3,02] 0,889
Age = 40-64 years			
N'	144	155	
Number of patients with at least one event, n (%)	26 (18,1)	46 (29,7)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	81,82 [75,50; 88,14]	70,01 [62,76; 77,27]	0,60 [0,37; 0,96] 0,035 *
Age = ≥65 years			
N'	42	45	
Number of patients with at least one event, n (%)	12 (28,6)	16 (35,6)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	71,43 [57,77; 85,09]	64,00 [49,85; 78,15]	0,70 [0,33; 1,47] 0,344
Severe asthma exacerbation			
Interaction Test:	p=0,220		
Age = 18-39 years			
N'	44	40	
Number of patients with at least one event, n (%)	3 (6,8)	2 (5,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	93,02 [85,39; 100,00]	95,00 [88,25; 100,00]	1,32 [0,22; 7,89] 0,764

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Age = 40-64 years			
N'	144	155	
Number of patients with at least one event, n (%)	15 (10,4)	20 (12,9)	
Median (in weeks)	-	-	
% of outcome-free patients+	89,50 [84,47; 94,53]	86,92 [81,58; 92,27]	0,83 [0,42; 1,62] 0,588
Age = ≥65 years			
N'	42	45	
Number of patients with at least one event, n (%)	3 (7,1)	10 (22,2)	
Median (in weeks)	-	-	
% of outcome-free patients+	92,86 [85,07; 100,00]	77,41 [65,06; 89,75]	0,26 [0,07; 0,94] 0,040 *
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,238		
Age = 18-39 years			
N'	44	40	
Number of patients with at least one event, n (%)	5 (11,4)	2 (5,0)	
Median (in weeks)	-	-	
% of outcome-free patients+	88,46 [78,94; 97,98]	95,00 [88,25; 100,00]	2,30 [0,45; 11,90] 0,319
Age = 40-64 years			
N'	144	155	
Number of patients with at least one event, n (%)	16 (11,1)	22 (14,2)	
Median (in weeks)	-	-	
% of outcome-free patients+	88,80 [83,63; 93,97]	85,61 [80,04; 91,17]	0,80 [0,42; 1,52] 0,491

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Age = ≥65 years			
N'	42	45	
Number of patients with at least one event, n (%)	4 (9,5)	9 (20,0)	
Median (in weeks)	-	-	
% of outcome-free patients+	90,48 [81,60; 99,35]	79,64 [67,75; 91,53]	0,40 [0,12; 1,31] 0,132
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Age = 18-39 years			
N'	44	40	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients+	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,21 [0,00; -] 1,000
Age = 40-64 years			
N'	144	155	
Number of patients with at least one event, n (%)	1 (0,7)	1 (0,6)	
Median (in weeks)	-	-	
% of outcome-free patients+	99,31 [97,95; 100,00]	99,35 [98,07; 100,00]	1,05 [0,07; 16,82] 0,972
Age = ≥65 years			
N'	42	45	
Number of patients with at least one event, n (%)	1 (2,4)	1 (2,2)	
Median (in weeks)	-	-	
% of outcome-free patients+	97,62 [93,01; 100,00]	97,78 [93,47; 100,00]	1,03 [0,06; 16,44] 0,985

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
ER visit due to asthma exacerbation			
Interaction Test:	p=1,000		
Age = 18-39 years			
N'	44	40	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,65 [0,00; -] 1,000
Age = 40-64 years			
N'	144	155	
Number of patients with at least one event, n (%)	1 (0,7)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	99,31 [97,95; 100,00]	100,00 [100,00; 100,00]	-
Age = ≥65 years			
N'	42	45	
Number of patients with at least one event, n (%)	0 (0,0)	1 (2,2)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	97,78 [93,47; 100,00]	0,00 [0,00; -] 0,998
Hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Age = 18-39 years			
N'	44	40	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,42 [0,00; -] 1,000

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Age = 40-64 years			
N'	144	155	
Number of patients with at least one event, n (%)	0 (0,0)	1 (0,6)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	99,35 [98,07; 100,00]	0,00 [0,00; -] 0,996
Age = ≥65 years			
N'	42	45	
Number of patients with at least one event, n (%)	1 (2,4)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	97,62 [93,01; 100,00]	100,00 [100,00; 100,00]	-

N': Number of patients in the analysis
CI: Confidence Interval
HR: Hazard Ratio
*: $p < 0,05$
[+] K-M estimate (%) of outcome-free patients

Applied model for HR: log(hazard ratio) = treatment + region + history of asthma exacerbation + age + age * treatment
If it was not possible to fit the minimal model, the HR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 11.3 Exacerbations - Time-to-event Analysis by Gender (FAS)

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,252		
Gender = Male			
N'	97	88	
Number of patients with at least one event, n (%)	22 (22,7)	23 (26,1)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	77,18 [68,79; 85,56]	73,68 [64,45; 82,92]	0,83 [0,46; 1,49] 0,538
Gender = Female			
N'	133	152	
Number of patients with at least one event, n (%)	22 (16,5)	44 (28,9)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	83,37 [77,03; 89,72]	70,68 [63,39; 77,97]	0,53 [0,32; 0,88] 0,014 *
Severe asthma exacerbation			
Interaction Test:	p=0,541		
Gender = Male			
N'	97	88	
Number of patients with at least one event, n (%)	10 (10,3)	11 (12,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	89,63 [83,55; 95,72]	87,40 [80,44; 94,36]	0,82 [0,35; 1,93] 0,645
Gender = Female			
N'	133	152	
Number of patients with at least one event, n (%)	11 (8,3)	21 (13,8)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	91,65 [86,92; 96,38]	85,95 [80,38; 91,53]	0,57 [0,28; 1,19] 0,138

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,480		
Gender = Male			
N'	97	88	
Number of patients with at least one event, n (%)	12 (12,4)	11 (12,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	87,56 [80,97; 94,15]	87,39 [80,43; 94,36]	0,98 [0,43; 2,23] 0,960
Gender = Female			
N'	133	152	
Number of patients with at least one event, n (%)	13 (9,8)	22 (14,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	90,15 [85,06; 95,23]	85,27 [79,58; 90,96]	0,66 [0,33; 1,32] 0,245
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Gender = Male			
N'	97	88	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	0,95 [0,00; -] 1,000
Gender = Female			
N'	133	152	
Number of patients with at least one event, n (%)	2 (1,5)	2 (1,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	98,50 [96,43; 100,00]	98,67 [96,84; 100,00]	1,17 [0,17; 8,33] 0,873

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
ER visit due to asthma exacerbation			
Interaction Test:	p=1,000		
Gender = Male			
N'	97	88	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	0,86 [0,00; -] 1,000
Gender = Female			
N'	133	152	
Number of patients with at least one event, n (%)	1 (0,8)	1 (0,7)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	99,25 [97,78; 100,00]	99,34 [98,04; 100,00]	1,22 [0,08; 19,46] 0,890
Hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Gender = Male			
N'	97	88	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,04 [0,00; -] 1,000

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Gender = Female			
N'	133	152	
Number of patients with at least one event, n (%)	1 (0,8)	1 (0,7)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	99,25 [97,78; 100,00]	99,33 [98,03; 100,00]	1,13 [0,07; 18,02] 0,933

N': Number of patients in the analysis
CI: Confidence Interval
HR: Hazard Ratio
*: $p < 0,05$
[+] K-M estimate (%) of outcome-free patients

Applied model for HR: log(hazard ratio) = treatment + region + history of asthma exacerbation + gender + gender * treatment
If it was not possible to fit the minimal model, the HR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 11.4 Exacerbations - Time-to-event Analysis by Region (FAS)

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,906		
Region = Asia			
N'	70	72	
Number of patients with at least one event, n (%)	20 (28,6)	29 (40,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	71,25 [60,61; 81,89]	59,72 [48,39; 71,05]	0,68 [0,39; 1,20] 0,186
Region = Europe			
N'	83	85	
Number of patients with at least one event, n (%)	14 (16,9)	20 (23,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	82,86 [74,69; 91,04]	76,15 [67,02; 85,28]	0,69 [0,35; 1,36] 0,279
Region = Latin America			
N'	61	75	
Number of patients with at least one event, n (%)	7 (11,5)	16 (21,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	88,49 [80,47; 96,51]	78,29 [68,87; 87,71]	0,47 [0,19; 1,14] 0,096
Region = Others			
N'	16	8	
Number of patients with at least one event, n (%)	3 (18,8)	2 (25,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	81,25 [62,13; 100,00]	75,00 [44,99; 100,00]	0,71 [0,12; 4,26] 0,710

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Severe asthma exacerbation			
Interaction Test:	p=0,559		
Region = Asia			
N'	70	72	
Number of patients with at least one event, n (%)	8 (11,4)	8 (11,1)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	88,53 [81,04; 96,01]	88,89 [81,63; 96,15]	1,05 [0,39; 2,79] 0,925
Region = Europe			
N'	83	85	
Number of patients with at least one event, n (%)	8 (9,6)	13 (15,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	90,20 [83,75; 96,65]	84,42 [76,64; 92,21]	0,62 [0,26; 1,50] 0,288
Region = Latin America			
N'	61	75	
Number of patients with at least one event, n (%)	3 (4,9)	10 (13,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	95,05 [89,60; 100,00]	86,41 [78,57; 94,24]	0,33 [0,09; 1,22] 0,096
Region = Others			
N'	16	8	
Number of patients with at least one event, n (%)	2 (12,5)	1 (12,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	87,50 [71,30; 100,00]	87,50 [64,58; 100,00]	1,03 [0,09; 11,37] 0,980

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,719		
Region = Asia			
N'	70	72	
Number of patients with at least one event, n (%)	8 (11,4)	10 (13,9)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	88,53 [81,04; 96,01]	86,07 [78,05; 94,08]	0,84 [0,33; 2,12] 0,704
Region = Europe			
N'	83	85	
Number of patients with at least one event, n (%)	10 (12,0)	12 (14,1)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	87,77 [80,67; 94,88]	85,60 [78,07; 93,14]	0,86 [0,37; 1,99] 0,726
Region = Latin America			
N'	61	75	
Number of patients with at least one event, n (%)	4 (6,6)	10 (13,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	93,41 [87,17; 99,65]	86,41 [78,57; 94,24]	0,45 [0,14; 1,43] 0,175
Region = Others			
N'	16	8	
Number of patients with at least one event, n (%)	3 (18,8)	1 (12,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	81,25 [62,13; 100,00]	87,50 [64,58; 100,00]	1,61 [0,17; 15,51] 0,679

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Region = Asia			
N'	70	72	
Number of patients with at least one event, n (%)	1 (1,4)	1 (1,4)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	98,57 [95,79; 100,00]	98,61 [95,91; 100,00]	1,04 [0,06; 16,57] 0,980
Region = Europe			
N'	83	85	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,02 [0,00; -] 1,000
Region = Latin America			
N'	61	75	
Number of patients with at least one event, n (%)	0 (0,0)	1 (1,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	98,65 [96,02; 100,00]	0,00 [0,00; -] 0,998
Region = Others			
N'	16	8	
Number of patients with at least one event, n (%)	1 (6,3)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	93,75 [81,89; 100,00]	100,00 [100,00; 100,00]	-

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
ER visit due to asthma exacerbation			
Interaction Test:	p=1,000		
Region = Asia			
N'	70	72	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	0,82 [0,00; -] 1,000
Region = Europe			
N'	83	85	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	0,93 [0,00; -] 1,000
Region = Latin America			
N'	61	75	
Number of patients with at least one event, n (%)	0 (0,0)	1 (1,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	98,65 [96,02; 100,00]	0,00 [0,00; -] 0,998
Region = Others			
N'	16	8	
Number of patients with at least one event, n (%)	1 (6,3)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	93,75 [81,89; 100,00]	100,00 [100,00; 100,00]	-

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Region = Asia			
N'	70	72	
Number of patients with at least one event, n (%)	1 (1,4)	1 (1,4)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	98,57 [95,79; 100,00]	98,61 [95,91; 100,00]	1,04 [0,06; 16,57] 0,980
Region = Europe			
N'	83	85	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,00 [0,00; -] 1,000
Region = Latin America			
N'	61	75	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,00 [0,00; -] 1,000

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Region = Others			
N'	16	8	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,00 [0,00; -] 1,000

N': Number of patients in the analysis
CI: Confidence Interval
HR: Hazard Ratio
*: $p < 0,05$
[+] K-M estimate (%) of outcome-free patients

Applied model for HR: log(hazard ratio) = treatment + history of asthma exacerbation + region + region * treatment
If it was not possible to fit the minimal model, the HR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 11.5 Exacerbations - Time-to-event Analysis by History of Asthma Exacerbation (FAS)

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,540		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with at least one event, n (%)	38 (19,4)	52 (26,3)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	80,50 [74,93; 86,07]	73,47 [67,28; 79,65]	0,69 [0,45; 1,05] 0,081
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with at least one event, n (%)	6 (17,6)	15 (35,7)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	82,15 [69,19; 95,11]	63,84 [49,19; 78,49]	0,50 [0,19; 1,29] 0,150
Severe asthma exacerbation			
Interaction Test:	p=0,724		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with at least one event, n (%)	18 (9,2)	25 (12,6)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	90,75 [86,68; 94,82]	87,21 [82,53; 91,89]	0,70 [0,38; 1,29] 0,254

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with at least one event, n (%)	3 (8,8)	7 (16,7)	
Median (in weeks)	-	-	
% of outcome-free patients+	91,08 [81,45; 100,00]	83,08 [71,65; 94,51]	0,54 [0,14; 2,09] 0,370
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,728		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with at least one event, n (%)	21 (10,7)	25 (12,6)	
Median (in weeks)	-	-	
% of outcome-free patients+	89,21 [84,85; 93,57]	87,20 [82,51; 91,89]	0,83 [0,46; 1,48] 0,523
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with at least one event, n (%)	4 (11,8)	8 (19,0)	
Median (in weeks)	-	-	
% of outcome-free patients+	88,14 [77,22; 99,06]	80,64 [68,58; 92,70]	0,65 [0,20; 2,18] 0,488
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	p=0,997		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with at least one event, n (%)	1 (0,5)	2 (1,0)	
Median (in weeks)	-	-	
% of outcome-free patients+	99,49 [98,49; 100,00]	98,98 [97,58; 100,00]	0,51 [0,05; 5,65] 0,585

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with at least one event, n (%)	1 (2,9)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	97,06 [91,38; 100,00]	100,00 [100,00; 100,00]	-
ER visit due to asthma exacerbation			
Interaction Test:	p=0,997		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with at least one event, n (%)	0 (0,0)	1 (0,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	99,49 [98,50; 100,00]	0,00 [0,00; -] 0,997
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with at least one event, n (%)	1 (2,9)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	97,06 [91,38; 100,00]	100,00 [100,00; 100,00]	-
Hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with at least one event, n (%)	1 (0,5)	1 (0,5)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	99,49 [98,49; 100,00]	99,49 [98,50; 100,00]	1,01 [0,06; 16,13] 0,995

	Treatment groups		Comparison
Time-to-first outcome by subgroup (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**HR [95% CI] p-value**
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with at least one event, n (%)	0 (0,0)	0 (0,0)	
Median (in weeks)	-	-	
% of outcome-free patients[+]	100,00 [100,00; 100,00]	100,00 [100,00; 100,00]	1,01 [0,00; -] 1,000

N': Number of patients in the analysis
CI: Confidence Interval
HR: Hazard Ratio
*: $p < 0,05$
[+] K-M estimate (%) of outcome-free patients

Applied model for HR: log(hazard ratio) = treatment + region + history of asthma exacerbation + history of asthma exacerbation * treatment
If it was not possible to fit the minimal model, the HR is not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

12. Exacerbations - Annualized Exacerbation Rate

Table 12.1 Exacerbations - Annualized Exacerbation Rate (FAS)

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Asthma exacerbation			
N'	230	240	
Number of patients with outcome	44	67	
Number of outcomes	59	114	
Annualized Rate [95% CI]	0,49 [0,36; 0,68]	0,90 [0,70; 1,17]	0,55 [0,36; 0,82] 0,003 *
Severe asthma exacerbation			
N'	230	240	
Number of patients with outcome	21	32	
Number of outcomes	25	36	
Annualized Rate [95% CI]	0,23 [0,15; 0,36]	0,32 [0,22; 0,47]	0,72 [0,40; 1,29] 0,268
SCS use due to asthma exacerbation (for at least three consecutive days)			
N'	230	240	
Number of patients with outcome	25	33	
Number of outcomes	29	37	
Annualized Rate [95% CI]	0,27 [0,18; 0,40]	0,33 [0,23; 0,48]	0,81 [0,47; 1,39] 0,450
ER visit and/or hospitalization due to asthma exacerbation			
N'	230	240	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	-	-	-
ER visit due to asthma exacerbation			
N'	230	240	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	-	-	-

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Hospitalization due to asthma exacerbation			
N'	230	240	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	0,01 [0,00; 0,07]	0,01 [0,00; 0,06]	1,04 [0,06; 16,60] 0,979

N': Number of patients in the analysis
CI: Confidence Interval
RR: Rate Ratio
*: $p < 0,05$

Annualized Rate and Rate Ratio are calculated based on negative binomial regression model.
Applied model for Annualized Rate/Rate Ratio: Number of events = treatment + region + history of asthma exacerbation, offset variable: log(exposure in years)
Exceptional model(s) for Annualized Rate/Rate Ratio: Number of events = treatment + history of asthma exacerbation (for ER visit and/or hospitalization due to asthma exacerbation), treatment + history of asthma exacerbation (for ER visit due to asthma exacerbation), treatment + history of asthma exacerbation (for Hospitalization due to asthma exacerbation), offset variable: log(exposure in years)
If it was not possible to fit the minimal model, the Annualized Rate and Rate Ratio are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 12.2 Exacerbations - Annualized Exacerbation Rate by Age (FAS)

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,592		
Age = 18-39 years			
N'	44	40	
Number of patients with outcome	6	5	
Number of outcomes	7	6	
Annualized Rate [95% CI]	0,38 [0,16; 0,87]	0,37 [0,15; 0,91]	1,02 [0,30; 3,48] 0,976
Age = 40-64 years			
N'	144	155	
Number of patients with outcome	26	46	
Number of outcomes	36	77	
Annualized Rate [95% CI]	0,48 [0,32; 0,72]	0,93 [0,68; 1,28]	0,52 [0,31; 0,85] 0,010 *
Age = ≥65 years			
N'	42	45	
Number of patients with outcome	12	16	
Number of outcomes	16	31	
Annualized Rate [95% CI]	0,66 [0,35; 1,24]	1,27 [0,75; 2,17]	0,51 [0,23; 1,17] 0,113
Severe asthma exacerbation			
Interaction Test:	p=0,250		
Age = 18-39 years			
N'	44	40	
Number of patients with outcome	3	2	
Number of outcomes	3	2	
Annualized Rate [95% CI]	0,14 [0,04; 0,48]	0,11 [0,02; 0,46]	1,35 [0,20; 8,98] 0,754

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Age = 40-64 years			
N'	144	155	
Number of patients with outcome	15	20	
Number of outcomes	19	23	
Annualized Rate [95% CI]	0,29 [0,17; 0,48]	0,32 [0,20; 0,51]	0,92 [0,46; 1,83] 0,803
Age = ≥65 years			
N'	42	45	
Number of patients with outcome	3	10	
Number of outcomes	3	11	
Annualized Rate [95% CI]	0,15 [0,04; 0,50]	0,55 [0,27; 1,15]	0,27 [0,06; 1,09] 0,066
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,260		
Age = 18-39 years			
N'	44	40	
Number of patients with outcome	5	2	
Number of outcomes	5	2	
Annualized Rate [95% CI]	0,24 [0,09; 0,62]	0,11 [0,02; 0,45]	2,28 [0,41; 12,80] 0,347
Age = 40-64 years			
N'	144	155	
Number of patients with outcome	16	22	
Number of outcomes	20	25	
Annualized Rate [95% CI]	0,30 [0,19; 0,49]	0,34 [0,22; 0,53]	0,88 [0,46; 1,68] 0,693
Age = ≥65 years			
N'	42	45	
Number of patients with outcome	4	9	
Number of outcomes	4	10	
Annualized Rate [95% CI]	0,20 [0,07; 0,58]	0,51 [0,25; 1,05]	0,39 [0,11; 1,40] 0,149

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	N.E.		
Age = 18-39 years			
N'	44	40	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	0,00 [0,00; -]	0,00 [0,00; 0,00]	0,15 [0,00; -] 1,000
Age = 40-64 years			
N'	144	155	
Number of patients with outcome	1	0	
Number of outcomes	1	0	
Annualized Rate [95% CI]	0,02 [0,00; 0,11]	-	-
Age = ≥65 years			
N'	42	45	
Number of patients with outcome	0	1	
Number of outcomes	0	1	
Annualized Rate [95% CI]	-	-	-
ER visit due to asthma exacerbation			
Interaction Test:	N.E.		
Age = 18-39 years			
N'	44	40	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	0,00 [0,00; -]	0,00 [0,00; 0,00]	0,15 [0,00; -] 1,000
Age = 40-64 years			
N'	144	155	
Number of patients with outcome	1	0	
Number of outcomes	1	0	
Annualized Rate [95% CI]	0,02 [0,00; 0,11]	-	-

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Age = ≥65 years			
N'	42	45	
Number of patients with outcome	0	1	
Number of outcomes	0	1	
Annualized Rate [95% CI]	-	-	-
Hospitalization due to asthma exacerbation			
Interaction Test:	N.E.		
Age = 18-39 years			
N'	44	40	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-
Age = 40-64 years			
N'	144	155	
Number of patients with outcome	0	1	
Number of outcomes	0	1	
Annualized Rate [95% CI]	-	-	-
Age = ≥65 years			
N'	42	45	
Number of patients with outcome	1	0	
Number of outcomes	1	0	
Annualized Rate [95% CI]	-	-	-

N': Number of patients in the analysis
CI: Confidence Interval
RR: Rate Ratio
*: $p < 0,05$

Annualized Rate and Rate Ratio are calculated based on negative binomial regression model.
Applied model for Annualized Rate/Rate Ratio: Number of events = treatment + region + history of asthma exacerbation + age + age * treatment, offset variable: log(exposure in years)
Exceptional model(s) for Annualized Rate/Rate Ratio: Number of events = treatment + history of asthma exacerbation [by age] (for ER visit and/or hospitalization due to asthma exacerbation), treatment + history of asthma exacerbation [by age] (for ER visit due to asthma exacerbation), treatment + history of asthma exacerbation [by age] (for Hospitalization due to asthma exacerbation), offset variable: log(exposure in years)
If it was not possible to fit the minimal model, the Annualized Rate and Rate Ratio are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 12.3 Exacerbations - Annualized Exacerbation Rate by Gender (FAS)

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,640		
Gender = Male			
N'	97	88	
Number of patients with outcome	22	23	
Number of outcomes	25	37	
Annualized Rate [95% CI]	0,52 [0,32; 0,84]	0,84 [0,54; 1,29]	0,62 [0,32; 1,19] 0,147
Gender = Female			
N'	133	152	
Number of patients with outcome	22	44	
Number of outcomes	34	77	
Annualized Rate [95% CI]	0,47 [0,31; 0,72]	0,94 [0,68; 1,29]	0,51 [0,30; 0,85] 0,010 *
Severe asthma exacerbation			
Interaction Test:	p=0,745		
Gender = Male			
N'	97	88	
Number of patients with outcome	10	11	
Number of outcomes	11	12	
Annualized Rate [95% CI]	0,24 [0,12; 0,47]	0,30 [0,15; 0,57]	0,82 [0,32; 2,07] 0,670
Gender = Female			
N'	133	152	
Number of patients with outcome	11	21	
Number of outcomes	14	24	
Annualized Rate [95% CI]	0,23 [0,13; 0,41]	0,34 [0,21; 0,54]	0,67 [0,32; 1,41] 0,293

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,713		
Gender = Male			
N'	97	88	
Number of patients with outcome	12	11	
Number of outcomes	13	12	
Annualized Rate [95% CI]	0,28 [0,15; 0,51]	0,30 [0,16; 0,56]	0,93 [0,39; 2,22] 0,868
Gender = Female			
N'	133	152	
Number of patients with outcome	13	22	
Number of outcomes	16	25	
Annualized Rate [95% CI]	0,27 [0,15; 0,45]	0,35 [0,23; 0,55]	0,75 [0,37; 1,51] 0,423
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Gender = Male			
N'	97	88	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	0,00 [0,00; -]	0,00 [0,00; -]	0,53 [0,00; -] 1,000
Gender = Female			
N'	133	152	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	0,00 [0,00; -]	0,00 [0,00; -]	1,22 [0,08; 19,45] 0,890

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
ER visit due to asthma exacerbation			
Interaction Test:	p=1,000		
Gender = Male			
N'	97	88	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	0,00 [0,00; -]	0,00 [0,00; -]	0,53 [0,00; -] 1,000
Gender = Female			
N'	133	152	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	0,00 [0,00; -]	0,00 [0,00; -]	1,22 [0,08; 19,45] 0,890
Hospitalization due to asthma exacerbation			
Interaction Test:	N.E.		
Gender = Male			
N'	97	88	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-
Gender = Female			
N'	133	152	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	0,02 [0,00; 0,12]	0,01 [0,00; 0,10]	1,15 [0,07; 18,35] 0,922

N': Number of patients in the analysis
CI: Confidence Interval
RR: Rate Ratio
*: $p < 0,05$

Annualized Rate and Rate Ratio are calculated based on negative binomial regression model.
Applied model for Annualized Rate/Rate Ratio: Number of events = treatment + region + history of asthma exacerbation + gender + gender * treatment, offset variable: log(exposure in years)
Exceptional model(s) for Annualized Rate/Rate Ratio: Number of events = treatment + history of asthma exacerbation [by gender] (for Hospitalization due to asthma exacerbation), offset variable: log(exposure in years)
If it was not possible to fit the minimal model, the Annualized Rate and Rate Ratio are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 12.4 Exacerbations - Annualized Exacerbation Rate by Region (FAS)

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,746		
Region = Asia			
N'	70	72	
Number of patients with outcome	20	29	
Number of outcomes	30	61	
Annualized Rate [95% CI]	0,92 [0,57; 1,48]	1,82 [1,22; 2,70]	0,51 [0,27; 0,94] 0,031 *
Region = Europe			
N'	83	85	
Number of patients with outcome	14	20	
Number of outcomes	17	24	
Annualized Rate [95% CI]	0,45 [0,26; 0,79]	0,64 [0,39; 1,04]	0,71 [0,34; 1,49] 0,368
Region = Latin America			
N'	61	75	
Number of patients with outcome	7	16	
Number of outcomes	8	26	
Annualized Rate [95% CI]	0,28 [0,13; 0,61]	0,75 [0,46; 1,23]	0,38 [0,15; 0,93] 0,035 *
Region = Others			
N'	16	8	
Number of patients with outcome	3	2	
Number of outcomes	4	3	
Annualized Rate [95% CI]	0,53 [0,16; 1,73]	0,81 [0,19; 3,45]	0,66 [0,10; 4,29] 0,665

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Severe asthma exacerbation			
Interaction Test:	p=0,498		
Region = Asia			
N'	70	72	
Number of patients with outcome	8	8	
Number of outcomes	9	8	
Annualized Rate [95% CI]	0,28 [0,13; 0,58]	0,24 [0,11; 0,51]	1,17 [0,40; 3,41] 0,767
Region = Europe			
N'	83	85	
Number of patients with outcome	8	13	
Number of outcomes	10	14	
Annualized Rate [95% CI]	0,27 [0,13; 0,54]	0,37 [0,20; 0,69]	0,71 [0,28; 1,80] 0,473
Region = Latin America			
N'	61	75	
Number of patients with outcome	3	10	
Number of outcomes	3	12	
Annualized Rate [95% CI]	0,11 [0,03; 0,35]	0,35 [0,18; 0,67]	0,30 [0,08; 1,18] 0,084
Region = Others			
N'	16	8	
Number of patients with outcome	2	1	
Number of outcomes	3	2	
Annualized Rate [95% CI]	0,40 [0,10; 1,52]	0,54 [0,10; 2,97]	0,74 [0,08; 6,51] 0,789

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,687		
Region = Asia			
N'	70	72	
Number of patients with outcome	8	10	
Number of outcomes	9	10	
Annualized Rate [95% CI]	0,28 [0,14; 0,57]	0,30 [0,15; 0,59]	0,94 [0,35; 2,52] 0,901
Region = Europe			
N'	83	85	
Number of patients with outcome	10	12	
Number of outcomes	12	13	
Annualized Rate [95% CI]	0,32 [0,17; 0,60]	0,35 [0,19; 0,64]	0,92 [0,39; 2,21] 0,857
Region = Latin America			
N'	61	75	
Number of patients with outcome	4	10	
Number of outcomes	4	12	
Annualized Rate [95% CI]	0,14 [0,05; 0,40]	0,35 [0,19; 0,66]	0,40 [0,12; 1,35] 0,141
Region = Others			
N'	16	8	
Number of patients with outcome	3	1	
Number of outcomes	4	2	
Annualized Rate [95% CI]	0,53 [0,17; 1,69]	0,54 [0,11; 2,73]	0,99 [0,14; 7,31] 0,995
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	N.E.		
Region = Asia			
N'	70	72	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Region = Europe			
N'	83	85	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-
Region = Latin America			
N'	61	75	
Number of patients with outcome	0	1	
Number of outcomes	0	1	
Annualized Rate [95% CI]	-	-	-
Region = Others			
N'	16	8	
Number of patients with outcome	1	0	
Number of outcomes	1	0	
Annualized Rate [95% CI]	-	-	-
ER visit due to asthma exacerbation			
Interaction Test:	N.E.		
Region = Asia			
N'	70	72	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-
Region = Europe			
N'	83	85	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-
Region = Latin America			
N'	61	75	
Number of patients with outcome	0	1	
Number of outcomes	0	1	
Annualized Rate [95% CI]	-	-	-

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Region = Others			
N'	16	8	
Number of patients with outcome	1	0	
Number of outcomes	1	0	
Annualized Rate [95% CI]	-	-	-
Hospitalization due to asthma exacerbation			
Interaction Test:	N.E.		
Region = Asia			
N'	70	72	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	0,03 [0,00; 0,22]	0,03 [0,00; 0,21]	1,04 [0,07; 16,63] 0,978
Region = Europe			
N'	83	85	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-
Region = Latin America			
N'	61	75	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Region = Others			
N'	16	8	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	-	-	-

N': Number of patients in the analysis
CI: Confidence Interval
RR: Rate Ratio
*: $p < 0,05$

Annualized Rate and Rate Ratio are calculated based on negative binomial regression model.
Applied model for Annualized Rate/Rate Ratio: Number of events = treatment + history of asthma exacerbation + region + region * treatment, offset variable: log(exposure in years)
Exceptional model(s) for Annualized Rate/Rate Ratio: Number of events = treatment + history of asthma exacerbation [by region] (for ER visit and/or hospitalization due to asthma exacerbation), treatment + history of asthma exacerbation [by region] (for ER visit due to asthma exacerbation), treatment + history of asthma exacerbation [by region] (for Hospitalization due to asthma exacerbation), offset variable: log(exposure in years)
If it was not possible to fit the minimal model, the Annualized Rate and Rate Ratio are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 12.5 Exacerbations - Annualized Exacerbation Rate by History of Asthma Exacerbation (FAS)

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Asthma exacerbation			
Interaction Test:	p=0,847		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with outcome	38	52	
Number of outcomes	52	93	
Annualized Rate [95% CI]	0,49 [0,35; 0,69]	0,87 [0,66; 1,16]	0,56 [0,36; 0,86] 0,009 *
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with outcome	6	15	
Number of outcomes	7	21	
Annualized Rate [95% CI]	0,52 [0,22; 1,25]	1,04 [0,57; 1,91]	0,50 [0,17; 1,44] 0,199
Severe asthma exacerbation			
Interaction Test:	p=0,846		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with outcome	18	25	
Number of outcomes	21	28	
Annualized Rate [95% CI]	0,23 [0,14; 0,37]	0,30 [0,20; 0,46]	0,75 [0,40; 1,41] 0,369
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with outcome	3	7	
Number of outcomes	4	8	
Annualized Rate [95% CI]	0,27 [0,09; 0,82]	0,42 [0,18; 0,96]	0,64 [0,16; 2,54] 0,529

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
SCS use due to asthma exacerbation (for at least three consecutive days)			
Interaction Test:	p=0,829		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with outcome	21	25	
Number of outcomes	24	28	
Annualized Rate [95% CI]	0,26 [0,17; 0,40]	0,31 [0,20; 0,46]	0,85 [0,47; 1,54] 0,589
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with outcome	4	8	
Number of outcomes	5	9	
Annualized Rate [95% CI]	0,33 [0,13; 0,89]	0,46 [0,21; 0,99]	0,73 [0,21; 2,51] 0,616
ER visit and/or hospitalization due to asthma exacerbation			
Interaction Test:	N.E.		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with outcome	0	1	
Number of outcomes	0	1	
Annualized Rate [95% CI]	-	-	-
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with outcome	1	0	
Number of outcomes	1	0	
Annualized Rate [95% CI]	-	-	-
ER visit due to asthma exacerbation			
Interaction Test:	N.E.		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with outcome	0	1	
Number of outcomes	0	1	
Annualized Rate [95% CI]	-	-	-

	Treatment groups		Comparison
Annualized Outcome Rate (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**RR [95% CI] p-value**
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with outcome	1	0	
Number of outcomes	1	0	
Annualized Rate [95% CI]	-	-	-
Hospitalization due to asthma exacerbation			
Interaction Test:	p=1,000		
Asthma exacerbations in the 12 months prior to screening = 1			
N'	196	198	
Number of patients with outcome	1	1	
Number of outcomes	1	1	
Annualized Rate [95% CI]	-	-	0,99 [0,06; 15,80] 0,993
Asthma exacerbations in the 12 months prior to screening = ≥2			
N'	34	42	
Number of patients with outcome	0	0	
Number of outcomes	0	0	
Annualized Rate [95% CI]	0,00 [0,00; -]	0,00 [0,00; -]	0,86 [0,00; -] 1,000

N': Number of patients in the analysis
CI: Confidence Interval
RR: Rate Ratio
*: $p < 0,05$

Annualized Rate and Rate Ratio are calculated based on negative binomial regression model.
Applied model for Annualized Rate/Rate Ratio: Number of events = treatment + region + history of asthma exacerbation + history of asthma exacerbation * treatment, offset variable: log(exposure in years)
Exceptional model(s) for Annualized Rate/Rate Ratio: Number of events = treatment [by history of asthma exacerbation] (for ER visit and/or hospitalization due to asthma exacerbation), treatment [by history of asthma exacerbation] (for ER visit due to asthma exacerbation), offset variable: log(exposure in years)
If it was not possible to fit the minimal model, the Annualized Rate and Rate Ratio are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

13. Adverse Events - Binary Analysis (SAF)

Table 13.1 Adverse Events - Binary Analysis (SAF)

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
Any AE, n (%)	108 (47,0)	125 (52,1)	0,81 [0,57; 1,17] 0,267	0,90 [0,75; 1,08] 0,268	-0,05 [-0,14; 0,04] 0,266
Any AE, disease specific events excluded, n (%)	98 (42,6)	111 (46,3)	0,86 [0,60; 1,24] 0,427	0,92 [0,75; 1,13] 0,428	-0,04 [-0,13; 0,05] 0,427
Any SAE, n (%)	8 (3,5)	8 (3,3)	1,05 [0,39; 2,83] 0,931	1,04 [0,40; 2,73] 0,931	0,00 [-0,03; 0,03] 0,931
Any SAE, disease specific events excluded, n (%)	7 (3,0)	7 (2,9)	1,04 [0,36; 3,03] 0,936	1,04 [0,37; 2,93] 0,936	0,00 [-0,03; 0,03] 0,936
Any severe AE, n (%)	25 (10,9)	37 (15,4)	0,67 [0,39; 1,15] 0,147	0,71 [0,44; 1,13] 0,149	-0,05 [-0,11; 0,02] 0,143
Any severe AE, disease specific events excluded, n (%)	11 (4,8)	13 (5,4)	0,88 [0,38; 2,00] 0,755	0,88 [0,40; 1,93] 0,755	-0,01 [-0,05; 0,03] 0,755
Any AE leading to study drug discontinuation, n (%)	2 (0,9)	0 (0,0)	-	5,22 [0,25; 108,07] 0,285	0,01 [-0,00; 0,02] 0,155
Any AE leading to study discontinuation, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316

CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 13.2 Adverse Events - Binary Analysis by Age (SAF)

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Age = 18-39 years	44	40			
N' Age = 40-64 years	144	155			
N' Age = ≥65 years	42	45			
Any AE					
Interaction Test:	p=0,085				
Age = 18-39 years	16 (36,4)	8 (20,0)	2,29 [0,85; 6,14] 0,101	1,82 [0,87; 3,78] 0,110	0,16 [-0,02; 0,35] 0,089
Age = 40-64 years	69 (47,9)	87 (56,1)	0,72 [0,46; 1,13] 0,156	0,85 [0,69; 1,06] 0,159	-0,08 [-0,20; 0,03] 0,154
Age = ≥65 years	23 (54,8)	30 (66,7)	0,61 [0,25; 1,44] 0,257	0,82 [0,58; 1,16] 0,262	-0,12 [-0,32; 0,08] 0,253
Any AE, disease specific events excluded					
Interaction Test:	p=0,118				
Age = 18-39 years	16 (36,4)	8 (20,0)	2,29 [0,85; 6,14] 0,101	1,82 [0,87; 3,78] 0,110	0,16 [-0,02; 0,35] 0,089
Age = 40-64 years	62 (43,1)	78 (50,3)	0,75 [0,47; 1,18] 0,209	0,86 [0,67; 1,09] 0,211	-0,07 [-0,19; 0,04] 0,207
Age = ≥65 years	20 (47,6)	25 (55,6)	0,73 [0,31; 1,69] 0,460	0,86 [0,57; 1,29] 0,462	-0,08 [-0,29; 0,13] 0,458
Any severe AE					
Interaction Test:	p=0,096				
Age = 18-39 years	5 (11,4)	2 (5,0)	2,44 [0,45; 13,33] 0,305	2,27 [0,47; 11,07] 0,309	0,06 [-0,05; 0,18] 0,280
Age = 40-64 years	16 (11,1)	22 (14,2)	0,76 [0,38; 1,50] 0,425	0,78 [0,43; 1,43] 0,426	-0,03 [-0,11; 0,04] 0,422
Age = ≥65 years	4 (9,5)	13 (28,9)	0,26 [0,08; 0,87] 0,029 *	0,33 [0,12; 0,93] 0,036 *	-0,19 [-0,35; -0,03] 0,017 *

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE, disease specific events excluded					
Interaction Test:	p=0,668				
Age = 18-39 years	2 (4,5)	2 (5,0)	0,90 [0,12; 6,74] 0,922	0,91 [0,13; 6,16] 0,922	-0,00 [-0,10; 0,09] 0,922
Age = 40-64 years	8 (5,6)	8 (5,2)	1,08 [0,39; 2,96] 0,880	1,08 [0,41; 2,79] 0,880	0,00 [-0,05; 0,06] 0,880
Age = ≥65 years	1 (2,4)	3 (6,7)	0,34 [0,03; 3,42] 0,361	0,36 [0,04; 3,30] 0,364	-0,04 [-0,13; 0,04] 0,330

CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + age + age * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 13.3 Adverse Events - Binary Analysis by Gender (SAF)

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Gender = Male	97	88			
N' Gender = Female	133	152			
Any AE					
Interaction Test:	p=0,313				
Gender = Male	42 (43,3)	37 (42,0)	1,05 [0,59; 1,89] 0,863	1,03 [0,74; 1,44] 0,863	0,01 [-0,13; 0,16] 0,863
Gender = Female	66 (49,6)	88 (57,9)	0,72 [0,45; 1,14] 0,163	0,86 [0,69; 1,07] 0,167	-0,08 [-0,20; 0,03] 0,161
Any AE, disease specific events excluded					
Interaction Test:	p=0,524				
Gender = Male	36 (37,1)	32 (36,4)	1,03 [0,57; 1,88] 0,916	1,02 [0,70; 1,49] 0,916	0,01 [-0,13; 0,15] 0,916
Gender = Female	62 (46,6)	79 (52,0)	0,81 [0,51; 1,29] 0,367	0,90 [0,71; 1,14] 0,369	-0,05 [-0,17; 0,06] 0,366
Any SAE					
Interaction Test:	p=0,191				
Gender = Male	1 (1,0)	3 (3,4)	0,30 [0,03; 2,89] 0,295	0,30 [0,03; 2,85] 0,296	-0,02 [-0,07; 0,02] 0,277
Gender = Female	7 (5,3)	5 (3,3)	1,63 [0,51; 5,27] 0,412	1,60 [0,52; 4,92] 0,412	0,02 [-0,03; 0,07] 0,414
Any SAE, disease specific events excluded					
Interaction Test:	p=0,183				
Gender = Male	1 (1,0)	3 (3,4)	0,30 [0,03; 2,89] 0,295	0,30 [0,03; 2,85] 0,296	-0,02 [-0,07; 0,02] 0,277
Gender = Female	6 (4,5)	4 (2,6)	1,75 [0,48; 6,33] 0,395	1,71 [0,49; 5,95] 0,396	0,02 [-0,02; 0,06] 0,397

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE					
Interaction Test:	p=0,544				
Gender = Male	12 (12,4)	13 (14,8)	0,81 [0,35; 1,89] 0,634	0,84 [0,40; 1,74] 0,634	-0,02 [-0,12; 0,07] 0,634
Gender = Female	13 (9,8)	24 (15,8)	0,58 [0,28; 1,19] 0,135	0,62 [0,33; 1,17] 0,138	-0,06 [-0,14; 0,02] 0,125
Any severe AE, disease specific events excluded					
Interaction Test:	p=0,979				
Gender = Male	4 (4,1)	4 (4,5)	0,90 [0,22; 3,73] 0,888	0,91 [0,23; 3,52] 0,888	-0,00 [-0,06; 0,05] 0,888
Gender = Female	7 (5,3)	9 (5,9)	0,88 [0,32; 2,44] 0,810	0,89 [0,34; 2,32] 0,810	-0,01 [-0,06; 0,05] 0,809

CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + gender + gender * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 13.4 Adverse Events - Binary Analysis by Region (SAF)

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Region = Asia	70	72			
N' Region = Europe	83	85			
N' Region = Latin America	61	75			
N' Region = Others	16	8			
Any AE					
Interaction Test:	p=0,782				
Region = Asia	42 (60,0)	52 (72,2)	0,58 [0,29; 1,17] 0,125	0,83 [0,65; 1,06] 0,128	-0,12 [-0,28; 0,03] 0,121
Region = Europe	37 (44,6)	40 (47,1)	0,90 [0,49; 1,66] 0,747	0,95 [0,68; 1,32] 0,747	-0,02 [-0,18; 0,13] 0,747
Region = Latin America	22 (36,1)	29 (38,7)	0,89 [0,44; 1,80] 0,755	0,93 [0,60; 1,45] 0,756	-0,03 [-0,19; 0,14] 0,755
Region = Others	7 (43,8)	4 (50,0)	0,78 [0,14; 4,27] 0,772	0,88 [0,36; 2,13] 0,768	-0,06 [-0,49; 0,36] 0,772
Any AE, disease specific events excluded					
Interaction Test:	p=0,548				
Region = Asia	37 (52,9)	48 (66,7)	0,56 [0,28; 1,10] 0,095	0,79 [0,60; 1,04] 0,098	-0,14 [-0,30; 0,02] 0,090
Region = Europe	35 (42,2)	34 (40,0)	1,09 [0,59; 2,02] 0,775	1,05 [0,73; 1,51] 0,775	0,02 [-0,13; 0,17] 0,775
Region = Latin America	19 (31,1)	25 (33,3)	0,90 [0,44; 1,87] 0,787	0,93 [0,57; 1,53] 0,787	-0,02 [-0,18; 0,14] 0,786
Region = Others	7 (43,8)	4 (50,0)	0,78 [0,14; 4,27] 0,772	0,88 [0,36; 2,13] 0,768	-0,06 [-0,49; 0,36] 0,772

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Any severe AE					
Interaction Test:	p=0,734				
Region = Asia	8 (11,4)	11 (15,3)	0,72 [0,27; 1,90] 0,502	0,75 [0,32; 1,75] 0,503	-0,04 [-0,15; 0,07] 0,499
Region = Europe	12 (14,5)	15 (17,6)	0,79 [0,34; 1,80] 0,574	0,82 [0,41; 1,64] 0,575	-0,03 [-0,14; 0,08] 0,573
Region = Latin America	3 (4,9)	10 (13,3)	0,34 [0,09; 1,28] 0,110	0,37 [0,11; 1,28] 0,116	-0,08 [-0,18; 0,01] 0,080
Region = Others	2 (12,5)	1 (12,5)	1,00 [0,08; 13,02] 1,000	1,00 [0,11; 9,44] 1,000	0,00 [-0,28; 0,28] 1,000
Any severe AE, disease specific events excluded					
Interaction Test:	N.E.				
Region = Asia	4 (5,7)	5 (6,9)	-	0,82 [0,23; 2,94] 0,764	-0,01 [-0,09; 0,07] 0,763
Region = Europe	6 (7,2)	4 (4,7)	-	1,54 [0,45; 5,25] 0,493	0,03 [-0,05; 0,10] 0,490
Region = Latin America	0 (0,0)	4 (5,3)	-	0,14 [0,01; 2,48] 0,178	-0,05 [-0,10; -0,00] 0,040 *
Region = Others	1 (6,3)	0 (0,0)	-	1,59 [0,07; 35,15] 0,770	0,06 [-0,06; 0,18] 0,302

CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
N.E.: not estimable
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + region + region * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 13.5 Adverse Events - Binary Analysis by History of Asthma Exacerbation (SAF)

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Asthma exacerbations in the 12 months prior to screening = 1	196	198			
N' Asthma exacerbations in the 12 months prior to screening = ≥2	34	42			
Any AE					
Interaction Test:	p=0,252				
Asthma exacerbations in the 12 months prior to screening = 1	91 (46,4)	97 (49,0)	0,90 [0,61; 1,34] 0,611	0,95 [0,77; 1,17] 0,611	-0,03 [-0,12; 0,07] 0,611
Asthma exacerbations in the 12 months prior to screening = ≥2	17 (50,0)	28 (66,7)	0,50 [0,20; 1,27] 0,144	0,75 [0,50; 1,12] 0,157	-0,17 [-0,39; 0,05] 0,138
Any AE, disease specific events excluded					
Interaction Test:	p=0,257				
Asthma exacerbations in the 12 months prior to screening = 1	83 (42,3)	86 (43,4)	0,96 [0,64; 1,43] 0,827	0,97 [0,78; 1,22] 0,827	-0,01 [-0,11; 0,09] 0,827
Asthma exacerbations in the 12 months prior to screening = ≥2	15 (44,1)	25 (59,5)	0,54 [0,21; 1,34] 0,183	0,74 [0,47; 1,17] 0,195	-0,15 [-0,38; 0,07] 0,176
Any SAE					
Interaction Test:	p=0,426				
Asthma exacerbations in the 12 months prior to screening = 1	6 (3,1)	7 (3,5)	0,86 [0,28; 2,61] 0,792	0,87 [0,30; 2,53] 0,792	-0,00 [-0,04; 0,03] 0,792
Asthma exacerbations in the 12 months prior to screening = ≥2	2 (5,9)	1 (2,4)	2,56 [0,22; 29,54] 0,451	2,47 [0,23; 26,10] 0,452	0,04 [-0,06; 0,13] 0,453
Any SAE, disease specific events excluded					
Interaction Test:	p=0,421				
Asthma exacerbations in the 12 months prior to screening = 1	5 (2,6)	6 (3,0)	0,84 [0,25; 2,79] 0,773	0,84 [0,26; 2,71] 0,773	-0,00 [-0,04; 0,03] 0,773

	Treatment groups		Comparison		
Adverse Events - Binary Analysis (SAF)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Asthma exacerbations in the 12 months prior to screening = ≥2	2 (5,9)	1 (2,4)	2,56 [0,22; 29,53] 0,451	2,47 [0,23; 26,10] 0,452	0,04 [-0,06; 0,13] 0,453
Any severe AE					
Interaction Test:	p=0,991				
Asthma exacerbations in the 12 months prior to screening = 1	21 (10,7)	30 (15,2)	0,67 [0,37; 1,22] 0,192	0,71 [0,42; 1,19] 0,193	-0,04 [-0,11; 0,02] 0,188
Asthma exacerbations in the 12 months prior to screening = ≥2	4 (11,8)	7 (16,7)	0,67 [0,18; 2,50] 0,548	0,71 [0,23; 2,21] 0,550	-0,05 [-0,21; 0,11] 0,539
Any severe AE, disease specific events excluded					
Interaction Test:	p=0,157				
Asthma exacerbations in the 12 months prior to screening = 1	8 (4,1)	12 (6,1)	0,66 [0,26; 1,65] 0,374	0,67 [0,28; 1,61] 0,375	-0,02 [-0,06; 0,02] 0,370
Asthma exacerbations in the 12 months prior to screening = ≥2	3 (8,8)	1 (2,4)	3,97 [0,39; 39,99] 0,242	3,71 [0,40; 34,04] 0,247	0,06 [-0,04; 0,17] 0,233

CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + history of asthma exacerbation + history of asthma exacerbation * treatment
If it was not possible to fit the minimal model, the OR is not given.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

14. Any AE by SOC and PT - Binary Analysis (SAF)

Table 14.1 Any AE by SOC, PT and Severity - Binary Analysis (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
Any adverse event, n (%)**	108 (47,0)	125 (52,1)	0,81 [0,57; 1,17] 0,267	0,90 [0,75; 1,08] 0,268	-0,05 [-0,14; 0,04] 0,266
Mild, n (%)	70 (30,4)	89 (37,1)	0,74 [0,51; 1,09] 0,128	0,82 [0,64; 1,06] 0,130	-0,07 [-0,15; 0,02] 0,126
Moderate, n (%)	50 (21,7)	62 (25,8)	0,80 [0,52; 1,22] 0,298	0,84 [0,61; 1,17] 0,299	-0,04 [-0,12; 0,04] 0,297
Severe, n (%)	25 (10,9)	37 (15,4)	0,67 [0,39; 1,15] 0,147	0,71 [0,44; 1,13] 0,149	-0,05 [-0,11; 0,02] 0,143
Infections and infestations, n (%)	67 (29,1)	68 (28,3)	1,04 [0,70; 1,55] 0,849	1,03 [0,77; 1,37] 0,849	0,01 [-0,07; 0,09] 0,849
Mild, n (%)	42 (18,3)	39 (16,3)	1,15 [0,71; 1,86] 0,564	1,12 [0,76; 1,67] 0,564	0,02 [-0,05; 0,09] 0,564
Moderate, n (%)	26 (11,3)	35 (14,6)	0,75 [0,43; 1,29] 0,291	0,78 [0,48; 1,25] 0,292	-0,03 [-0,09; 0,03] 0,289
Severe, n (%)	7 (3,0)	7 (2,9)	1,04 [0,36; 3,03] 0,936	1,04 [0,37; 2,93] 0,936	0,00 [-0,03; 0,03] 0,936
Nasopharyngitis, n (%)	14 (6,1)	23 (9,6)	0,61 [0,31; 1,22] 0,163	0,64 [0,34; 1,20] 0,164	-0,03 [-0,08; 0,01] 0,157
Mild, n (%)	11 (4,8)	16 (6,7)	0,70 [0,32; 1,55] 0,383	0,72 [0,34; 1,51] 0,383	-0,02 [-0,06; 0,02] 0,378
Moderate, n (%)	3 (1,3)	9 (3,8)	0,34 [0,09; 1,27] 0,108	0,35 [0,10; 1,27] 0,110	-0,02 [-0,05; 0,00] 0,089
Severe, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Bronchitis, n (%)	11 (4,8)	5 (2,1)	2,36 [0,81; 6,90] 0,117	2,30 [0,81; 6,50] 0,118	0,03 [-0,01; 0,06] 0,109
Mild, n (%)	4 (1,7)	1 (0,4)	4,23 [0,47; 38,13] 0,199	4,17 [0,47; 37,07] 0,200	0,01 [-0,01; 0,03] 0,167
Moderate, n (%)	7 (3,0)	4 (1,7)	1,85 [0,53; 6,41] 0,331	1,83 [0,54; 6,15] 0,331	0,01 [-0,01; 0,04] 0,326
Severe, n (%)	0 (0,0)	0 (0,0)	-	-	-
Respiratory, thoracic and mediastinal disorders, n (%)	55 (23,9)	80 (33,3)	0,63 [0,42; 0,94] 0,025 *	0,72 [0,54; 0,96] 0,026 *	-0,09 [-0,18; -0,01] 0,023 *
Mild, n (%)	23 (10,0)	41 (17,1)	0,54 [0,31; 0,93] 0,027 *	0,59 [0,36; 0,94] 0,028 *	-0,07 [-0,13; -0,01] 0,024 *
Moderate, n (%)	17 (7,4)	21 (8,8)	0,83 [0,43; 1,62] 0,590	0,84 [0,46; 1,56] 0,590	-0,01 [-0,06; 0,04] 0,588
Severe, n (%)	21 (9,1)	32 (13,3)	0,65 [0,36; 1,17] 0,152	0,68 [0,41; 1,15] 0,153	-0,04 [-0,10; 0,01] 0,148
Asthma, n (%)	44 (19,1)	67 (27,9)	0,61 [0,40; 0,94] 0,026 *	0,69 [0,49; 0,96] 0,027 *	-0,09 [-0,16; -0,01] 0,024 *
Mild, n (%)	16 (7,0)	29 (12,1)	0,54 [0,29; 1,03] 0,062	0,58 [0,32; 1,03] 0,063	-0,05 [-0,10; 0,00] 0,057
Moderate, n (%)	12 (5,2)	19 (7,9)	0,64 [0,30; 1,35] 0,242	0,66 [0,33; 1,33] 0,243	-0,03 [-0,07; 0,02] 0,236
Severe, n (%)	21 (9,1)	32 (13,3)	0,65 [0,36; 1,17] 0,152	0,68 [0,41; 1,15] 0,153	-0,04 [-0,10; 0,01] 0,148

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Gastrointestinal disorders, n (%)	10 (4,3)	11 (4,6)	0,95 [0,39; 2,27] 0,902	0,95 [0,41; 2,19] 0,902	-0,00 [-0,04; 0,03] 0,902
Mild, n (%)	5 (2,2)	8 (3,3)	0,64 [0,21; 2,00] 0,447	0,65 [0,22; 1,96] 0,447	-0,01 [-0,04; 0,02] 0,441
Moderate, n (%)	4 (1,7)	4 (1,7)	1,04 [0,26; 4,23] 0,952	1,04 [0,26; 4,12] 0,952	0,00 [-0,02; 0,02] 0,952
Severe, n (%)	1 (0,4)	1 (0,4)	-	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Nervous system disorders, n (%)	8 (3,5)	11 (4,6)	0,75 [0,30; 1,90] 0,544	0,76 [0,31; 1,85] 0,545	-0,01 [-0,05; 0,02] 0,542
Mild, n (%)	5 (2,2)	8 (3,3)	0,64 [0,21; 2,00] 0,447	0,65 [0,22; 1,96] 0,447	-0,01 [-0,04; 0,02] 0,441
Moderate, n (%)	3 (1,3)	3 (1,3)	1,04 [0,21; 5,23] 0,958	1,04 [0,21; 5,12] 0,958	0,00 [-0,02; 0,02] 0,958
Severe, n (%)	0 (0,0)	0 (0,0)	-	-	-

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment

SOCs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group. PTs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group within their SOC.

A patient with multiple AEs with the same SOC/PT is counted only once for that SOC/PT. A patient with multiple AEs is counted only once in the 'any adverse event' row.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 14.2 Any AE by SOC and PT - Binary Analysis by Age (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Age = 18-39 years	44	40			
N' Age = 40-64 years	144	155			
N' Age = ≥65 years	42	45			
SOC Respiratory, thoracic and mediastinal disorders					
Interaction test:	p=0,296				
Age = 18-39 years	7 (15,9)	5 (12,5)	1,32 [0,38; 4,56] 0,656	1,27 [0,44; 3,69] 0,657	0,03 [-0,11; 0,18] 0,654
Age = 40-64 years	33 (22,9)	57 (36,8)	0,51 [0,31; 0,85] 0,010 *	0,62 [0,43; 0,90] 0,011 *	-0,14 [-0,24; -0,04] 0,008 *
Age = ≥65 years	15 (35,7)	18 (40,0)	0,83 [0,35; 1,99] 0,681	0,89 [0,52; 1,53] 0,681	-0,04 [-0,25; 0,16] 0,680
PT Asthma					
Interaction test:	p=0,526				
Age = 18-39 years	6 (13,6)	5 (12,5)	1,11 [0,31; 3,95] 0,878	1,09 [0,36; 3,30] 0,878	0,01 [-0,13; 0,16] 0,877
Age = 40-64 years	26 (18,1)	46 (29,7)	0,52 [0,30; 0,90] 0,020 *	0,61 [0,40; 0,93] 0,022 *	-0,12 [-0,21; -0,02] 0,017 *
Age = ≥65 years	12 (28,6)	16 (35,6)	0,72 [0,29; 1,79] 0,487	0,80 [0,43; 1,49] 0,489	-0,07 [-0,27; 0,13] 0,484

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + age + treatment * age

SOCs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group. PTs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group within their SOC.

A patient with multiple AEs with the same SOC/PT is counted only once for that SOC/PT.

SOCs/PTs are only displayed in this subgroup analysis, if the p-value for RR in the entire population is significant ($p<0.05$).

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 14.3 Any AE by SOC and PT - Binary Analysis by Gender (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Gender = Male	97	88			
N' Gender = Female	133	152			
SOC Respiratory, thoracic and mediastinal disorders					
Interaction test:	p=0,408				
Gender = Male	24 (24,7)	26 (29,5)	0,78 [0,41; 1,50] 0,463	0,84 [0,52; 1,35] 0,463	-0,05 [-0,18; 0,08] 0,463
Gender = Female	31 (23,3)	54 (35,5)	0,55 [0,33; 0,93] 0,025 *	0,66 [0,45; 0,95] 0,028 *	-0,12 [-0,23; -0,02] 0,022 *
PT Asthma					
Interaction test:	p=0,238				
Gender = Male	22 (22,7)	23 (26,1)	0,83 [0,42; 1,62] 0,585	0,87 [0,52; 1,44] 0,584	-0,03 [-0,16; 0,09] 0,585
Gender = Female	22 (16,5)	44 (28,9)	0,49 [0,27; 0,87] 0,014 *	0,57 [0,36; 0,90] 0,016 *	-0,12 [-0,22; -0,03] 0,011 *

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: p < 0,05

Applied model for OR: logit(proportion) = treatment + gender + treatment * gender

SOCs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group. PTs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group within their SOC.

A patient with multiple AEs with the same SOC/PT is counted only once for that SOC/PT.

SOCs/PTs are only displayed in this subgroup analysis, if the p-value for RR in the entire population is significant (p<0.05).

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 14.4 Any AE by SOC and PT - Binary Analysis by Region (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Region = Asia	70	72			
N' Region = Europe	83	85			
N' Region = Latin America	61	75			
N' Region = Others	16	8			
SOC Respiratory, thoracic and mediastinal disorders					
Interaction test:	p=0,983				
Region = Asia	23 (32,9)	33 (45,8)	0,58 [0,29; 1,14] 0,115	0,72 [0,47; 1,09] 0,119	-0,13 [-0,29; 0,03] 0,110
Region = Europe	19 (22,9)	26 (30,6)	0,67 [0,34; 1,34] 0,261	0,75 [0,45; 1,24] 0,264	-0,08 [-0,21; 0,06] 0,258
Region = Latin America	9 (14,8)	18 (24,0)	0,55 [0,23; 1,33] 0,182	0,61 [0,30; 1,27] 0,189	-0,09 [-0,22; 0,04] 0,168
Region = Others	4 (25,0)	3 (37,5)	0,56 [0,09; 3,44] 0,528	0,67 [0,19; 2,29] 0,519	-0,13 [-0,52; 0,27] 0,537
PT Asthma					
Interaction test:	p=0,962				
Region = Asia	20 (28,6)	29 (40,3)	0,59 [0,29; 1,19] 0,144	0,71 [0,45; 1,13] 0,148	-0,12 [-0,27; 0,04] 0,139
Region = Europe	14 (16,9)	20 (23,5)	0,66 [0,31; 1,41] 0,284	0,72 [0,39; 1,32] 0,287	-0,07 [-0,19; 0,05] 0,280
Region = Latin America	7 (11,5)	16 (21,3)	0,48 [0,18; 1,25] 0,133	0,54 [0,24; 1,22] 0,139	-0,10 [-0,22; 0,02] 0,115

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Region = Others	3 (18,8)	2 (25,0)	0,69 [0,09; 5,29] 0,723	0,75 [0,16; 3,62] 0,720	-0,06 [-0,42; 0,29] 0,731

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + region + treatment * region

SOCs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group. PTs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group within their SOC.

A patient with multiple AEs with the same SOC/PT is counted only once for that SOC/PT.

SOCs/PTs are only displayed in this subgroup analysis, if the p-value for RR in the entire population is significant ($p<0.05$).

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 14.5 Any AE by SOC and PT - Binary Analysis by History of Asthma Exacerbation (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Asthma exacerbations in the 12 months prior to screening = 1	196	198			
N' Asthma exacerbations in the 12 months prior to screening = ≥2	34	42			
SOC Respiratory, thoracic and mediastinal disorders					
Interaction test:	p=0,168				
Asthma exacerbations in the 12 months prior to screening = 1	49 (25,0)	63 (31,8)	0,71 [0,46; 1,11] 0,134	0,79 [0,57; 1,08] 0,136	-0,07 [-0,16; 0,02] 0,132
Asthma exacerbations in the 12 months prior to screening = ≥2	6 (17,6)	17 (40,5)	0,32 [0,11; 0,92] 0,035 *	0,44 [0,19; 0,98] 0,045 *	-0,23 [-0,42; -0,03] 0,023 *
PT Asthma					
Interaction test:	p=0,354				
Asthma exacerbations in the 12 months prior to screening = 1	38 (19,4)	52 (26,3)	0,68 [0,42; 1,09] 0,105	0,74 [0,51; 1,07] 0,107	-0,07 [-0,15; 0,01] 0,103
Asthma exacerbations in the 12 months prior to screening = ≥2	6 (17,6)	15 (35,7)	0,39 [0,13; 1,14] 0,085	0,49 [0,22; 1,14] 0,097	-0,18 [-0,37; 0,01] 0,067

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + history of asthma exacerbation + treatment * history of asthma exacerbation

SOCs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group. PTs are sorted by descending frequencies in the IND/GLY/MF 160 treatment group within their SOC.

A patient with multiple AEs with the same SOC/PT is counted only once for that SOC/PT.

SOCs/PTs are only displayed in this subgroup analysis, if the p-value for RR in the entire population is significant ($p<0.05$).

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 14.7 Any severe AE by SOC and PT - Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

Table 14.8 Any severe AE by SOC and PT - Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

Table 14.9 Any severe AE by SOC and PT - Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

Table 14.10 Any severe AE by SOC and PT - Binary Analysis by History of Asthma Exacerbation (SAF)

There are no data meeting the display criteria for this table.

15. Any SAE by SOC and PT - Binary Analysis (SAF)

Table 15.1 Any SAE by SOC and PT - Binary Analysis (SAF)

There are no data meeting the display criteria for this table.

Table 15.2 Any SAE by SOC and PT - Binary Analysis by Age (SAF)

There are no data meeting the display criteria for this table.

Table 15.3 Any SAE by SOC and PT - Binary Analysis by Gender (SAF)

There are no data meeting the display criteria for this table.

Table 15.4 Any SAE by SOC and PT - Binary Analysis by Region (SAF)

There are no data meeting the display criteria for this table.

Table 15.5 Any SAE by SOC and PT - Binary Analysis by History of Asthma Exacerbation (SAF)

There are no data meeting the display criteria for this table.

16. Any AE leading to Study Discontinuation by SOC and PT - Binary Analysis

Table 16.1 Any AE leading to Study Discontinuation by SOC and PT - Binary Analysis (SAF)

	Treatment groups	
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**
N'	230	240
Infections and infestations, n (%)	0 (0,0)	0 (0,0)
Laryngitis, n (%)	0 (0,0)	0 (0,0)
Respiratory, thoracic and mediastinal disorders, n (%)	1 (0,4)	0 (0,0)
Dysphonia, n (%)	1 (0,4)	0 (0,0)

N': Number of patients in the analysis
SOCs are sorted alphabetically. PTs are sorted alphabetically within their SOC.

A patient with multiple AEs with the same SOC/PT is counted only once for that SOC/PT.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

17. Any AE leading to Study Drug Discontinuation by SOC and PT - Binary Analysis

Table 17.1 Any AE leading to Study Drug Discontinuation by SOC and PT - Binary Analysis (SAF)

	Treatment groups	
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**
N'	230	240
General disorders and administration site conditions, n (%)	0 (0,0)	0 (0,0)
Hyperpyrexia, n (%)	0 (0,0)	0 (0,0)
Infections and infestations, n (%)	0 (0,0)	0 (0,0)
Laryngitis, n (%)	0 (0,0)	0 (0,0)
Nervous system disorders, n (%)	1 (0,4)	0 (0,0)
Burning sensation, n (%)	1 (0,4)	0 (0,0)
Headache, n (%)	1 (0,4)	0 (0,0)
Respiratory, thoracic and mediastinal disorders, n (%)	1 (0,4)	0 (0,0)
Dysphonia, n (%)	1 (0,4)	0 (0,0)

N': Number of patients in the analysis
SOCs are sorted alphabetically. PTs are sorted alphabetically within their SOC.

A patient with multiple AEs with the same SOC/PT is counted only once for that SOC/PT.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

18. AESI - Binary Analysis (SAF)

Table 18.1 AESI by Severity - Binary Analysis (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
Bladder obstruction-Urinary retention, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Mild, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Moderate, n (%)	0 (0,0)	0 (0,0)	-	-	-
Severe, n (%)	0 (0,0)	0 (0,0)	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-
Bone fracture, n (%)	1 (0,4)	1 (0,4)	-	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Mild, n (%)	0 (0,0)	0 (0,0)	-	-	-
Moderate, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Severe, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Serious, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
CCV events: Cardiac arrhythmia terms (incl brady- and tachyarrhythmias): Conduction abnormalities, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Mild, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Moderate, n (%)	0 (0,0)	0 (0,0)	-	-	-
Severe, n (%)	0 (0,0)	0 (0,0)	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CCV events: Cardiac arrhythmia terms (incl brady- and tachyarrhythmias): Tachyarrhythmias, n (%)	1 (0,4)	1 (0,4)	1,04 [0,06; 16,78] 0,976	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Mild, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Moderate, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Severe, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Serious, n (%)	1 (0,4)	1 (0,4)	-	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
CCV events: Cardiac failure, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Mild, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Moderate, n (%)	0 (0,0)	0 (0,0)	-	-	-
Severe, n (%)	0 (0,0)	0 (0,0)	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-
CCV events: Ischaemic heart disease, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Mild, n (%)	0 (0,0)	0 (0,0)	-	-	-
Moderate, n (%)	0 (0,0)	0 (0,0)	-	-	-
Severe, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
CCV events: Myocardial infarction, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Mild, n (%)	0 (0,0)	0 (0,0)	-	-	-
Moderate, n (%)	0 (0,0)	0 (0,0)	-	-	-
Severe, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Serious, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Cataracts, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Mild, n (%)	0 (0,0)	0 (0,0)	-	-	-
Moderate, n (%)	0 (0,0)	0 (0,0)	-	-	-
Severe, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-
Diabetes mellitus/hyperglycaemia, n (%)	1 (0,4)	2 (0,8)	0,52 [0,05; 5,77] 0,594	0,52 [0,05; 5,71] 0,594	-0,00 [-0,02; 0,01] 0,585
Mild, n (%)	0 (0,0)	2 (0,8)	-	0,21 [0,01; 4,32] 0,311	-0,01 [-0,02; 0,00] 0,156
Moderate, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Severe, n (%)	0 (0,0)	0 (0,0)	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Hypersensitivity, n (%)	46 (20,0)	74 (30,8)	0,56 [0,37; 0,86] 0,007 *	0,65 [0,47; 0,89] 0,008 *	-0,11 [-0,19; -0,03] 0,006 *
Mild, n (%)	16 (7,0)	35 (14,6)	0,44 [0,24; 0,82] 0,009 *	0,48 [0,27; 0,84] 0,010 *	-0,08 [-0,13; -0,02] 0,007 *
Moderate, n (%)	14 (6,1)	20 (8,3)	0,71 [0,35; 1,45] 0,349	0,73 [0,38; 1,41] 0,350	-0,02 [-0,07; 0,02] 0,345
Severe, n (%)	21 (9,1)	32 (13,3)	0,65 [0,36; 1,17] 0,152	0,68 [0,41; 1,15] 0,153	-0,04 [-0,10; 0,01] 0,148
Serious, n (%)	1 (0,4)	1 (0,4)	1,04 [0,06; 16,78] 0,976	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Immunosuppression, n (%)	17 (7,4)	14 (5,8)	1,29 [0,62; 2,68] 0,497	1,27 [0,64; 2,51] 0,497	0,02 [-0,03; 0,06] 0,497
Mild, n (%)	6 (2,6)	2 (0,8)	3,19 [0,64; 15,95] 0,158	3,13 [0,64; 15,35] 0,160	0,02 [-0,01; 0,04] 0,140
Moderate, n (%)	10 (4,3)	8 (3,3)	1,32 [0,51; 3,40] 0,568	1,30 [0,52; 3,25] 0,568	0,01 [-0,02; 0,04] 0,568
Severe, n (%)	2 (0,9)	4 (1,7)	0,52 [0,09; 2,85] 0,450	0,52 [0,10; 2,82] 0,450	-0,01 [-0,03; 0,01] 0,438
Serious, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Intubation hospitalization and death due to asthma related events, n (%)	1 (0,4)	1 (0,4)	1,04 [0,06; 16,78] 0,976	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Mild, n (%)	0 (0,0)	0 (0,0)	-	-	-
Moderate, n (%)	0 (0,0)	0 (0,0)	-	-	-
Severe, n (%)	1 (0,4)	1 (0,4)	1,04 [0,06; 16,78] 0,976	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Serious, n (%)	1 (0,4)	1 (0,4)	1,04 [0,06; 16,78] 0,976	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Liver toxicity, n (%)	1 (0,4)	1 (0,4)	1,04 [0,06; 16,78] 0,976	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Mild, n (%)	0 (0,0)	0 (0,0)	-	-	-
Moderate, n (%)	1 (0,4)	1 (0,4)	1,04 [0,06; 16,78] 0,976	1,04 [0,07; 16,58] 0,976	0,00 [-0,01; 0,01] 0,976
Severe, n (%)	0 (0,0)	0 (0,0)	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-
Adjudicated serious cardiovascular and cerebrovascular (CCV) events: MACE, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	0 (0,0)	1 (0,4)	-	0,35 [0,01; 8,49] 0,517	-0,00 [-0,01; 0,00] 0,316
Adjudicated serious cardiovascular and cerebrovascular (CCV) events: Non-MACE, n (%)	2 (0,9)	0 (0,0)	-	5,22 [0,25; 108,07] 0,285	0,01 [-0,00; 0,02] 0,155
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	2 (0,9)	0 (0,0)	-	5,22 [0,25; 108,07] 0,285	0,01 [-0,00; 0,02] 0,155
Adjudicated new onset of atrial fibrillation/ flutter: New onset, n (%)	0 (0,0)	0 (0,0)	-	-	-
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Adjudicated new onset of atrial fibrillation/ flutter: Recurrent/persistent, n (%)	0 (0,0)	0 (0,0)	-	-	-
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-
Adjudicated new onset of atrial fibrillation/ flutter: Unknown, n (%)	0 (0,0)	0 (0,0)	-	-	-
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-
Composite endpoint of serious asthma outcomes: Asthma-related hospitalization, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	1 (0,4)	0 (0,0)	-	3,13 [0,13; 76,44] 0,484	0,00 [-0,00; 0,01] 0,316
Composite endpoint of serious asthma outcomes: Asthma-related intubation, n (%)	0 (0,0)	0 (0,0)	-	-	-
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Composite endpoint of serious asthma outcomes: Asthma-related death, n (%)	0 (0,0)	0 (0,0)	-	-	-
Mild, n (%)	-	-	-	-	-
Moderate, n (%)	-	-	-	-	-
Severe, n (%)	-	-	-	-	-
Serious, n (%)	0 (0,0)	0 (0,0)	-	-	-

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment

For adjudicated data severity was not collected.

Adjudicated data is sorted as listed in the SAP. Other events are sorted alphabetically.

A patient with multiple events in the same AESI category is counted only once for that AESI category.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 18.2 AESI - Binary Analysis by Age (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Age = 18-39 years	44	40			
N' Age = 40-64 years	144	155			
N' Age = ≥65 years	42	45			
Hypersensitivity					
Interaction test:	p=0,282				
Age = 18-39 years	7 (15,9)	5 (12,5)	1,32 [0,38; 4,56] 0,656	1,27 [0,44; 3,69] 0,657	0,03 [-0,11; 0,18] 0,654
Age = 40-64 years	27 (18,8)	52 (33,5)	0,46 [0,27; 0,78] 0,004 *	0,56 [0,37; 0,84] 0,005 *	-0,15 [-0,25; -0,05] 0,003 *
Age = ≥65 years	12 (28,6)	17 (37,8)	0,66 [0,27; 1,62] 0,364	0,76 [0,41; 1,39] 0,368	-0,09 [-0,29; 0,10] 0,359
Immunosuppression					
Interaction test:	p=0,961				
Age = 18-39 years	3 (6,8)	2 (5,0)	1,39 [0,22; 8,78] 0,726	1,36 [0,24; 7,75] 0,726	0,02 [-0,08; 0,12] 0,723
Age = 40-64 years	10 (6,9)	8 (5,2)	1,37 [0,53; 3,58] 0,519	1,35 [0,55; 3,31] 0,519	0,02 [-0,04; 0,07] 0,519
Age = ≥65 years	4 (9,5)	4 (8,9)	1,08 [0,25; 4,62] 0,918	1,07 [0,29; 4,01] 0,918	0,01 [-0,12; 0,13] 0,919

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + age + treatment * age

For adjudicated data severity was not collected.

Adjudicated data is sorted as listed in the SAP. Other events are sorted alphabetically.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 18.3 AESI - Binary Analysis by Gender (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Gender = Male	97	88			
N' Gender = Female	133	152			
Hypersensitivity					
Interaction test:	p=0,290				
Gender = Male	22 (22,7)	25 (28,4)	0,74 [0,38; 1,44] 0,372	0,80 [0,49; 1,31] 0,373	-0,06 [-0,18; 0,07] 0,372
Gender = Female	24 (18,0)	49 (32,2)	0,46 [0,26; 0,81] 0,007 *	0,56 [0,36; 0,86] 0,008 *	-0,14 [-0,24; -0,04] 0,005 *
Immunosuppression					
Interaction test:	p=0,373				
Gender = Male	7 (7,2)	3 (3,4)	2,20 [0,55; 8,80] 0,263	2,12 [0,56; 7,94] 0,266	0,04 [-0,03; 0,10] 0,243
Gender = Female	10 (7,5)	11 (7,2)	1,04 [0,43; 2,54] 0,928	1,04 [0,46; 2,37] 0,928	0,00 [-0,06; 0,06] 0,928

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + gender + treatment * gender

For adjudicated data severity was not collected.

Adjudicated data is sorted as listed in the SAP. Other events are sorted alphabetically.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 18.4 AESI - Binary Analysis by Region (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Region = Asia	70	72			
N' Region = Europe	83	85			
N' Region = Latin America	61	75			
N' Region = Others	16	8			
Hypersensitivity					
Interaction test:	p=0,892				
Region = Asia	20 (28,6)	32 (44,4)	0,50 [0,25; 1,00] 0,051	0,64 [0,41; 1,01] 0,055	-0,16 [-0,31; -0,00] 0,046 *
Region = Europe	14 (16,9)	21 (24,7)	0,62 [0,29; 1,32] 0,213	0,68 [0,37; 1,25] 0,216	-0,08 [-0,20; 0,04] 0,208
Region = Latin America	7 (11,5)	18 (24,0)	0,41 [0,16; 1,06] 0,066	0,48 [0,21; 1,07] 0,072	-0,13 [-0,25; 0,00] 0,050
Region = Others	5 (31,3)	3 (37,5)	0,76 [0,13; 4,49] 0,760	0,83 [0,26; 2,64] 0,757	-0,06 [-0,47; 0,34] 0,762
Immunosuppression					
Interaction test:	N.E.				
Region = Asia	5 (7,1)	1 (1,4)	-	5,14 [0,62; 42,92] 0,130	0,06 [-0,01; 0,12] 0,088
Region = Europe	11 (13,3)	5 (5,9)	-	2,25 [0,82; 6,20] 0,116	0,07 [-0,01; 0,16] 0,102
Region = Latin America	0 (0,0)	7 (9,3)	-	0,08 [0,00; 1,40] 0,084	-0,09 [-0,16; -0,03] 0,005 *

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
Region = Others	1 (6,3)	1 (12,5)	-	0,50 [0,04; 7,00] 0,607	-0,06 [-0,32; 0,20] 0,635

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
N.E.: not estimable
*: $p < 0,05$

Applied model for OR: logit(proportion) = treatment + region + treatment * region

For adjudicated data severity was not collected.

Adjudicated data is sorted as listed in the SAP. Other events are sorted alphabetically.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

Table 18.5 AESI - Binary Analysis by History of Asthma Exacerbation (SAF)

	Treatment groups		Comparison		
	IND/GLY/ MF 160 (N=230)	**SAL/FLU + TIO (N=240)**	**OR [95% CI] p-value**	**RR [95% CI] p-value**	**RD [95% CI] p-value**
N'	230	240			
N' Asthma exacerbations in the 12 months prior to screening = 1	196	198			
N' Asthma exacerbations in the 12 months prior to screening = ≥2	34	42			
Hypersensitivity					
Interaction test:	p=0,299				
Asthma exacerbations in the 12 months prior to screening = 1	39 (19,9)	56 (28,3)	0,63 [0,39; 1,01] 0,053	0,70 [0,49; 1,01] 0,054	-0,08 [-0,17; 0,00] 0,050
Asthma exacerbations in the 12 months prior to screening = ≥2	7 (20,6)	18 (42,9)	0,35 [0,12; 0,97] 0,044 *	0,48 [0,23; 1,01] 0,054	-0,22 [-0,42; -0,02] 0,031 *
Immunosuppression					
Interaction test:	p=0,980				
Asthma exacerbations in the 12 months prior to screening = 1	15 (7,7)	12 (6,1)	1,28 [0,59; 2,82] 0,532	1,26 [0,61; 2,63] 0,533	0,02 [-0,03; 0,07] 0,532
Asthma exacerbations in the 12 months prior to screening = ≥2	2 (5,9)	2 (4,8)	1,25 [0,17; 9,37] 0,828	1,24 [0,18; 8,32] 0,828	0,01 [-0,09; 0,11] 0,830

N': Number of patients in the analysis
CI: Confidence Interval
OR: Odds Ratio
RR: Relative Risk
RD: Risk Difference
*: p < 0,05

Applied model for OR: logit(proportion) = treatment + history of asthma exacerbation + treatment * history of asthma exacerbation

For adjudicated data severity was not collected.

Adjudicated data is sorted as listed in the SAP. Other events are sorted alphabetically.

Analysis population: B2306 SAF subpopulation "mid-dose ICS/LABA"

19. Trough FEV1 - Change from Baseline

Table 19.1 Trough FEV1 - Change from Baseline (FAS)

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS)	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Trough FEV1				
N'	221	222		
Baseline Mean (SD)	1,92 (0,606)	1,88 (0,663)		
Week 8:				
Adjusted Mean Change (SE)	0,34 (0,040)	0,26 (0,040)	0,08 [0,008; 0,151] 0,029 *	0,142 [-0,057; 0,341]
Week 16:				
Adjusted Mean Change (SE)	0,34 (0,040)	0,27 (0,040)	0,07 [-0,001; 0,138] 0,053	0,123 [-0,075; 0,322]
Week 24:				
Adjusted Mean Change (SE)	0,37 (0,041)	0,25 (0,041)	0,11 [0,040; 0,186] 0,002 *	0,199 [0,001; 0,397]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 19.2 Trough FEV1 - Change from Baseline by Age (FAS)

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Trough FEV1				
Interaction Test	0,518			
Age = 18-39 years				
N'	43	36		
Baseline Mean (SD)	2,37 (0,538)	2,23 (0,716)		
Week 8:				
Adjusted Mean Change (SE)	0,46 (0,067)	0,37 (0,071)	0,09 [-0,073; 0,262] 0,267	0,228 [-0,236; 0,693]
Week 16:				
Adjusted Mean Change (SE)	0,47 (0,066)	0,34 (0,071)	0,14 [-0,028; 0,303] 0,103	0,349 [-0,138; 0,836]
Week 24:				
Adjusted Mean Change (SE)	0,49 (0,069)	0,38 (0,074)	0,11 [-0,062; 0,287] 0,205	0,271 [-0,210; 0,752]
Age = 40-64 years				
N'	138	142		
Baseline Mean (SD)	1,91 (0,568)	1,92 (0,625)		
Week 8:				
Adjusted Mean Change (SE)	0,31 (0,044)	0,26 (0,044)	0,05 [-0,042; 0,136] 0,300	0,097 [-0,153; 0,346]
Week 16:				
Adjusted Mean Change (SE)	0,32 (0,043)	0,28 (0,043)	0,03 [-0,052; 0,122] 0,431	0,072 [-0,176; 0,320]
Week 24:				
Adjusted Mean Change (SE)	0,34 (0,044)	0,25 (0,044)	0,09 [-0,004; 0,179] 0,060	0,177 [-0,071; 0,424]
Age = ≥65 years				
N'	40	44		
Baseline Mean (SD)	1,48 (0,456)	1,44 (0,508)		

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	0,30 (0,071)	0,14 (0,068)	0,16 [-0,003; 0,325] 0,054	0,391 [-0,082; 0,864]
Week 16:				
Adjusted Mean Change (SE)	0,25 (0,069)	0,14 (0,067)	0,11 [-0,049; 0,268] 0,175	0,263 [-0,192; 0,718]
Week 24:				
Adjusted Mean Change (SE)	0,33 (0,072)	0,15 (0,069)	0,18 [0,012; 0,347] 0,035 *	0,416 [-0,042; 0,874]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + age + age * treatment + age * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 19.3 Trough FEV1 - Change from Baseline by Gender (FAS)

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Trough FEV1				
Interaction Test	0,179			
Gender = Male				
N'	94	82		
Baseline Mean (SD)	2,21 (0,639)	2,28 (0,722)		
Week 8:				
Adjusted Mean Change (SE)	0,41 (0,048)	0,32 (0,053)	0,09 [-0,023; 0,201] 0,119	0,198 [-0,117; 0,513]
Week 16:				
Adjusted Mean Change (SE)	0,43 (0,048)	0,30 (0,052)	0,13 [0,021; 0,240] 0,020 *	0,294 [-0,021; 0,610]
Week 24:				
Adjusted Mean Change (SE)	0,49 (0,049)	0,30 (0,054)	0,19 [0,074; 0,302] 0,001 *	0,412 [0,097; 0,727]
Gender = Female				
N'	127	140		
Baseline Mean (SD)	1,71 (0,479)	1,64 (0,491)		
Week 8:				
Adjusted Mean Change (SE)	0,26 (0,047)	0,20 (0,045)	0,06 [-0,027; 0,155] 0,170	0,129 [-0,129; 0,388]
Week 16:				
Adjusted Mean Change (SE)	0,25 (0,047)	0,23 (0,044)	0,02 [-0,070; 0,108] 0,671	0,039 [-0,218; 0,296]

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	0,25 (0,048)	0,20 (0,045)	0,05 [-0,043; 0,143] 0,288	0,100 [-0,156; 0,356]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + gender + gender * treatment + gender * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 19.4 Trough FEV1 - Change from Baseline by Region (FAS)

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Trough FEV1				
Interaction Test	0,521			
Region = Asia				
N'	69	68		
Baseline Mean (SD)	1,66 (0,544)	1,61 (0,608)		
Week 8:				
Adjusted Mean Change (SE)	0,36 (0,046)	0,26 (0,047)	0,10 [-0,031; 0,225] 0,136	0,270 [-0,089; 0,630]
Week 16:				
Adjusted Mean Change (SE)	0,36 (0,046)	0,25 (0,048)	0,11 [-0,016; 0,242] 0,085	0,318 [-0,051; 0,686]
Week 24:				
Adjusted Mean Change (SE)	0,42 (0,046)	0,25 (0,046)	0,16 [0,035; 0,290] 0,013 *	0,448 [0,088; 0,807]
Region = Europe				
N'	78	80		
Baseline Mean (SD)	2,15 (0,599)	2,14 (0,633)		
Week 8:				
Adjusted Mean Change (SE)	0,29 (0,043)	0,21 (0,043)	0,07 [-0,045; 0,193] 0,224	0,206 [-0,130; 0,542]
Week 16:				
Adjusted Mean Change (SE)	0,30 (0,043)	0,25 (0,043)	0,05 [-0,071; 0,165] 0,434	0,128 [-0,196; 0,453]
Week 24:				
Adjusted Mean Change (SE)	0,33 (0,043)	0,23 (0,043)	0,10 [-0,018; 0,219] 0,096	0,277 [-0,053; 0,608]
Region = Latin America				
N'	58	67		
Baseline Mean (SD)	1,96 (0,603)	1,82 (0,636)		

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 8:				
Adjusted Mean Change (SE)	0,53 (0,049)	0,39 (0,047)	0,14 [0,007; 0,274] 0,040 *	0,389 [0,016; 0,763]
Week 16:				
Adjusted Mean Change (SE)	0,50 (0,050)	0,41 (0,047)	0,10 [-0,038; 0,231] 0,160	0,271 [-0,108; 0,650]
Week 24:				
Adjusted Mean Change (SE)	0,49 (0,050)	0,38 (0,047)	0,11 [-0,026; 0,242] 0,115	0,303 [-0,075; 0,681]
Region = Others				
N'	16	7		
Baseline Mean (SD)	1,81 (0,462)	2,04 (0,754)		
Week 8:				
Adjusted Mean Change (SE)	0,22 (0,097)	0,46 (0,141)	-0,24 [-0,572; 0,098] 0,166	-0,665 [-1,607; 0,277]
Week 16:				
Adjusted Mean Change (SE)	0,29 (0,094)	0,39 (0,141)	-0,10 [-0,436; 0,229] 0,541	-0,282 [-1,183; 0,619]
Week 24:				
Adjusted Mean Change (SE)	0,33 (0,095)	0,34 (0,141)	-0,01 [-0,342; 0,326] 0,963	-0,022 [-0,929; 0,885]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: unstructured covariance matrix
Exceptional model(s): **Trough FEV1**: treatment + visit + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + region + region * treatment + region * treatment * visit, within-patient correlation: compound symmetry covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Table 19.5 Trough FEV1 - Change from Baseline by History of Asthma Exacerbation (FAS)

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Trough FEV1				
Interaction Test	0,043 *			
Asthma exacerbations in the 12 months prior to screening = 1				
N'	189	183		
Baseline Mean (SD)	1,95 (0,590)	1,90 (0,662)		
Week 8:				
Adjusted Mean Change (SE)	0,35 (0,041)	0,26 (0,042)	0,10 [0,019; 0,173] 0,015 *	0,179 [-0,037; 0,395]
Week 16:				
Adjusted Mean Change (SE)	0,36 (0,041)	0,27 (0,042)	0,10 [0,022; 0,172] 0,012 *	0,183 [-0,033; 0,399]
Week 24:				
Adjusted Mean Change (SE)	0,40 (0,042)	0,25 (0,043)	0,15 [0,070; 0,229] <0,001 *	0,276 [0,060; 0,493]
Asthma exacerbations in the 12 months prior to screening = ≥2				
N'	32	39		
Baseline Mean (SD)	1,77 (0,684)	1,75 (0,663)		
Week 8:				
Adjusted Mean Change (SE)	0,22 (0,076)	0,24 (0,069)	-0,02 [-0,199; 0,163] 0,845	-0,046 [-0,561; 0,469]
Week 16:				
Adjusted Mean Change (SE)	0,17 (0,074)	0,27 (0,067)	-0,10 [-0,275; 0,076] 0,265	-0,261 [-0,775; 0,254]

	Treatment groups		Comparison	
Outcome - Change from Baseline (FAS) by Subgroup	**IND/GLY/ MF 160 N=230**	**SAL/FLU + TIO N=240**	**Mean Difference [95% CI] p-value**	**Hedges' G [95% CI]**
Week 24:				
Adjusted Mean Change (SE)	0,18 (0,077)	0,27 (0,069)	-0,10 [-0,279; 0,086] 0,300	-0,236 [-0,735; 0,262]

N': Number of patients in the analysis
CI: Confidence Interval
*: $p < 0,05$

Applied model for Adjusted Mean Change and Mean Difference: Change from baseline = treatment + visit + region + baseline value + baseline-by-visit interaction + treatment-by-visit interaction + history of asthma exacerbation + history of asthma exacerbation * treatment + history of asthma exacerbation * treatment * visit, within-patient correlation: unstructured covariance matrix
If it was not possible to fit the minimal model, the Adjusted Mean Change and Mean Difference are not given.


Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figures

3. Boxplot: ACQ-5 - Change from Baseline (FAS)

3.1 Boxplot: ACQ-5 - Change from Baseline (FAS)

Figure 3.1 ACQ-5 - Change from Baseline (FAS)



3.2 Boxplot: ACQ-5 - Change from Baseline by Age (FAS)

Figure 3.2.1 ACQ-5 - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 3.2.2 ACQ-5 - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 3.2.3 ACQ-5 - Change from Baseline by Age (FAS), Age = ≥65 years



3.3 Boxplot: ACQ-5 - Change from Baseline by Gender (FAS)

Figure 3.3.1 ACQ-5 - Change from Baseline by Gender (FAS), Gender = Male





Figure 3.3.2 ACQ-5 - Change from Baseline by Gender (FAS), Gender = Female



3.4 Boxplot: ACQ-5 - Change from Baseline by Region (FAS)

Figure 3.4.1 ACQ-5 - Change from Baseline by Region (FAS), Region = Asia




Figure 3.4.2 ACQ-5 - Change from Baseline by Region (FAS), Region = Europe




Figure 3.4.3 ACQ-5 - Change from Baseline by Region (FAS), Region = Latin America





Figure 3.4.4 ACQ-5 - Change from Baseline by Region (FAS), Region = Others



3.5 Boxplot: ACQ-5 - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 3.5.1 ACQ-5 - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 3.5.2 ACQ-5 - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



5. Boxplot: AQLQ-S - Change from Baseline (FAS)

5.1 Boxplot: AQLQ-S (Total Score) - Change from Baseline (FAS)

Figure 5.1 AQLQ-S (Total Score) - Change from Baseline (FAS)



5.2 Boxplot: AQLQ-S (Total Score) - Change from Baseline by Age (FAS)

Figure 5.2.1 AQLQ-S (Total Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.2.2 AQLQ-S (Total Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.2.3 AQLQ-S (Total Score) - Change from Baseline by Age (FAS), Age = ≥65 years



5.3 Boxplot: AQLQ-S (Total Score) - Change from Baseline by Gender (FAS)

Figure 5.3.1 AQLQ-S (Total Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.3.2 AQLQ-S (Total Score) - Change from Baseline by Gender (FAS), Gender = Female



5.4 Boxplot: AQLQ-S (Total Score) - Change from Baseline by Region (FAS)

Figure 5.4.1 AQLQ-S (Total Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.4.2 AQLQ-S (Total Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.4.3 AQLQ-S (Total Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.4.4 AQLQ-S (Total Score) - Change from Baseline by Region (FAS), Region = Others



5.5 Boxplot: AQLQ-S (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.5.1 AQLQ-S (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.5.2 AQLQ-S (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



5.7 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline (FAS)

Figure 5.7 AQLQ-S (Symptom Score) - Change from Baseline (FAS)



5.8 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by Age (FAS)

Figure 5.8.1 AQLQ-S (Symptom Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.8.2 AQLQ-S (Symptom Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.8.3 AQLQ-S (Symptom Score) - Change from Baseline by Age (FAS), Age = ≥65 years



5.9 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by Gender (FAS)

Figure 5.9.1 AQLQ-S (Symptom Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.9.2 AQLQ-S (Symptom Score) - Change from Baseline by Gender (FAS), Gender = Female



5.10 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by Region (FAS)

Figure 5.10.1 AQLQ-S (Symptom Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.10.2 AQLQ-S (Symptom Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.10.3 AQLQ-S (Symptom Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.10.4 AQLQ-S (Symptom Score) - Change from Baseline by Region (FAS), Region = Others



5.11 Boxplot: AQLQ-S (Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.11.1 AQLQ-S (Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.11.2 AQLQ-S (Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



5.13 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline (FAS)

Figure 5.13 AQLQ-S (Activity Limitation Score) - Change from Baseline (FAS)



5.14 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by Age (FAS)

Figure 5.14.1 AQLQ-S (Activity Limitation Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.14.2 AQLQ-S (Activity Limitation Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.14.3 AQLQ-S (Activity Limitation Score) - Change from Baseline by Age (FAS), Age = ≥65 years



5.15 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by Gender (FAS)

Figure 5.15.1 AQLQ-S (Activity Limitation Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.15.2 AQLQ-S (Activity Limitation Score) - Change from Baseline by Gender (FAS), Gender = Female



5.16 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by Region (FAS)

Figure 5.16.1 AQLQ-S (Activity Limitation Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.16.2 AQLQ-S (Activity Limitation Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.16.3 AQLQ-S (Activity Limitation Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.16.4 AQLQ-S (Activity Limitation Score) - Change from Baseline by Region (FAS), Region = Others



5.17 Boxplot: AQLQ-S (Activity Limitation Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.17.1 AQLQ-S (Activity Limitation Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.17.2 AQLQ-S (Activity Limitation Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



5.19 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline (FAS)

Figure 5.19 AQLQ-S (Emotional Function Score) - Change from Baseline (FAS)



5.20 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by Age (FAS)

Figure 5.20.1 AQLQ-S (Emotional Function Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.20.2 AQLQ-S (Emotional Function Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.20.3 AQLQ-S (Emotional Function Score) - Change from Baseline by Age (FAS), Age = ≥65 years



5.21 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by Gender (FAS)

Figure 5.21.1 AQLQ-S (Emotional Function Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.21.2 AQLQ-S (Emotional Function Score) - Change from Baseline by Gender (FAS), Gender = Female



5.22 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by Region (FAS)

Figure 5.22.1 AQLQ-S (Emotional Function Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.22.2 AQLQ-S (Emotional Function Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.22.3 AQLQ-S (Emotional Function Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.22.4 AQLQ-S (Emotional Function Score) - Change from Baseline by Region (FAS), Region = Others



5.23 Boxplot: AQLQ-S (Emotional Function Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.23.1 AQLQ-S (Emotional Function Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.23.2 AQLQ-S (Emotional Function Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



5.25 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline (FAS)

Figure 5.25 AQLQ-S (Environmental Stimuli Score) - Change from Baseline (FAS)



5.26 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Age (FAS)

Figure 5.26.1 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.26.2 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.26.3 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Age (FAS), Age = ≥65 years



5.27 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Gender (FAS)

Figure 5.27.1 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.27.2 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Gender (FAS), Gender = Female



5.28 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Region (FAS)

Figure 5.28.1 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.28.2 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.28.3 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.28.4 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by Region (FAS), Region = Others



5.29 Boxplot: AQLQ-S (Environmental Stimuli Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.29.1 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.29.2 AQLQ-S (Environmental Stimuli Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



7. Boxplot: SGRQ - Change from Baseline (FAS)

7.1 Boxplot: SGRQ (Total Score) - Change from Baseline (FAS)

Figure 7.1 SGRQ (Total Score) - Change from Baseline (FAS)



7.2 Boxplot: SGRQ (Total Score) - Change from Baseline by Age (FAS)

Figure 7.2.1 SGRQ (Total Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 7.2.2 SGRQ (Total Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 7.2.3 SGRQ (Total Score) - Change from Baseline by Age (FAS), Age = ≥65 years



7.3 Boxplot: SGRQ (Total Score) - Change from Baseline by Gender (FAS)

Figure 7.3.1 SGRQ (Total Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 7.3.2 SGRQ (Total Score) - Change from Baseline by Gender (FAS), Gender = Female



7.4 Boxplot: SGRQ (Total Score) - Change from Baseline by Region (FAS)

Figure 7.4.1 SGRQ (Total Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 7.4.2 SGRQ (Total Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 7.4.3 SGRQ (Total Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 7.4.4 SGRQ (Total Score) - Change from Baseline by Region (FAS), Region = Others



7.5 Boxplot: SGRQ (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 7.5.1 SGRQ (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 7.5.2 SGRQ (Total Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



7.7 Boxplot: SGRQ (Symptoms Score) - Change from Baseline (FAS)

Figure 7.7 SGRQ (Symptoms Score) - Change from Baseline (FAS)



7.8 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by Age (FAS)

Figure 7.8.1 SGRQ (Symptoms Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 7.8.2 SGRQ (Symptoms Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 7.8.3 SGRQ (Symptoms Score) - Change from Baseline by Age (FAS), Age = ≥65 years



7.9 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by Gender (FAS)

Figure 7.9.1 SGRQ (Symptoms Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 7.9.2 SGRQ (Symptoms Score) - Change from Baseline by Gender (FAS), Gender = Female



7.10 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by Region (FAS)

Figure 7.10.1 SGRQ (Symptoms Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 7.10.2 SGRQ (Symptoms Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 7.10.3 SGRQ (Symptoms Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 7.10.4 SGRQ (Symptoms Score) - Change from Baseline by Region (FAS), Region = Others



7.11 Boxplot: SGRQ (Symptoms Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 7.11.1 SGRQ (Symptoms Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 7.11.2 SGRQ (Symptoms Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



7.13 Boxplot: SGRQ (Activity Score) - Change from Baseline (FAS)

Figure 7.13 SGRQ (Activity Score) - Change from Baseline (FAS)



7.14 Boxplot: SGRQ (Activity Score) - Change from Baseline by Age (FAS)

Figure 7.14.1 SGRQ (Activity Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 7.14.2 SGRQ (Activity Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 7.14.3 SGRQ (Activity Score) - Change from Baseline by Age (FAS), Age = ≥65 years



7.15 Boxplot: SGRQ (Activity Score) - Change from Baseline by Gender (FAS)

Figure 7.15.1 SGRQ (Activity Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 7.15.2 SGRQ (Activity Score) - Change from Baseline by Gender (FAS), Gender = Female



7.16 Boxplot: SGRQ (Activity Score) - Change from Baseline by Region (FAS)

Figure 7.16.1 SGRQ (Activity Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 7.16.2 SGRQ (Activity Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 7.16.3 SGRQ (Activity Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 7.16.4 SGRQ (Activity Score) - Change from Baseline by Region (FAS), Region = Others



7.17 Boxplot: SGRQ (Activity Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 7.17.1 SGRQ (Activity Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 7.17.2 SGRQ (Activity Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



7.19 Boxplot: SGRQ (Impacts Score) - Change from Baseline (FAS)

Figure 7.19 SGRQ (Impacts Score) - Change from Baseline (FAS)



7.20 Boxplot: SGRQ (Impacts Score) - Change from Baseline by Age (FAS)

Figure 7.20.1 SGRQ (Impacts Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 7.20.2 SGRQ (Impacts Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 7.20.3 SGRQ (Impacts Score) - Change from Baseline by Age (FAS), Age = ≥65 years



7.21 Boxplot: SGRQ (Impacts Score) - Change from Baseline by Gender (FAS)

Figure 7.21.1 SGRQ (Impacts Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 7.21.2 SGRQ (Impacts Score) - Change from Baseline by Gender (FAS), Gender = Female



7.22 Boxplot: SGRQ (Impacts Score) - Change from Baseline by Region (FAS)

Figure 7.22.1 SGRQ (Impacts Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 7.22.2 SGRQ (Impacts Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 7.22.3 SGRQ (Impacts Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 7.22.4 SGRQ (Impacts Score) - Change from Baseline by Region (FAS), Region = Others



7.23 Boxplot: SGRQ (Impacts Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 7.23.1 SGRQ (Impacts Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 7.23.2 SGRQ (Impacts Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9. Boxplot: Symptoms - Change from Baseline (FAS)

9.1 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline (FAS)

Figure 9.1 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline (FAS)



9.2 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Age (FAS)

Figure 9.2.1 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.2.2 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.2.3 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Age (FAS), Age = ≥65 years



9.3 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Gender (FAS)

Figure 9.3.1 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.3.2 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Gender (FAS), Gender = Female



9.4 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Region (FAS)

Figure 9.4.1 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.4.2 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.4.3 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.4.4 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by Region (FAS), Region = Others



9.5 Boxplot: Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.5.1 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.5.2 Symptoms (Percentage of Mornings with no Symptoms on Rising) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.7 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline (FAS)

Figure 9.7 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline (FAS)



9.8 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Age (FAS)

Figure 9.8.1 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.8.2 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.8.3 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Age (FAS), Age = ≥65 years



9.9 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Gender (FAS)

Figure 9.9.1 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.9.2 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Gender (FAS), Gender = Female



9.10 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Region (FAS)

Figure 9.10.1 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.10.2 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.10.3 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.10.4 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by Region (FAS), Region = Others



9.11 Boxplot: Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.11.1 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.11.2 Symptoms (Percentage of Days with no Day-Time Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.13 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline (FAS)

Figure 9.13 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline (FAS)



9.14 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Age (FAS)

Figure 9.14.1 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.14.2 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.14.3 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Age (FAS), Age = ≥65 years



9.15 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Gender (FAS)

Figure 9.15.1 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.15.2 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Gender (FAS), Gender = Female



9.16 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Region (FAS)

Figure 9.16.1 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.16.2 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.16.3 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.16.4 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by Region (FAS), Region = Others



9.17 Boxplot: Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.17.1 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.17.2 Symptoms (Percentage of Days with no Night-Time Awakenings) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.19 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline (FAS)

Figure 9.19 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline (FAS)



9.20 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Age (FAS)

Figure 9.20.1 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.20.2 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.20.3 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Age (FAS), Age = ≥65 years



9.21 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Gender (FAS)

Figure 9.21.1 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.21.2 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Gender (FAS), Gender = Female



9.22 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Region (FAS)

Figure 9.22.1 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.22.2 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.22.3 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.22.4 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by Region (FAS), Region = Others



9.23 Boxplot: Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.23.1 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.23.2 Symptoms (Percentage of Days with no Asthma Symptoms) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.25 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline (FAS)

Figure 9.25 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline (FAS)



9.26 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Age (FAS)

Figure 9.26.1 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.26.2 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.26.3 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Age (FAS), Age = ≥65 years



9.27 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Gender (FAS)

Figure 9.27.1 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.27.2 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Gender (FAS), Gender = Female



9.28 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Region (FAS)

Figure 9.28.1 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.28.2 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.28.3 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.28.4 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by Region (FAS), Region = Others



9.29 Boxplot: Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.29.1 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.29.2 Symptoms (Mean Total Daily Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.31 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline (FAS)

Figure 9.31 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline (FAS)



9.32 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Age (FAS)

Figure 9.32.1 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.32.2 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.32.3 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Age (FAS), Age = ≥65 years



9.33 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Gender (FAS)

Figure 9.33.1 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.33.2 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Gender (FAS), Gender = Female



9.34 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Region (FAS)

Figure 9.34.1 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.34.2 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.34.3 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.34.4 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Others



9.35 Boxplot: Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.35.1 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.35.2 Symptoms (Mean Day-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.37 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline (FAS)

Figure 9.37 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline (FAS)



9.38 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Age (FAS)

Figure 9.38.1 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.38.2 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.38.3 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Age (FAS), Age = ≥65 years



9.39 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Gender (FAS)

Figure 9.39.1 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.39.2 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Gender (FAS), Gender = Female



9.40 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Region (FAS)

Figure 9.40.1 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.40.2 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.40.3 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.40.4 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by Region (FAS), Region = Others



9.41 Boxplot: Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.41.1 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.41.2 Symptoms (Mean Night-Time Symptom Score) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.43 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline (FAS)

Figure 9.43 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline (FAS)



9.44 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Age (FAS)

Figure 9.44.1 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.44.2 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.44.3 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Age (FAS), Age = ≥65 years



9.45 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Gender (FAS)

Figure 9.45.1 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.45.2 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Gender (FAS), Gender = Female



9.46 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Region (FAS)

Figure 9.46.1 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.46.2 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.46.3 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.46.4 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by Region (FAS), Region = Others



9.47 Boxplot: Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.47.1 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.47.2 Symptoms (Mean of: How Did You Sleep Last Night?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.49 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline (FAS)

Figure 9.49 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline (FAS)



9.50 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Age (FAS)

Figure 9.50.1 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.50.2 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.50.3 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Age (FAS), Age = ≥65 years



9.51 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Gender (FAS)

Figure 9.51.1 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.51.2 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Gender (FAS), Gender = Female



9.52 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Region (FAS)

Figure 9.52.1 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.52.2 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.52.3 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.52.4 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by Region (FAS), Region = Others



9.53 Boxplot: Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.53.1 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.53.2 Symptoms (Mean of: Did You Have Asthma Symptoms upon Awakening in the Morning?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.55 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline (FAS)

Figure 9.55 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline (FAS)



9.56 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Age (FAS)

Figure 9.56.1 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.56.2 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.56.3 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Age (FAS), Age = ≥65 years



9.57 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Gender (FAS)

Figure 9.57.1 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.57.2 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Gender (FAS), Gender = Female



9.58 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Region (FAS)

Figure 9.58.1 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.58.2 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.58.3 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.58.4 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by Region (FAS), Region = Others



9.59 Boxplot: Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.59.1 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.59.2 Symptoms (Mean of: Did Your Respiratory Symptoms Stop You from Performing Your Usual Daily Activities?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.61 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline (FAS)

Figure 9.61 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline (FAS)



9.62 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Age (FAS)

Figure 9.62.1 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.62.2 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.62.3 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Age (FAS), Age = ≥65 years



9.63 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Gender (FAS)

Figure 9.63.1 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.63.2 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Gender (FAS), Gender = Female



9.64 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Region (FAS)

Figure 9.64.1 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.64.2 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.64.3 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.64.4 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by Region (FAS), Region = Others



9.65 Boxplot: Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.65.1 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.65.2 Symptoms (Mean of: How Severe Was Your Shortness of Breath Today?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.67 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline (FAS)

Figure 9.67 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline (FAS)



9.68 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Age (FAS)

Figure 9.68.1 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.68.2 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.68.3 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = ≥65 years



9.69 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Gender (FAS)

Figure 9.69.1 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.69.2 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Gender (FAS), Gender = Female



9.70 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Region (FAS)

Figure 9.70.1 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.70.2 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.70.3 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.70.4 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Others



9.71 Boxplot: Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.71.1 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.71.2 Symptoms (Mean of: How Was Your Wheeze During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.73 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline (FAS)

Figure 9.73 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline (FAS)



9.74 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Age (FAS)

Figure 9.74.1 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.74.2 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.74.3 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = ≥65 years



9.75 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Gender (FAS)

Figure 9.75.1 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.75.2 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Gender (FAS), Gender = Female



9.76 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Region (FAS)

Figure 9.76.1 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.76.2 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.76.3 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.76.4 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Others



9.77 Boxplot: Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.77.1 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.77.2 Symptoms (Mean of: How Was Your Cough During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



9.79 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline (FAS)

Figure 9.79 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline (FAS)



9.80 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Age (FAS)

Figure 9.80.1 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 9.80.2 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 9.80.3 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Age (FAS), Age = ≥65 years



9.81 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Gender (FAS)

Figure 9.81.1 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Gender (FAS), Gender = Male





Figure 9.81.2 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Gender (FAS), Gender = Female



9.82 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Region (FAS)

Figure 9.82.1 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Asia




Figure 9.82.2 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Europe




Figure 9.82.3 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Latin America





Figure 9.82.4 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by Region (FAS), Region = Others



9.83 Boxplot: Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 9.83.1 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 9.83.2 Symptoms (Mean of: Did You Have Chest Tightness During the Past 12 Hours?) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



10. Boxplot: Rescue Medication Change from Baseline (FAS)

10.1 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline (FAS)

Figure 5.1 Rescue Medication (Rescue medication during the night) - Change from Baseline (FAS)



10.2 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by Age (FAS)

Figure 5.2.1 Rescue Medication (Rescue medication during the night) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.2.2 Rescue Medication (Rescue medication during the night) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.2.3 Rescue Medication (Rescue medication during the night) - Change from Baseline by Age (FAS), Age = ≥65 years



10.3 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by Gender (FAS)

Figure 5.3.1 Rescue Medication (Rescue medication during the night) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.3.2 Rescue Medication (Rescue medication during the night) - Change from Baseline by Gender (FAS), Gender = Female



10.4 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by Region (FAS)

Figure 5.4.1 Rescue Medication (Rescue medication during the night) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.4.2 Rescue Medication (Rescue medication during the night) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.4.3 Rescue Medication (Rescue medication during the night) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.4.4 Rescue Medication (Rescue medication during the night) - Change from Baseline by Region (FAS), Region = Others



10.5 Boxplot: Rescue Medication (Rescue medication during the night) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.5.1 Rescue Medication (Rescue medication during the night) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.5.2 Rescue Medication (Rescue medication during the night) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



10.7 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline (FAS)

Figure 5.7 Rescue Medication (Rescue medication during the day) - Change from Baseline (FAS)



10.8 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by Age (FAS)

Figure 5.8.1 Rescue Medication (Rescue medication during the day) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.8.2 Rescue Medication (Rescue medication during the day) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.8.3 Rescue Medication (Rescue medication during the day) - Change from Baseline by Age (FAS), Age = ≥65 years



10.9 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by Gender (FAS)

Figure 5.9.1 Rescue Medication (Rescue medication during the day) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.9.2 Rescue Medication (Rescue medication during the day) - Change from Baseline by Gender (FAS), Gender = Female



10.10 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by Region (FAS)

Figure 5.10.1 Rescue Medication (Rescue medication during the day) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.10.2 Rescue Medication (Rescue medication during the day) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.10.3 Rescue Medication (Rescue medication during the day) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.10.4 Rescue Medication (Rescue medication during the day) - Change from Baseline by Region (FAS), Region = Others



10.11 Boxplot: Rescue Medication (Rescue medication during the day) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.11.1 Rescue Medication (Rescue medication during the day) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.11.2 Rescue Medication (Rescue medication during the day) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



10.13 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline (FAS)

Figure 5.13 Rescue Medication (Rescue medication free days) - Change from Baseline (FAS)



10.14 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by Age (FAS)

Figure 5.14.1 Rescue Medication (Rescue medication free days) - Change from Baseline by Age (FAS), Age = 18-39 years




Figure 5.14.2 Rescue Medication (Rescue medication free days) - Change from Baseline by Age (FAS), Age = 40-64 years





Figure 5.14.3 Rescue Medication (Rescue medication free days) - Change from Baseline by Age (FAS), Age = ≥65 years



10.15 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by Gender (FAS)

Figure 5.15.1 Rescue Medication (Rescue medication free days) - Change from Baseline by Gender (FAS), Gender = Male





Figure 5.15.2 Rescue Medication (Rescue medication free days) - Change from Baseline by Gender (FAS), Gender = Female



10.16 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by Region (FAS)

Figure 5.16.1 Rescue Medication (Rescue medication free days) - Change from Baseline by Region (FAS), Region = Asia




Figure 5.16.2 Rescue Medication (Rescue medication free days) - Change from Baseline by Region (FAS), Region = Europe




Figure 5.16.3 Rescue Medication (Rescue medication free days) - Change from Baseline by Region (FAS), Region = Latin America





Figure 5.16.4 Rescue Medication (Rescue medication free days) - Change from Baseline by Region (FAS), Region = Others



10.17 Boxplot: Rescue Medication (Rescue medication free days) - Change from Baseline by History of Asthma Exacerbation (FAS)

Figure 5.17.1 Rescue Medication (Rescue medication free days) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1






Figure 5.17.2 Rescue Medication (Rescue medication free days) - Change from Baseline by History of Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



11. Kaplan-Meier-Plot: Asthma exacerbations (FAS)

11.1 Kaplan-Meier-Plot: Asthma Exacerbation (All) (FAS)

Figure 11.1 Asthma Exacerbation (All) (FAS)




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 230/240, Week 8: 210/204, Week 16: 195/184, Week 24: 182/168

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.2 Kaplan-Meier-Plot: Asthma Exacerbation (All) by Age (FAS)


Figure 11.2.1 Asthma Exacerbation (All) (FAS), Age = 18-39 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 44/40, Week 8: 41/37, Week 16: 40/36, Week 24: 37/34

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.2.2 Asthma Exacerbation (All) (FAS), Age = 40-64 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 144/155, Week 8: 130/134, Week 16: 121/118, Week 24: 115/107

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.2.3 Asthma Exacerbation (All) (FAS), Age = ≥65 years




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 42/45, Week 8: 39/33, Week 16: 34/30, Week 24: 30/27

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.3 Kaplan-Meier-Plot: Asthma Exacerbation (All) by Gender (FAS)


Figure 11.3.1 Asthma Exacerbation (All) (FAS), Gender = Male



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 97/88, Week 8: 90/79, Week 16: 81/71, Week 24: 75/64

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.3.2 Asthma Exacerbation (All) (FAS), Gender = Female




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 133/152, Week 8: 120/125, Week 16: 114/113, Week 24: 107/104

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.4 Kaplan-Meier-Plot: Asthma Exacerbation (All) by Region (FAS)


Figure 11.4.1 Asthma Exacerbation (All) (FAS), Region = Asia



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 70/72, Week 8: 57/59, Week 16: 51/48, Week 24: 49/43

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.4.2 Asthma Exacerbation (All) (FAS), Region = Europe



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 83/85, Week 8: 79/76, Week 16: 73/69, Week 24: 66/63

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.4.3 Asthma Exacerbation (All) (FAS), Region = Latin America



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 61/75, Week 8: 60/62, Week 16: 57/60, Week 24: 54/56

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.4.4 Asthma Exacerbation (All) (FAS), Region = Others




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 16/8, Week 8: 14/7, Week 16: 14/7, Week 24: 13/6

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.5 Kaplan-Meier-Plot: Asthma Exacerbation (All) by History of Asthma Exacerbation (FAS)


Figure 11.5.1 Asthma Exacerbation (All) (FAS), Asthma exacerbations in the 12 months prior to screening = 1



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 196/198, Week 8: 178/171, Week 16: 167/156, Week 24: 155/142

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.5.2 Asthma Exacerbation (All) (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 34/42, Week 8: 32/33, Week 16: 28/28, Week 24: 27/26

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.7 Kaplan-Meier-Plot: Severe Asthma Exacerbation (FAS)

Figure 11.7 Severe Asthma Exacerbation (FAS)




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 230/240, Week 8: 221/228, Week 16: 215/214, Week 24: 205/202

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.8 Kaplan-Meier-Plot: Severe Asthma Exacerbation by Age (FAS)


Figure 11.8.1 Severe Asthma Exacerbation (FAS), Age = 18-39 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 44/40, Week 8: 43/40, Week 16: 43/39, Week 24: 40/37

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.8.2 Severe Asthma Exacerbation (FAS), Age = 40-64 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 144/155, Week 8: 137/149, Week 16: 131/140, Week 24: 126/132

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.8.3 Severe Asthma Exacerbation (FAS), Age = ≥65 years




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 42/45, Week 8: 41/39, Week 16: 41/35, Week 24: 39/33

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.9 Kaplan-Meier-Plot: Severe Asthma Exacerbation by Gender (FAS)


Figure 11.9.1 Severe Asthma Exacerbation (FAS), Gender = Male



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 97/88, Week 8: 94/84, Week 16: 90/80, Week 24: 87/76

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.9.2 Severe Asthma Exacerbation (FAS), Gender = Female




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 133/152, Week 8: 127/144, Week 16: 125/134, Week 24: 118/126

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.10 Kaplan-Meier-Plot: Severe Asthma Exacerbation by Region (FAS)


Figure 11.10.1 Severe Asthma Exacerbation (FAS), Region = Asia



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 70/72, Week 8: 64/70, Week 16: 62/64, Week 24: 61/63

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.10.2 Severe Asthma Exacerbation (FAS), Region = Europe



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 83/85, Week 8: 81/82, Week 16: 77/76, Week 24: 72/70

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.10.3 Severe Asthma Exacerbation (FAS), Region = Latin America



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 61/75, Week 8: 61/68, Week 16: 61/66, Week 24: 58/62

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.10.4 Severe Asthma Exacerbation (FAS), Region = Others




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 16/8, Week 8: 15/8, Week 16: 15/8, Week 24: 14/7

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.11 Kaplan-Meier-Plot: Severe Asthma Exacerbation by History of Asthma Exacerbation (FAS)


Figure 11.11.1 Severe Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 196/198, Week 8: 189/189, Week 16: 184/178, Week 24: 175/168

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.11.2 Severe Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 34/42, Week 8: 32/39, Week 16: 31/36, Week 24: 30/34

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.13 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS)

Figure 11.13 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS)




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 230/240, Week 8: 220/229, Week 16: 211/215, Week 24: 201/201

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.14 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by Age (FAS)


Figure 11.14.1 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Age = 18-39 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 44/40, Week 8: 42/40, Week 16: 41/39, Week 24: 38/37

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.14.2 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Age = 40-64 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 144/155, Week 8: 137/149, Week 16: 130/140, Week 24: 125/130

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.14.3 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Age = ≥65 years




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 42/45, Week 8: 41/40, Week 16: 40/36, Week 24: 38/34

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.15 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by Gender (FAS)


Figure 11.15.1 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Gender = Male



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 97/88, Week 8: 94/85, Week 16: 88/81, Week 24: 85/76

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.15.2 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Gender = Female




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 133/152, Week 8: 126/144, Week 16: 123/134, Week 24: 116/125

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.16 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by Region (FAS)


Figure 11.16.1 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Region = Asia



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 70/72, Week 8: 64/70, Week 16: 62/64, Week 24: 61/61

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.16.2 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Region = Europe



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 83/85, Week 8: 81/83, Week 16: 75/77, Week 24: 70/71

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.16.3 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Region = Latin America



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 61/75, Week 8: 61/68, Week 16: 60/66, Week 24: 57/62

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.16.4 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Region = Others




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 16/8, Week 8: 14/8, Week 16: 14/8, Week 24: 13/7

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.17 Kaplan-Meier-Plot: SCS Use Due to Asthma Exacerbation (for at least three consecutive days) by History of Asthma Exacerbation (FAS)


Figure 11.17.1 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Asthma exacerbations in the 12 months prior to screening = 1



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 196/198, Week 8: 188/190, Week 16: 181/179, Week 24: 172/168

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.17.2 SCS Use Due to Asthma Exacerbation (for at least three consecutive days) (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 34/42, Week 8: 32/39, Week 16: 30/36, Week 24: 29/33

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.19 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS)

Figure 11.19 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS)




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 230/240, Week 8: 228/238, Week 16: 226/234, Week 24: 221/232

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.20 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by Age (FAS)


Figure 11.20.1 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Age = 18-39 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 44/40, Week 8: 44/40, Week 16: 44/40, Week 24: 42/39

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.20.2 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Age = 40-64 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 144/155, Week 8: 143/154, Week 16: 141/152, Week 24: 138/151

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.20.3 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Age = ≥65 years




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 42/45, Week 8: 41/44, Week 16: 41/42, Week 24: 41/42

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.21 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by Gender (FAS)


Figure 11.21.1 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Gender = Male



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 97/88, Week 8: 97/88, Week 16: 96/87, Week 24: 96/87

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.21.2 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Gender = Female




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 133/152, Week 8: 131/150, Week 16: 130/147, Week 24: 125/145

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.22 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by Region (FAS)


Figure 11.22.1 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Region = Asia



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 70/72, Week 8: 69/72, Week 16: 68/71, Week 24: 68/70

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.22.2 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Region = Europe



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 83/85, Week 8: 83/85, Week 16: 82/83, Week 24: 79/83

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.22.3 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Region = Latin America



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 61/75, Week 8: 61/73, Week 16: 61/72, Week 24: 59/71

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.22.4 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Region = Others




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 16/8, Week 8: 15/8, Week 16: 15/8, Week 24: 15/8

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.23 Kaplan-Meier-Plot: ER Visit and/or Hospitalization Due to Asthma Exacerbation by History of Asthma Exacerbation (FAS)


Figure 11.23.1 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 196/198, Week 8: 195/196, Week 16: 194/193, Week 24: 189/191

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.23.2 ER Visit and/or Hospitalization Due to Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 34/42, Week 8: 33/42, Week 16: 32/41, Week 24: 32/41

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.25 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation (FAS)

Figure 11.25 ER Visit Due to Asthma Exacerbation (FAS)




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 230/240, Week 8: 229/238, Week 16: 227/235, Week 24: 222/233

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.26 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by Age (FAS)


Figure 11.26.1 ER Visit Due to Asthma Exacerbation (FAS), Age = 18-39 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 44/40, Week 8: 44/40, Week 16: 44/40, Week 24: 42/39

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.26.2 ER Visit Due to Asthma Exacerbation (FAS), Age = 40-64 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 144/155, Week 8: 143/154, Week 16: 141/153, Week 24: 138/152

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.26.3 ER Visit Due to Asthma Exacerbation (FAS), Age = ≥65 years




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 42/45, Week 8: 42/44, Week 16: 42/42, Week 24: 42/42

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.27 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by Gender (FAS)


Figure 11.27.1 ER Visit Due to Asthma Exacerbation (FAS), Gender = Male



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 97/88, Week 8: 97/88, Week 16: 96/87, Week 24: 96/87

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.27.2 ER Visit Due to Asthma Exacerbation (FAS), Gender = Female




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 133/152, Week 8: 132/150, Week 16: 131/148, Week 24: 126/146

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.28 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by Region (FAS)


Figure 11.28.1 ER Visit Due to Asthma Exacerbation (FAS), Region = Asia



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 70/72, Week 8: 70/72, Week 16: 69/72, Week 24: 69/71

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.28.2 ER Visit Due to Asthma Exacerbation (FAS), Region = Europe



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 83/85, Week 8: 83/85, Week 16: 82/83, Week 24: 79/83

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.28.3 ER Visit Due to Asthma Exacerbation (FAS), Region = Latin America



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 61/75, Week 8: 61/73, Week 16: 61/72, Week 24: 59/71

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.28.4 ER Visit Due to Asthma Exacerbation (FAS), Region = Others




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 16/8, Week 8: 15/8, Week 16: 15/8, Week 24: 15/8

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.29 Kaplan-Meier-Plot: ER Visit Due to Asthma Exacerbation by History of Asthma Exacerbation (FAS)


Figure 11.29.1 ER Visit Due to Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 196/198, Week 8: 196/196, Week 16: 195/194, Week 24: 190/192

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.29.2 ER Visit Due to Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 34/42, Week 8: 33/42, Week 16: 32/41, Week 24: 32/41

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.31 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation (FAS)

Figure 11.31 Hospitalization Due to Asthma Exacerbation (FAS)




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 230/240, Week 8: 229/239, Week 16: 227/235, Week 24: 222/233

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.32 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by Age (FAS)


Figure 11.32.1 Hospitalization Due to Asthma Exacerbation (FAS), Age = 18-39 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 44/40, Week 8: 44/40, Week 16: 44/40, Week 24: 42/39

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.32.2 Hospitalization Due to Asthma Exacerbation (FAS), Age = 40-64 years



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 144/155, Week 8: 144/154, Week 16: 142/152, Week 24: 139/151

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.32.3 Hospitalization Due to Asthma Exacerbation (FAS), Age = ≥65 years




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 42/45, Week 8: 41/45, Week 16: 41/43, Week 24: 41/43

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.33 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by Gender (FAS)


Figure 11.33.1 Hospitalization Due to Asthma Exacerbation (FAS), Gender = Male



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 97/88, Week 8: 97/88, Week 16: 96/87, Week 24: 96/87

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.33.2 Hospitalization Due to Asthma Exacerbation (FAS), Gender = Female




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 133/152, Week 8: 132/151, Week 16: 131/148, Week 24: 126/146

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.34 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by Region (FAS)


Figure 11.34.1 Hospitalization Due to Asthma Exacerbation (FAS), Region = Asia



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 70/72, Week 8: 69/72, Week 16: 68/71, Week 24: 68/70

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.34.2 Hospitalization Due to Asthma Exacerbation (FAS), Region = Europe



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 83/85, Week 8: 83/85, Week 16: 82/83, Week 24: 79/83

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"


Figure 11.34.3 Hospitalization Due to Asthma Exacerbation (FAS), Region = Latin America



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 61/75, Week 8: 61/74, Week 16: 61/73, Week 24: 59/72

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.34.4 Hospitalization Due to Asthma Exacerbation (FAS), Region = Others




Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 16/8, Week 8: 16/8, Week 16: 16/8, Week 24: 16/8

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

11.35 Kaplan-Meier-Plot: Hospitalization Due to Asthma Exacerbation by History of Asthma Exacerbation (FAS)


Figure 11.35.1 Hospitalization Due to Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = 1



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 196/198, Week 8: 195/197, Week 16: 194/194, Week 24: 189/192

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"

Figure 11.35.2 Hospitalization Due to Asthma Exacerbation (FAS), Asthma exacerbations in the 12 months prior to screening = ≥2



Patients at risk (IND/GLY/MF 160 / SAL/FLU + TIO): Week 0: 34/42, Week 8: 34/42, Week 16: 33/41, Week 24: 33/41

Analysis population: B2306 FAS subpopulation "mid-dose ICS/LABA"